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I N V I V O S T A B I L I T Y OF R A D I O L A B E L L E D 
MACROCYCLE COMPLEXES. 
ABSTRACT 
The gadolinium (iSSgd) complexes of 21 aza-phosphinic and 
aza-carboxylic a c i d macrocycles based on 1,4,7,10-
tetraazacyclododecane were studied as possible contrast 
agents f o r magnetic resonance imaging. The a c i d d i s s o c i a t i o n 
r a t e s and p a r t i t i o n c o e f f i c i e n t s of gadolinium complexes were 
measured and r e l a t e d t o t h e i r i n v i v o s t a b i l i t y and route of 
e l i m i n a t i o n i n mice. The anionic aza-phosphinic acids had low 
a c i d d i s s o c i a t i o n rates (24-78 x 10'^ sec'^ at pH i ) which 
c o r r e l a t e d w i t h high i n v i v o s t a b i l i t y (<0.025% dose i n the 
skeleton at 24 hours). [Gd.l2N4P4Bz4]' shows p o t e n t i a l as a 
g a l l bladder, b i l e duct contrast imaging agent at doses of 
0.1 t o 10 /unol/kg , and f o r tumour d e t e c t i o n w i t h i n the 
h e p a t o b i l i a r y system at doses of 100 t o 200 /xmol/kg . 
Macrocycles based on l,4,7,10-tetraazacyclododecane can 
be used t o complex y t t r i u m (^Oy) f o r tumour therapy. ^^ Y 
complexes of aza-phosphinic and aza-carboxylic acid 
d e r i v a t i v e s showed slow a c i d catalysed d i s s o c i a t i o n rates of 
1-14 X 10"^ s e c ' l at pH 1, and r a p i d association k i n e t i c s of 
g r e a t e r than 80% y t t r i u m uptake w i t h i n 30 minutes at 5 ^ 
l i g a n d . A t e t r a a z a - c a r b o x y l i c a c i d and a t r i - p h o s p h i n i c a c i d 
d e r i v a t i v e modified w i t h maleimide were l i n k e d t o monoclonal 
antibodies and l a b e l l e d w i t h ^^Y. Both were h i g h l y stable i n 
v i v o w i t h <0.0l% dose i n the mouse femur shaft at 48 
hours. 
Seven aza-phosphinic and aza-carboxylic acid macrocycles 
based on i,4,7,-triazacyclononane were l a b e l l e d w i t h 
r a d i o a c t i v e g a l l i u m or indium. Gallium complexes were 
g e n e r a l l y more stable i n v i v o than the corresponding indium 
complexes. Three "^^ Ga and two m i n complexes showed 
p o t e n t i a l as imaging agents and one g a l l i u m complex as a 
h e p a t o b i l i a r y imaging agent. Several complexes were examined 
as po s s i b l e tumour l o c a l i s a t i o n agents, [Ga.9N3] g i v i n g a 
tumour t o blood r a t i o of 22:1 at 4 hours a f t e r i n j e c t i o n . 
LOUISE ROYLE (1995). 
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1, 4, 7, lO-tetraazacyclododecane-N,Nl,N2,N3-
t e t r a a c e t i c a c i d 
1,4, 7-triazacyclononane-N,Nl,N2-triacetic acid 
Ethylenediamine-tetraacetic acid 
Diethylenetriamine-pentaacetic acid 
DTPA c y c l i c anhydride 
Computed tomography 
Magnetic resonance imaging 
Nuclear magnetic resonance 
Single photon emission computerised tomography 
Positron emission tomography 
High performance l i q u i d chromatography 




Physical h a l f l i f e 
Alpha p a r t i c l e 
Beta p a r t i c l e or e l e c t r o n 
Positron 
Gamma photon 
Curie, equivalent t o 3.7 x lO^^ becquerels 
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CHAPTER ONE 
INTRODUCTION 
1.1 MEDICAL IMAGING. 
Medical imaging i s used t o study hxaman i n t e r n a l organs 
and t o demonstrate p a t h o l o g i c a l lesions. The most basic 
imaging technique involves X-rays. I t i s 100 years since 
Roentgen f i r s t discovered the X-ray, and simple radiography 
i s s t i l l the most r o u t i n e l y used imaging technique today. 
However, the l a s t 40 years have seen great advances i n 
medical imaging techniques w i t h the i n t r o d u c t i o n i n t o 
c l i n i c a l p r a c t i c e of radioisotope imaging i n the 1950s, 
ultrasound i n the 1960s, computed tomography (CT) i n the 
1970s and magnetic resonance imaging (MRI) i n the I980s^. 
A l l of these imaging techniques r e l y i n one way or 
another on electromagnetic r a d i a t i o n : -
1. X-rays. The simple X-ray image i s produced by passing 
e x t e r n a l l y produced X-rays through a p a t i e n t onto a 
photographic p l a t e . The v i s i b i l i t y of s t r u c t u r e s depends on 
t h e i r absorption of X-rays. C a l c i f i e d tissues such as bone 
absorb X-rays most s t r o n g l y and ther e f o r e show up white on 
the photographic p l a t e . 
2. Radioisotope imaging. The radioisotope i s detected by 
v i r t u e of the gamma photons which i t emits during r a d i o a c t i v e 
decay. The imaging method depends on c e r t a i n r a d i o l a b e l l e d 
substances concentrating i n p a r t i c u l a r p a r ts of the body. 
This can be a simple chemical form of the radioisotope e.g. 
iodin e concentrates i n the t h y r o i d when i n j e c t e d as iodide. 
However the radi o i s o t o p e i s u s u a l l y attached t o a 
pharmaceutical the chemistry of which determines the f a t e of 
the r a d i o l a b e l i n v i v o . 
3. n i t r a s o t i n d . Images are produced f o l l o w i n g the passage 
of high frequency sound waves through the body. When these 
waves encounter an object or a surface of d i f f e r e n t density, 
they are r e f l e c t e d . This r e f l e c t e d echo i s detected, 
converted t o an e l e c t r i c a l s i g n a l and an image i s 
constructed. 
4. Computed Tomography. CT r e l i e s on e x t e r n a l l y produced 
X-rays which are picked up by gas or c r y s t a l detectors which 
are much more s e n s i t i v e than simple photographic p l a t e s . A 
f a r higher r e s o l u t i o n of d i f f e r e n t d ensity tissues i s 
obtained than from a conventional X-ray image. Sophisticated 
computing tomography methods are employed t o construct high 
r e s o l u t i o n 2-dimensional images of s l i c e s through the body. 
5. Magnetic Resonance Imaging. MRI i s based on the f a c t 
t h a t c e r t a i n n u c l e i behave l i k e t i n y magnets. The most 
abundant of these n u c l e i i n the human body are the protons i n 
water. A strong magnetic f i e l d i s applied e x t e r n a l l y t o the 
body causing a l l these protons t o a l i g n i n the same 
d i r e c t i o n . A pulse of r a d i o waves i s then applied at the 
appropriate frequency t o cause the protons t o be displaced 
from alignment w i t h the f i e l d . When the radiofrequency pulse 
i s stopped, the n u c l e i r e a l i g n and emit the absorbed 
radiofrequency. This r a d i o - s i g n a l i s then detected, the 
i n t e n s i t y of the s i g n a l being p r o p o r t i o n a l t o the 
concentration of protons. This allows an image t o be 
constructed mapping the water content of t i s s u e s . MRI uses 
s i m i l a r computing methods t o CT t o construct 2-dimensional 
s l i c e s through the body. 
The techniques of MRI and radioisotope imaging along w i t h 
r a d i o i s o t o p e therapy w i l l be d e a l t w i t h i n greater d e t a i l i n 
the f o l l o w i n g sections. 
1.2. RADIOACTIVITY.2/3 
Radioactive isotopes are those isotopes which possess an 
unstable r a t i o of protons t o neutrons. The isotope decays t o 
a s t a b l e c o n f i g u r a t i o n by e m i t t i n g energy i n the form of 
charged p a r t i c l e s , electromagnetic r a d i a t i o n or both. This 
emitted r a d i a t i o n may be:-
( i ) Alpha p a r t i c l e s . These consist of 2 neutrons and 2 
protons. A l p h a - p a r t i c l e s are heavy, slow moving, densely 
i o n i s i n g r a d i a t i o n capable of i n f l i c t i n g severe b i o l o g i c a l 
damage. 
( i i ) Beta p a r t i c l e s . These are energetic electrons (jS') 
or p o s i t r o n s (i8+) . Beta p a r t i c l e s are less dense than alpha-
p a r t i c l e s , consequently they can penetrate t i s s u e f u r t h e r and 
d e l i v e r t h e i r dose over a longer range. Positrons have a 
range i n t i s s u e s i m i l a r t o t h a t of electrons of the same 
energy, but at the end of i t s path the p o s i t r o n combines w i t h 
an e l e c t r o n ( a n n i h i l a t e s ) and two 511 kev 7-rays are created. 
( i i i ) Auger electrons'*. These electrons are sometimes 
emitted from an atom due t o the f i l l i n g of a vacancy i n an 
inner e l e c t r o n s h e l l a f t e r the process of e l e c t r o n capture or 
i n t e r n a l conversion, they lose t h e i r energy over a very short 
range (nm t o a few fim) . 
( i v ) Gamma rays or X rays. These are electromagnetic, not 
p a r t i c l e r a d i a t i o n s . They can t r a v e l much f u r t h e r distances 
than charged p a r t i c l e s , w i t h l i t t l e dose loss t o t h e i r 
surroundings. Gamma rays can be produced along w i t h any 
p a r t i c l e r a d i a t i o n or alone from e l e c t r o n capture (where a 
proton captures an o r b i t a l e l e c t r o n and i s thereby converted 
i n t o a neutron), or from an i n t e r n a l t r a n s i t i o n ( t h i s i s the 
decay of a nucleus from an ex c i t e d s t a t e ) . 
1.2.1. Radioisotopes for Imaging 
For d i a g n o s t i c imaging the f o l l o w i n g p r o p e r t i e s are 
d e s i r a b l e of a ra d i o n u c l i d e :-
1. Emission of 7-rays i n high abundance 
2. The 7-rays should be of s u f f i c i e n t energy t o penetrate 
the body, but low enough i n energy t o allow f o r 
e f f i c i e n t d e t e c t i o n , (100 t o 300 keV)^ 
3. Have a low abundance ( p r e f e r a b l y zero) of p a r t i c l e 
emissions i n order t o minimise the r a d i a t i o n dose t o 
the p a t i e n t . 
4. Have a short h a l f l i f e i n order t o keep the r a d i a t i o n 
dose t o a minimum. 
5. Have a s u f f i c i e n t l y long h a l f l i f e t o permit time f o r 
the r a d i o l a b e l l i n g , i n j e c t i o n and t a r g e t i n g of the 
pharmaceutical. 
6. Decay t o a stabl e daughter product. 
7. Be cheap and r e a d i l y a v a i l a b l e 
8. Be c a r r i e r f r e e 
9. Possess chemical p r o p e r t i e s which permit attachment 
to pharmaceuticals. 
Table 1.1 l i s t s some radioisotopes which have 7-emissions 
s u i t a b l e f o r imaging. The most widely used isotope i s ^^m^c, 
i t s 7-emission being i d e a l f o r d e t e c t i o n by an Anger camera. 
99m-pc l a b e l l e d pharmaceuticals are used f o r imaging b r a i n , 
l i v e r , lung, skeleton, t h y r o i d , kidneys and heart t i s s u e s ^ ' ^ . 
However the 6 hour h a l f l i f e of S^ m^ c i s too short f o r the 
l a b e l l i n g of pharmaceuticals which r e q u i r e lengthy 
p r e p a r a t i o n or those which take time t o t a r g e t w i t h i n the 
body (e.g. r a d i o l a b e l l e d a n t i b o d i e s ) . This i s where the 
longer h a l f l i f e m i n and ^ "^ Ga isotopes prove u s e f u l . Both 
m j n and ^ "^ Ga emit abundant 7-rays s u i t a b l e f o r imaging and 
have d i f f e r e n t chemical p r o p e r t i e s from technetiiam, making 
them more a t t r a c t i v e candidates f o r pharmaceutical l a b e l l i n g . 
has been widely used f o r imaging, but i t s physical 
p r o p e r t i e s are not i d e a l . The beta emission g i v i n g a high 
p a t i e n t dose, the gamma emissions being too energetic f o r 
e f f i c i e n t counting, and a long h a l f l i f e of 8 days. I 2 3 i ±Q 
more s u i t a b l e f o r imaging of the t h y r o i d , having an 
appropriate 7 emission and short 13 hour h a l f l i f e . Iodine 
has been used f o r l a b e l l i n g pharmaceuticals but these are 
susceptible t o dehalogenation i n v i v o . 
The isotopes ^^Cu, ^ ^Eb and ^ G^a are a l l p o s i t r o n 
e m i t t e r s s u i t a b l e f o r PET imaging. The dose t o the p a t i e n t 
from the p o s i t r o n i s u s u a l l y outweighed by the production of 
a high d e f i n i t i o n image. The short h a l f l i v e s of 82^]-, ^^d 
^^Ga make them uns u i t a b l e f o r the l a b e l l i n g of 
pharmaceuticals which take a long time t o prepare or t o 
l o c a l i s e i n the t a r g e t t i s s u e . 
Table 1.1. Radioisotopes for imaging^'^'^ 
Isotope Half Type of Average P r i n c i p l e Method of 
l i f e decay p a r t i c l e gamma production 
energy* energies 
MeV {%) MeV (? r) 
99mTc 6 hr I .T. 0 . 141 (89) Generator 
123i 13 hr E.G. 0 .159 (83) Cyclotron 
l l l l n 67 hr E.G. 0 .171 (91) C yclotron 
0 .245 (94) 
78 hr E.G. 0 093 (38) Cyclotron 
0 185 (21) 
0 300 (17) 
131i 193 hr 0 19 (89) 0 080 (3) Reactor 
0 284 (6) 
0 364 (81) 
13 hr 0 19 (37) Reactor 
0 28 (18) 0 511 (36) 
E.G. (41%) 1 346 (0.5) 
82Rb 75 min 1 16 (12) 0 511 (191) Generator 
E.G. (4%) 1 52 (83) 0 777 (13) 
68 min 0^ 0 35 (1) 0 511 (178) Generator 
E.G. (10%) 0 84 (88) 1 077 (3) 
I.T.= I s o m e r i c t r a n s i t i o n from upper to lower isomeric s t a t e . 
E.C.= O r b i t a l e l e c t r o n capture. 
* The average beta p a r t i c l e energy i s about a t h i r d of i t s maximum. 
1.2.2. Radioimaging Techniques. 
Single Photon Emission Tomography (SPECT)9'^0, 
A SPECT image of the d i s t r i b u t i o n of a gamma e m i t t i n g 
r a d i o i s o t o p e w i t h i n a p a t i e n t i s obtained by means of an 
Anger camera (also known as a gamma or s c i n t i l l a t i o n camera) 
The gamma r a d i a t i o n needs t o be of s u f f i c i e n t energy t o 
penetrate body t i s s u e s , but of low enough energy t o be 
detected by the Anger camera. Thus gamma energies i n the 
range 100 t o 300 keV are the most s u i t a b l e f o r imaging^. An 
Anger camera consists of a 0.25 t o 0.5 inch t h i c k Nal(Tl) 
c r y s t a l i n f r o n t of an array of p h o t o m u l t i p l i e r tubes. When a 
gamma photon s t r i k e s the Nal(Tl) c r y s t a l , a photon of l i g h t 
i s produced which i s then a m p l i f i e d i n the p h o t o m u l t i p l i e r 
tubes and counted as an e l e c t r i c a l pulse. The Anger camera 
detects the r a d i a t i o n from the whole f i e l d simultaneously. 
S p a t i a l r e s o l u t i o n i s provided by the use of m u l t i p l e 
p h o t o m u l t i p l i e r tubes, the tube nearest the i n c i d e n t gamma 
r a d i a t i o n producing the l a r g e s t s i g n a l . 
I n order t o l i m i t gamma photons from outside the f i e l d of 
view e n t e r i n g the detector, a c o l l i m a t o r i s employed. A 
c o l l i m a t o r ensures t h a t only gamma photons a r i s i n g from the 
f i e l d of view and t r a v e l l i n g p a r a l l e l t o the axis of the 
c o l l i m a t o r reach the detector. Collimators therefore increase 
the d e f i n i t i o n of the image, but at the expense of 
s e n s i t i v i t y . The s e n s i t i v i t y and r e s o l u t i o n of the Anger 
camera i s also depth dependent as the gamma photons are 
absorbed and scattere d by body t i s s u e (the number of gamma 
photons w i t h an energy of 100 keV reaching the detector i s 
halved by 5 cm of t i s s u e ^ ! ) . Thus the a b i l i t y t o detect small 
or low cont r a s t s t r u c t u r e s i s reduced w i t h depth, the 
e f f e c t i v e r e s o l u t i o n of SPECT i s about l cm. 
I n order t o o b t a i n a three-dimensional image, the Anger 
camera i s mounted on a gantry which r o t a t e s l o n g i t u d i n a l l y 
around the p a t i e n t at 3 t o 10° increments. This allows s l i c e s 
through the p a t i e n t t o be imaged from many angles then, by 
the process of computerised tomography, these images can be 
reconstructed i n t o a three-dimensional image. By mounting up 
to three cameras on the gantry, several p r o j e c t i o n s can be 
monitored simultaneously thereby reducing the t o t a l imaging 
time. 
Positron Emission Tomography (PET)5'^2,13^ 
Positrons t r a v e l only a short distance i n the body before 
being a n n i h i l a t e d by an e l e c t r o n . This process r e s u l t s i n the 
emission of two 511 keV gamma photons at 180° t o each other. 
I t i s the production of these two a n t i - p a r a l l e l photons which 
endows PET w i t h i t s a b i l i t y t o produce such high r e s o l u t i o n 
images. 
To detect these a n n i h i l a t i o n photons, a p a i r of 
s c i n t i l l a t i o n detectors (Nal, BaF2, or Bi(Ge04)3)^4 are 
mounted i n coincidence mode on opposite sides of the p a t i e n t . 
Only photons which are recorded by both detectors 
simultaneously are accepted f o r imaging. This coincident 
d e t e c t i o n acts as a s o r t of c o l l i m a t o r , as only information 
from unattenuated r a d i a t i o n i s processed. The r e s u l t i s t h a t 
the s e n s i t i v i t y and r e s o l u t i o n i n the f i e l d of view does not 
vary w i t h depth. By mounting p a i r s of detectors i n a r i n g or 
hexagonal array around the p a t i e n t , the s e n s i t i v i t y i s 
increased. The i n f o r m a t i o n gathered by t h i s array of 
detectors i s then processed by computers and a tomographic 
three-dimensional image of a s l i c e through a p a t i e n t i s 
produced. As no ph y s i c a l c o l l i m a t o r i s needed w i t h PET, a 
r e s o l u t i o n of 3 t o 5 mm i s obtained i n a l l d i r e c t i o n s ' ^ . This 
r e s o l u t i o n i s greater than w i t h SPECT. 
The only disadvantage of PET over SPECT i s the r a d i a t i o n 
dose t o the p a t i e n t . As posi t r o n s are p a r t i c u l a t e r a d i a t i o n 
they deposit a larg e amount of energy at t h e i r source i n 
t i s s u e before they are a n n i h i l a t e d . However the increased 
s e n s i t i v i t y and r e s o l u t i o n gained from the use of PET has t o 
be weighed up against t h i s . 
1.2.3. Radioisotopes for Therapy.8»15-18 
Many of the p r e v i o u s l y l i s t e d d esirable p r o p e r t i e s of 
radioisotopes f o r imaging (sec t i o n 1.2.1) are also applicable 
t o therapy. Radioisotopes f o r therapy are also required t o : -
decay t o a stab l e daughter product; be r e a d i l y a v a i l a b l e and 
not too expensive; be c a r r i e r - f r e e ; and t o have chemical 
p r o p e r t i e s which permit attachment t o pharmaceuticals. The 
major d i f f e r e n c e between isotopes used i n therapy and 
imaging, i s the requirement i n therapy of a large component 
of p a r t i c l e r a d i a t i o n capable of d e l i v e r i n g a high l o c a l i s e d 
r a d i a t i o n dose w i t h l i t t l e or no accompanying gamma 
r a d i a t i o n . However the presence of a small percentage of 
gammas can be u s e f u l f o r monitoring the l o c a t i o n of the 
therap e u t i c isotope w i t h i n the p a t i e n t . 
I n therapy the h a l f l i f e of the isotope needs t o be such 
t h a t the major p a r t of the r a d i a t i o n dose i s d e l i v e r e d during 
the residence time of the l a b e l l e d pharmaceutical i n the 
t a r g e t t i s s u e . The choice of p a r t i c l e emission and i t s range 
i n t i s s u e w i l l vary depending on the type of tumour being 
t r e a t e d . Cancerous t i s s u e can e x i s t as large masses (g-kg), 
or as small nodules (mg), or as si n g l e c e l l s from metastatic 
tumours or cancers of the haemopoetic system such as 
leukaemia. A l i s t of some radioisotopes s u i t a b l e f o r therapy 
i s given i n t a b l e 1.2. These isotopes are l i s t e d according t o 
t h e i r type of decay p a r t i c l e and estimated range i n s o f t 
t i s s u e . 
Radionuclides f o r therapy f a l l i n t o three major 
categories:- beta-emitters, alpha-emitters, and Auger 
e l e c t r o n e m i t t e r s . These d i f f e r e n t types of r a d i a t i o n have 
d i f f e r e n t ranges and i n t e n s i t i e s of energy deposition (the 
energy d e p o s i t i o n i s measured as l i n e a r energy t r a n s f e r or 
LET). B e t a - p a r t i c l e s have the longest range, the beta-
e m i t t e r s l i s t e d i n t a b l e 1.2 have average ranges of O.l t o 
3.9 mm. Alpha p a r t i c l e s have shorter ranges of -50 t o 90 urn, 
and a high LET of -100 KeV//xm. Because of i t s high LET an 
a l p h a - p a r t i c l e can cause i r r e p a r a b l e damage t o any DNA 
through which i t passes by causing double strand breaks. I t 
i s estimated t h a t only 3 t o 6 h i t s per c e l l nucleus are 
needed t o reduce the percentage of s u r v i v i n g c e l l s by 73%^^. 
The lower LET of b e t a - p a r t i c l e s (-0.2 KeV//xm) means tha t 
about 400 times more h i t s are required per c e l l nucleus t o 
produce the same e f f e c t . To be e f f e c t i v e i n therapy, an 
alpha-emitter needs t o be attached t o every c e l l , but because 
of t h e i r short range, non-specific i r r a d i a t i o n of d i s t a n t 
t i s s u e s i s el i m i n a t e d . Thus, alpha-emitters are best suited 
t o the treatment of s i n g l e c e l l s or small tumour masses. The 
Table 1.2. Radioisotopes for Therapy"^ 
Isotope Half Type of Average P r i n c i p l e Method of Mean 
l i f e decay p a r t i c l e photon production range i n 
energy* energ i e s t i s s u e 
MeV (%) MeV (%) 
90Y 64 hr ^- 0 .94 (100) none Generator 3.9 mm 
188Re 17 hr |8- 0 .73 (25) 0 155 (15) Generator 3.3 mm 
0 .79 (72) 
186Re 89 hr )3- 0 .31 (21) 0 137 (9) Reactor 1.1 mm 
0 .36 (76) 
l l l A g 179 hr 0 .36 (93) 0 245 (1) Reactor 1.1 mm 
0 342 (7) 
109pd 13.4hr 0 .36 (100) 0 088 (4) Reactor 1.1 mm 
39 hr 0- 0 23 (97) 0 239 (1.6) Cyclotron 0.5 mm 
0 250 (0.4) 
0 521 (0.6) 
131i 193 hr 0 19 (89) 0 080 (3) Reactor 0.4 ram 
0 284 (6) 
0 364 (81) 
16lTb 166 hr &- 0 14 (23) 0 026 (22) Reactor 0.3 mm 
0 15 (67) 0 049 (17) 
0 18 (10) 0 075 (10) 
177LU 161 hr 0 05 (12) 0 113 (6) Reactor 0.3 mm 
0 11 (9) 0 208 (11) 
0 15 (79) 
62 hr P- 0 12 (57) 0 091 (7) C yclotron 0.2 mm 
0 15 (22) 0 093 (16) 
0 19 (20) 0 185 (49) 
76 hr 0- 0 07 (19) 0 049 (0.3) Reactor 0.1 mm 
0 08 (66) 0 158 (37) 
0 13 (15) 0 208 (8) 
212Bi 1 hr &- (64%) 0 83 (48) 0 727 (12) Generator 
0 53 (8) 0. 785 (2) 50 to 
0 23 (3) 1. 621 (3) 90 im 
0. 19 (3) 
a (36%) 6. 05 (25) 
6. 09 (10) 
21lAt 7.2 hr a (42%) 5. 87 (42) C yclotron 50 to 
E. C,a(58%) 7. 45 (58) 0. 687 (0.2) 90 im 
0. 079 (21) 
E.C.= O r b i t a l e l e c t r o n capture. 
* The average beta p a r t i c l e energy i s about a t h i r d of i t s maximum. 
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longer range of b e t a - p a r t i c l e s i s more e f f e c t i v e i n the 
treatment of l a r g e r tumour masses where the 
radiopharmaceutical may not have been able t o penetrate 
through the whole mass, or where there i s heterogeneity i n 
the uptake of radiopharmaceutical by the tumour c e l l s ^ ^ ' ^ ^ . 
Auger electrons are high LET radiations'* which u s u a l l y 
only have a very short range i n the order of nm t o /xm. I n 
order t o d e l i v e r a l e t h a l dose t o DNA, the Auger emitter must 
be w i t h i n the c e l l nucleus i n very close p r o x i m i t y w i t h the 
DNA. Auger e m i t t e r l a b e l l e d DNA i n t e r c a l a t o r s ^ O are being 
i n v e s t i g a t e d as possible therapy agents, but the short range 
of these e l e c t r o n s makes them unsuitable f o r most 
radiotherapy a p p l i c a t i o n s . 
The choice of alpha-emitters s u i t a b l e f o r therapy i s 
l i m i t e d as most are heavy elements which decay t o unstable 
daughters. S u i t a b l e alpha e m i t t e r s are astatine-211 and 
bismuth-212. Astatine-211 l a b e l l e d monoclonal a n t i b o d i e s ^ l 
(McAbs) have been use f o r the treatment of lymphoma i n 
mice22,23^ or as 2llAt-methylene blue i n the treatment of 
metastatic melanoma i n mice^^. Bismuth-212 l a b e l l e d 
McAbs25,26 have been used t o t r e a t human lymphoma xenografts 
i n mice27 and a c s i t i c tumours i n mice^S-
There i s a much wider choice of beta-emitters g i v i n g more 
f l e x i b i l i t y i n choice of p a r t i c l e range, h a l f l i f e and 
chemistry. The most widely used isotope f o r 
radioimmumotherapy t o date has been iodine-131. l ^ l j - i a j - j e l l e ^ j 
McAbs have been used t o t r e a t p a t i e n t s w i t h lymphoma29-3l 
neuroblastoma-^^ _ ^nd melanoma^^. This p o p u l a r i t y has been due 
t o the ready a v a i l a b i l i t y , low cost and ease of chemical 
l a b e l l i n g . However, 1 3 i s not an i d e a l isotope f o r therapy 
as i t has a high y i e l d of gamma r a d i a t i o n , a r a t h e r long h a l f 
l i f e , and i o d i n e l a b e l l e d pharmaceuticals tend t o 
dehalagonate i n v i v o g i v i n g an even higher non-specific 
r a d i a t i o n dose. 
The i n t r o d u c t i o n of b i f u n c t i o n a l complexing agents has 
opened up the f i e l d t o the use of radiometal ions as l a b e l s 
f o r pharmaceuticals. Of these, yttrium-90 has shown the most 
promise. I t i s r e a d i l y a v a i l a b l e from a strontium-90 
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generator, has a shorter h a l f l i f e than ^ ^ i j and i s a pure 
beta e m i t t e r w i t h no accompanying gammas. The high energy of 
i t s beta p a r t i c l e , w i t h a mean range of 3.9 mm i n ti s s u e , 
makes ^^Y s u i t a b l e f o r the treatment of tumour masses. 
Several treatments w i t h ^Oy-McAbs of human colonic cancer^^-
38, lymphoma39, hepatoma'^O g^d glioma'^1 xenografts i n mice 
have proved successful.^^Y l a b e l l e d McAbs are being used i n 
c l i n i c a l t r i a l s on p a t i e n t s w i t h ovarian cancer^2-46^ 
lymphoma^"^ and breast cancer^8_ 
Of the other beta-emitters, ^^^Re l a b e l l e d McAbs have 
produced a p a r t i a l response i n the treatment of metastatic 
e p i t h e l i a l carcinoma i n patients'*^, having shown promise i n 
animal therapy experiments^^-52^ Copper-67 l a b e l l e d McAbs are 
being used t o t r e a t lymphoma patients^S f o l l o w i n g successful 
animal experiments54-58_ -phe r e s t of the isotopes i n table 
1.2 have not been studied i n as much d e t a i l : - Rhenium-188 
l a b e l l e d McAbs have been studied f o r i n v i v o s t a b i l i t y 5 2 ; 
Palladium-109 McAbs have been shown t o t a r g e t human melanoma 
xenografts'^; Lutetium-177 McAbs have been used i n therapy i n 
col o n i c cancer xenografts i n mice^O. ^nd s i l v e r - 1 1 1 i s being 
i n v e s t i g a t e d as a possible l a b e l f o r McAbs^^. 
For a l l of these isotopes used i n therapy, the dose 
l i m i t i n g f a c t o r i s proving t o be bone marrow t o x i c i t y ^ 2 _ ^s 
f r e e metal ions are known t o accumulate i n bone ti s s u e , t h i s 
makes the i n v i v o s t a b i l i t y of any r a d i o l a b e l l e d 
pharmaceutical of paramount importance. 
1.2.4. Targeting of Radiopharmacuticals. 
The radioisotopes discussed above f o r imaging and therapy 
need t o be tar g e t e d t o s p e c i f i c organs or tis s u e s . For 
successful imaging or therapy, a high t a r g e t t o non-target 
r a t i o i s needed. So although i t i s desirable t o get as much 
l a b e l as possible i n the t a r g e t t i s s u e , t h i s has t o be 
balanced against the o v e r a l l pharmacokinetics of the l a b e l l e d 
compound. I t i s important t h a t the l a b e l l e d pharmaceutical 
should b i n d q u i c k l y and w i t h high a f f i n i t y t o the t a r g e t 
t i s s u e , and t h a t t h i s i s followed by r a p i d clearance from 
12 
non-target t i s s u e s e s p e c i a l l y from c i r c u l a t i n g blood. A few 
isotopes t a r g e t s p e c i f i c tissues i n t h e i r simple chemical 
forms, f o r example:- anionic iodine isotopes concentrate i n 
t h y r o i d t i s s u e and are u t i l i s e d f o r the imaging and therapy 
of t h y r o i d cancer63,64. ^nd radiometal cations concentrate i n 
bone t i s s u e , strontium-89 (jS", t ^ / 2 51 days) can be used f o r 
the r e l i e f of pain i n metastatic cancer i n the bone^5,66_ 
order t o expand the scope of imaging and therapy, methods of 
a l t e r i n g the b i o d i s t r i b u t i o n and pharmacokinetics of these 
isotopes need t o be developed. 
Simple complexes of metals w i t h DTPA or DOTA which are 
h y d r o p h i l i c and have an o v e r a l l negative charge are 
d i s t r i b u t e d around the body i n t o the e x t r a c e l l u l a r spaces and 
then q u i c k l y excreted i n t o the u r i n e f o l l o w i n g intravenous 
i n j e c t i o n ^ ' ^ . As such, they are used t o assess blood flow, t o 
detect any breakdovm i n the blood-brain b a r r i e r which occurs 
w i t h b r a i n tumours, as w e l l as t o assess renal f u n c t i o n . 
Chemically a l t e r i n g the o v e r a l l charge and l i p o p h i l i c i t y of a 
metal complex can change i t s route of ex c r e t i o n from renal t o 
h e p a t o b i l i a r y , thus enabling the imaging of l i v e r and gut 
f u n c t i o n . Examples of t h i s are the indium and g a l l i u m 
complexes of HBED and PLED d e r i v a t i v e s ( f i g u r e 4.1), the most 
l i p o p h i l i c of these e x h i b i t the most h e p a t o b i l i a r y 
clearance^^. Another example of the e f f e c t of l i p o p h i l i c i t y 
i s w i t h a group of 99II^TC l a b e l l e d iminoacetic acids. Here, 
h e p a t o b i l i a r y clearance has been shown t o be d i r e c t l y 
p r o p o r t i o n a l t o the n a t u r a l l o g of the molecular weight of 
the complex d i v i d e d by the molecular charge^^. The a b i l i t y of 
small molecular weight compounds (<400 daltons) t o cross the 
blood-brain b a r r i e r has also been r e l a t e d t o the 
l i p o p h i l i c i t y of the compound"^0. These examples i l l u s t r a t e 
t h a t r e l a t i v e l y simple changes t o the chemistry of the 
complexing agent can be u t i l i s e d t o t a r g e t d i f f e r e n t organs. 
A more d i r e c t approach t o t a r g e t i n g i s the use of 
analogues t o n a t u r a l l y o ccurring biomolecules. ^^Q^. 
[Desferrioxamine B-Succinyl-(D)Phe^]-Octroetide i s a 
somatostatin analogue which i s used f o r the imaging of 
somatostatin p o s i t i v e tumours"^^, and fl u o r i n e - 1 8 l a b e l l e d 
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o e s t r o d i o l i s used t o assess the presence of oestrogen 
receptors i n breast tumours before treatment w i t h oestrogen-
receptor b l o c k i n g drugs''^ ( 1 8 F has a h a l f l i f e of 110 min and 
i s imaged by PET). 
The most promising approach t o t a r g e t i n g so f a r has been 
through the use of t a r g e t s p e c i f i c antibodies. By t a r g e t i n g 
McAbs t o tumour s p e c i f i c antigens such as CEA (carcino-
embrionic a n t i g e n ) , AFP ( a - f e t o p r o t e i n ) , and HCG (human 
ch o r i o n i c gonadotropin), the imaging and therapy of tumours 
should be p o s s i b l e . S e l e c t i v e l o c a l i s a t i o n of an iodine-131 
l a b e l l e d anti-CEA antibody was f i r s t demonstrated f o r 
xenografts of human colonic cancer i n hamsters i n 
197373 since then, the development of monoclonal antibodies'^^ 
has l e d t o the production of high a f f i n i t y antibodies which 
can be r a i s e d against s p e c i f i c antigens. This was heralded as 
'the magic b u l l e t ' f o r the t a r g e t i n g of cancers. I 3 l j 
l a b e l l e d anti-CEA monoclonal antibodies were f i r s t use i n the 
c l i n i c i n 1981"^', but there have been problems w i t h these 
'magic b u l l e t s ' . F i r s t l y , the tumour s p e c i f i c antigens are 
r a r e l y t r u l y tumour s p e c i f i c although the tumour has higher 
concentrations of antigen than normal tissues. Secondly, the 
whole antibodies are f a i r l y l arge w i t h molecular weights of 
about 160,000. These whole antibodies can have problems 
p e n e t r a t i n g throughout a tumour mass, and have a long 
c i r c u l a t i n g h a l f l i f e i n the blood g i v i n g low tumour t o blood 
c o n t r a s t . Smaller fragments of antibodies which r e t a i n the 
antigen b i n d i n g capacity of the antibody, can penetrate 
f u r t h e r i n t o tumour masses, and have a shorter c i r c u l a t i n g 
l i f e t i m e are c u r r e n t l y being i n v e s t i g a t e d . There are also 
however, problems w i t h p a t i e n t s developing t h e i r own immune 
response t o these f o r e i g n antibodies which are made from 
animal p r o t e i n s . Humanised monoclonal antibodies are being 
developed t o help overcome t h i s immune response. (Other 
problems are t h a t the iodine l a b e l i s proving t o be unstable 
i n v i v o and t h i s dehalagonation leads t o increased r a d i a t i o n 
doses t o normal t i s s u e s and high background l e v e l s i n imaging 
s t u d i e s ) . Methods of l a b e l l i n g antibodies w i t h b i f u n c t i o n a l 
complexing agents"^^'^^ have been developed f o r use w i t h 
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radiometals such as m i n , '^^ Ga and ^ ^Y, which as w e l l as 
increasing the scope of isotopes which mdy be used, should 
also provide much more stable r a d i o l a b e l l e d monoclonal 
ant i b o d i e s . 
1.2.5. In Vivo S t a b i l i t y of Radiolabelled Pharmaceuticals. 
When t a r g e t i n g r a d i o l a b e l l e d pharmaceuticals i t i s 
important t h a t the r a d i o l a b e l stays attached t o the 
pharmaceutical which i s responsible f o r i t s t a r g e t i n g 
p r o p e r t i e s . I f the r a d i o l a b e l becomes detached, then t h i s 
leads t o a lower t a r g e t t o non-target r a t i o . This r e s u l t s i n 
increased i r r a d i a t i o n of normal t i s s u e and a less c l e a r l y 
d efined p i c t u r e i n imaging studies. 
The nature of the released radioisotope determines i t s 
f a t e . Dehalogenation of io d i n a t e d antibodies leads t o a b u i l d 
up of r a d i o a c t i v e iodine i n the t h y r o i d . But f o r antibodies 
w i t h a radiometal l a b e l i t depends on whether the metal i s 
s t i l l attached t o the l i g a n d . I f the metal-ligand i s detached 
from the antibody i n t a c t , then r a p i d renal clearance i s 
l i k e l y t o f o l l o w thus removing any r a d i o a c t i v i t y from the 
body"^^. However, i f the metal ion i t s e l f becomes dissociated 
from i t s l i g a n d , then there w i l l be problems w i t h metal ions 
concentrating i n the bone'^^'^^ and l i v e r causing r a d i a t i o n 
damage"73. For any metal-ligand used i n t a r g e t i n g , e i t h e r as a 
simple complex or attached t o a l a r g e r biomolecule such as an 
antibody, i t s success i s l a r g e l y dependent on i t s i n v i v o 
s t a b i l i t y . 
1.2.6. Factors Influencing the In Vivo StsQjility of 
llacrocyclic and Acyclic Complexes. 
Metal ions such as Ga^^ and In3+ have small i o n i c r a d i i 
(0.62 and 0.80 A) 82 and form hexadentate complexes^"^, whereas 
metal ions such as and Gd3+ have l a r g e r i o n i c r a d i i (1.02 
and 1.05 A) 82 and p r e f e r t o form octadentate complexes^'*. Of 
the ligands p i c t u r e d i n f i g u r e l . l , 9N3 and EDTA have s i x 
donor atoms f o r forming hexadentate complexes, whereas DOTA 
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and D T P A both have e i g h t donor atoms f o r forming octadentate 
complexes. Closed r i n g macrocycle ligands e x h i b i t size-match 
s e l e c t i v i t y , i . e . the most stable complexes are formed where 
the size-match between the metal i o n and the c a v i t y i n the 
l i g a n d i s closest^5, whereas the more f l e x i b l e a c y c l i c E D T A 
and D T P A can accommodate a range of ion sizes^S. 
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Although a l l the ligands i n f i g u r e l . l have high 
thermodynamic s t a b i l i t y constants i n v i t r o , the s i t u a t i o n i n 
v i v o i s very d i f f e r e n t . I n an animal these complexes 
encounter many challenging environments. Amongst these are 
ac i d c o n d i t i o n s i n the stomach, endogenous metal ions such as 
Zn2+, Ca2+, Mg2+ and Cu2+ i n the plasma84,87^ as w e l l as 
n a t u r a l ligands such as c i t r a t e , albumin and 
t r a n s f e r r i n ^ ^ , 8 8 _ These components i n p r i n c i p l e may a l l 
compete w i t h the complex f o r e i t h e r the metal i o n or the 
l i g a n d , and i n doing so c o n t r i b u t e towards d i s s o c i a t i o n of 
the complex. 
Several thermodynamic considerations can a f f e c t the 
s t a b i l i t y of these metal complexes88-90_ por example, the 
thermodynamic s t a b i l i t y constant (K^herm) i s a measure of the 
a f f i n i t y of the metal i o n and l i g a n d f o r each other87,9l_ 
However, a b e t t e r measure of s t a b i l i t y under p h y s i o l o g i c a l 
c o n d i t i o n s i s the c o n d i t i o n a l s t a b i l i t y constant (K^Qnd) 
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which takes i n t o account the pK^ values of the complex and 
hence the b a s i c i t y and extent of pro t o n a t i o n of the liga n d . 
Even so, the c o r r e l a t i o n between both these values and i n 
v i v o s t a b i l i t y of metal complexes i s poor^'^'^S, ^ more 
important c o n s i d e r a t i o n i s t h a t of t r a n s m e t a l l a t i o n . This i s 
measured by the s e l e c t i v i t y constant (Kgei) which measures 
the s e l e c t i v i t y of the l i g a n d f o r the bound metal over 
competing endogenous metal ions i n the plasma (Zn2+, Ca2+, 
Mg2+ and Cu^+)8^. 
Although a l l these thermodynamic parameters c o n t r i b u t e 
towards i n v i v o d i s s o c i a t i o n of the complex, i t i s k i n e t i c 
considerations which are the main c o n t r i b u t o r s t o i n v i v o 
s t a b i l i t y . A c y c l i c ligands such as DTPA and EDTA have high 
r a t e s of transmetallation^^,92 ^nd thermodynamic e q u i l i b r i u m 
i s reached before the complex has been excreted from the 
body. I n t h i s case a c o r r e l a t i o n holds between Kggi and i n 
v i v o s t a b i l i t y f o r a c y c l i c ligands87,82^ However, macrocyclic 
ligands such as DOTA can have poor s e l e c t i v i t y ^ " ^ f o r t h e i r 
complexed metal i o n e.g. Gd3+ over endogenous ions such as 
Zn2+, which, from thermodynamic considerations alone, would 
i n d i c a t e t h a t they would be susceptible t o t r a n s m e t a l l a t i o n . 
But t h i s i s not the case. Due t o the r i g i d conformational 
s t a b i l i t y of macrocyclic ligands the r a t e of c a t i o n promoted 
d i s s o c i a t i o n i s extremely slow so there i s enough time f o r i n 
v i v o e l i m i n a t i o n of metal macrocycle complexes t o occur 
before any d i s s o c i a t i o n takes place^^. This k i n e t i c f a c t o r 
imparts these macrocyclic complexes w i t h t h e i r high i n v i v o 
s t a b i l i t y . 
The i n v i t r o measurement which has been shown t o 
c o r r e l a t e best w i t h the a c t u a l i n v i v o s t a b i l i t y of metal-
complexes i s t h e i r a c i d catalysed d i s s o c i a t i o n r a t e 
(kobs) "^^  • Regions of low pH are encountered i n the body 
p a r t i c u l a r l y i n the stomach. Under s t r o n g l y a c i d i c conditions 
p r o t o n a t i o n of the metal-complex occurs. E l e c t r o s t a t i c 
considerations also a f f e c t the r a t e of acid or ca t i o n 
promoted d i s s o c i a t i o n . A charge n e u t r a l complex w i l l 
protonate a t a lower pH than a nega t i v e l y charged complex, 
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and should t h e r e f o r e be more r e s i s t a n t towards acid catalysed 
d i s s o c i a t i o n ^ . 
1.3. NUCLEAR MAGNETIC RESONANCE 
The basic phenomenon of NMR was discovered i n 19465^'^^ 
and gave r i s e t o NMR spectroscopy. This became a valuable 
t o o l f o r a n a l y t i c a l chemistry as w e l l as a means of studying 
the metabolism of biochemicals i n v i t r o . Magnetic resonance 
imaging (MRI) emerged i n 1980 w i t h the development of 
instriamentation capable of whole body imaging^^. This r e l i e d 
on powerful magnets capable of producing stable magnetic 
f i e l d g radients as w e l l as advances i n computing methods f o r 
tomography. 
More r e c e n t l y developments have been made i n the use of 
paramagnetic co n t r a s t agents t o expand and improve the 
dia g n o s t i c a b i l i t y of MRI. The f i r s t of these agents t o be 
developed was [Gd-DTPA]2-, which i n 1984 was shown t o 
d i s t r i b u t e i n e x t r a c e l l u l a r water and t o be excreted by the 
kidneys i n rats^"^. [Gd-DTPA] 2 "was f i r s t used c l i n i c a l l y i n 
1981 f o r l i v e r and b r a i n imaging^^-lOO^ Since then other more 
sta b l e c o n t r a s t agents^Ol have been developed, notably [Gd-
DOTA]" which i s also i n current c l i n i c a l use. At present 
there i s much i n t e r e s t i n the development of contrast agents 
which can be d i r e c t e d t o s p e c i f i c t a r g e t s e.g. the l i v e r and 
g a s t r o i n t e s t i n a l t r a c t ([Gd.BOPTA]102^ [Mh.DPDP]103^ [Gd.EOB-
DTPA]104^ [Fe.5-Br-EHPG]105 ^nd [Fe.PGDF]106)^ c a l c i f i e d s o f t 
t i s s u e (Gd-EDTMP) 107 QJ- tumours (Gd-monoclonal 
antibodies)108,109. 
The major advantages of MRI over other imaging techniques 
are t h a t i t i s non invasive, does not use i o n i s i n g r a d i a t i o n 
and i s without known hazard. 
1.3.1. Principles of Nuclear Magnetic Resonance 110-113 
A l l NMR systems measure the c h a r a c t e r i s t i c absorption and 
re-emission of quanta of energy by n u c l e i i n atoms of body 
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t i s s u e s . The nucleus which i s most o f t e n studied by magnetic 
resonance imaging (MRI) i s the hydrogen atom or proton. 
Hydrogen i s the most abundant element i n the human body. The 
proton can be studied by NMR because i t possesses a nuclear 
spin, which means t h a t i t can be considered t o behave l i k e a 
t i n y bar magnet. 
I n the absence of an ex t e r n a l magnetic f i e l d these t i n y 
magnets are p o i n t i n g i n a l l d i r e c t i o n s and there i s no 
r e s u l t a n t net magnetism. When these protons are placed i n an 
ex t e r n a l magnetic f i e l d they a l i g n themselves i n the 
d i r e c t i o n of t h a t f i e l d . For protons there are two 
o r i e n t a t i o n s which they can take. The f i r s t i s i n the 
d i r e c t i o n of the app l i e d f i e l d , and t h i s s t a t e has the lowest 
energy l e v e l . The second o r i e n t a t i o n i s at 180° t o the f i e l d 
(upside-down), and has a s l i g h t l y higher energy s t a t e . I n 
e f f e c t more protons take the lower energy o r i e n t a t i o n 
(aligned w i t h the d i r e c t i o n of the f i e l d ) than the higher 
energy o r i e n t a t i o n . This leads t o a net magnetism i n the 
d i r e c t i o n of the app l i e d magnetic f i e l d . An NMR experiment 
involves inducing t r a n s i t i o n s between these two energy states 
by the absorption and emission of quanta. 
I f an a l t e r n a t i n g f i e l d of a s p e c i f i c radiofrequency i s 
appl i e d w h i l s t the s t a t i c f i e l d also e x i s t s , the spin system 
w i l l absorb energy and the population at the higher energy 
l e v e l w i l l increase, w h i l s t t h a t of the lower l e v e l w i l l 
decrease. The app l i e d radiofrequency must be of a value 
s p e c i f i c t o the d i f f e r e n c e i n energy l e v e l s , t h i s i s c a l l e d 
the Larmor frequency. I t i s t h i s e f f e c t which i s the resonant 
process i n NMR. The d i f f e r e n c e between energy l e v e l s changes 
w i t h the environment i n which the proton i s s i t u a t e d , thus 
the Larmor frequency i s dependent on the chemical state i n 
which the proton f i n d s i t s e l f . 
When the radiofrequency pulse i s stopped, the system 
r e t u r n s t o e q u i l i b r i u m w i t h a r e s u l t a n t loss of energy. There 
are two ways i n which t h i s energy can be l o s t . F i r s t l y i t can 
be l o s t by gradual t r a n s f e r t o n u c l e i and electrons i n the 
environment (or l a t t i c e ) r e s u l t i n g i n t r a n s i t i o n of n u c l e i 
from the higher energy s t a t e t o the lower energy s t a t e . This 
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i s termed s p i n - l a t t i c e r e l a x a t i o n and i s characterised by the 
time constant T^. Secondly the energy can be r e d i s t r i b u t e d 
w i t h i n the spin system by the t r a n s i t i o n of a n u c l e i from the 
higher t o lower energy l e v e l being accompanied by the 
t r a n s i t i o n of a n u c l e i from the lower t o the higher energy 
l e v e l . This i s c a l l e d spin-spin r e l a x a t i o n and i s 






(a) At e q u i l i b r i u m the net 
magnetism (M) i s a l i g n e d 




+ R.F. t4. 
(b) A f t e r a p p l i c a t i o n of a 
radiofrequency pulse {R.F.), 
the net magnetism r o t a t e s 
at an angle about the Z a x i s 
To measure these r e l a x i v i t i e s a s t a t i c f i e l d i s applied 
i n the Z d i r e c t i o n ( f i g u r e 1.2), and a l l the protons a l i g n 
themselves w i t h t h i s f i e l d . A radiofrequency pulse i s applied 
at 90° t o the main f i e l d ( i n the XY d i r e c t i o n ) , causing the 
net magnetism t o f l i p out of the Z d i r e c t i o n and r o t a t e 
around the Z a x i s , the angle of r o t a t i o n being p r o p o r t i o n a l 
t o the d i r e c t i o n and d u r a t i o n of the applied pulse ( f i g u r e 
1.2). The r e l a x a t i o n time T^ i s a measure of how f a s t energy 
can be t r a n s f e r r e d from the spinning n u c l e i t o the l a t t i c e . 
T2 i s a measure of how long the resonant n u c l e i hold t h i s 
temporary magnetism. 
The angular precession of the magnetism around the Z axis 
w i l l generate an electromagnetic force (by Faraday's law of 
electromagnetic induction) i n a c o i l which has been wrapped 
around the sample. This gives a means of d e t e c t i o n of the 
resonant frequency, the magnitude of which depends on the 
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concentration of the n u c l e i of i n t e r e s t . I n p r a c t i c e there i s 
a range of frequencies detected as not a l l n u c l e i experience 
e x a c t l y the same magnetic f i e l d . This i s due t o the s h i e l d i n g 
e f f e c t of the chemical environment on the nucleus. By 
performing a s p e c t r a l analysis of the t o t a l induced s i g n a l , 
the s i g n a l s t r e n g t h at d i f f e r e n t frequencies can be measured. 
Then the r e l a t i v e amounts of n u c l e i of the same type but i n 
d i f f e r e n t chemical environments can be calcu l a t e d . This i s 
the basis of NMR spectroscopy and the underlying p r i n c i p l e of 
MRI. 
1.3.2. NMR Using Nuclei Other Than Protons. 
Although protons are the most abundant n u c l e i s u i t a b l e 
f o r NMR found i n b i o l o g i c a l systems, they are not the only 
ones. Any nucleus which contains an odd nuitiber of protons or 
neutrons, or both, w i l l possess spin and a magnetic 
momentHO_ Examples of such n u c l e i are ^ H, ^E, "^Li, ^^C, ^ ^N, 
1^0, 19F, 23Na, 31p^ 3 5 c l , 63cu, ^iQa and 127i_ 
I f high f i e l d strengths are employed (higher than those 
used f o r proton MRI), measurements can be made on the 
chemical s t a t e of a s p e c i f i c nucleus. For example 
measurements of ^ ^P NMR spectra can be used t o determine the 
r e l a t i v e amounts of ATP and inorganic phosphate i n v i v o m . 
110-112 1^3.3. Magnetic Resonance Imaging 
Although many n u c l e i possess the p r o p e r t i e s required f o r 
MRI, i t i s the proton which i s u t i l i s e d f o r the imaging of 
p a t i e n t s . This i s because hydrogen i s the most abundant 
element i n l i v i n g t i s s u e . I n f a c t MRI r e l i e s mostly on the 
protons of water as the body i s composed of approximately 60% 
water. 
Images are obtained by measuring the si g n a l i n t e n s i t y of 
water protons which i s a s e n s i t i v e f u n c t i o n of t h e i r T^ and 
T2 r e l a x a t i o n times. F i r s t l y a magnetic f i e l d gradient i s set 
up across the p a t i e n t , then radiofrequency pulses are applied 
at an angle t o t h i s f i e l d . Because the frequency of the 
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absorbed and emitted radiofrequency i s dependent on the 
st r e n g t h of the l o c a l magnetic f i e l d , t h i s gradient makes the 
absorption and emission frequency p o s i t i o n dependent. The 
imager i s able t o apply magnetic f i e l d gradients i n three 
d i r e c t i o n s enabling three dimensional images t o be 
constructed. Analysis of the spectrum of frequencies obtained 
i s achieved by the mathematical process of Fourier 
Transformation which provides the inf o r m a t i o n needed t o 
construct an image. 
Tissue c o n t r a s t i s provided from the di f f e r e n c e s i n 
proton T^ and T2 r e l a x a t i o n times w i t h i n d i f f e r i n g l o c a l 
environments. The easier i t i s f o r protons t o pass t h e i r 
energy t o neighbouring molecules, the more q u i c k l y they can 
r e l a x t o t h e i r o r i g i n a l s t a t e and the f a s t e r the f a l l i n the 
T i s i g n a l . Thus protons which are c l o s e l y bound t o proteins 
i n t i s s u e s such as l i v e r and muscle, have short T^ values, 
whereas protons i n f l u i d s such as u r i n e , a s c i t i c and 
cerebrospinal f l u i d have longer T^ values^^. 
For example, MRI i s able t o d i f f e r e n t i a t e between the 
grey and white matter of the b r a i n . White matter has a higher 
p r o p o r t i o n of i t s water content bound t o f a t s and large 
molecules than grey matter. This, along w i t h i t s lower water 
content, gives white matter a shorter T^ value than grey 
matterlOO. D i f f e r e n t i a t i o n can also be detected between 
normal, c y s t i c and tiomour t i s s u e i n organs such as the 
l i v e r ^ S . Cancerous t i s s u e tends t o have a lower degree of 
or g a n i s a t i o n and less water s t r u c t u r e than normal t i s s u e , 
leading t o an increase i n proton r e l a x a t i o n timesH^. Moving 
blood u s u a l l y has no detectable s i g n a l . There i s a w a i t i n g 
time between e x c i t a t i o n and emission of the radiofrequency, 
i f water molecules move out of the f i e l d during t h i s time, no 
si g n a l w i l l be detected. The a b i l i t y of MRI t o provide high 
q u a l i t y images w i t h good s o f t t i s s u e contrast and s p a t i a l 
r e s o l u t i o n enables the diagnosis of abnormalities i n many 
body p a r t s t o be made. 
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1.3.4. Paramagnetic Contrast Agents 
The co n t r a s t between tissues i n MRI i s generated by 
v a r i a t i o n s i n the r e l a x a t i o n times T^ and T2. I n some cases 
the d i f f e r e n c e s between healthy and diseased t i s s u e i s small 
or the r e l a x a t i o n times may overlap. I n these cases, an agent 
t h a t could a l t e r the r e l a x a t i o n times would increase the 
c o n t r a s t . This has lead t o the development of paramagnetic 
co n t r a s t agents t o improve the diagnostic u t i l i t y and 
p r e c i s i o n of MRl88,114. 
Paramagnetic metal ions have magnetic dip o l e moments t h a t 
are about a 1,000 times greater than t h a t of protonsH^. 
These produce lar g e l o c a l magnetic f i e l d s and so enhance the 
r e l a x a t i o n r a tes of water protons which are i n t h e i r 
v i c i n i t y . Paramagnetic agents which are l i k e l y t o be of the 
most use c l i n i c a l l y are those based on the metals gadoliniiam 
( I I I ) , manganese ( I I ) or i r o n ( I I I ) owing t o t h e i r high 
magnetic moments and long r e l a x a t i o n times^S. These metal 
ions are h i g h l y t o x i c and need t o be i n a complexed form 
before they can be used f o r MRI. As w e l l as reducing the 
t o x i c i t y , complexation a l t e r s the b i o d i s t r i b u t i o n and 
e l i m i n a t i o n route of the metal i o n . 
O r a l l y administered Fe^ "*" has been i n v e s t i g a t e d as a means 
of enhancing the g a s t r o i n t e s t i n a l t r a c t H ^ * 119, and complexes 
of Mh2+ are being developed as h e p a t o b i l i a r y contrast 
agentsl03,118,119. However, at present only complexes 
c o n t a i n i n g Gd3+ are i n general c l i n i c a l use. 
The f i r s t paramagnetic agent i n wide use was [Gd.DTPA]^-. 
The lanthanide gadolinium has 7 unpaired o u t e r - s h e l l 
e l e c t r o n s which are potent promoters of T^ and T2 
r e l a x a t i o n l 2 0 . The complex [Gd.DTPA]^- r a p i d l y d i f f u s e s i n t o 
the e x t r a c e l l u l a r i n t e r s t i t i a l spaces a f t e r intravenous 
i n j e c t i o n 9 7 , 1 2 1 . This causes enhancement of contrast w i t h i n 
t i s s u e s which have a high p r o p o r t i o n of f l u i d content (e.g. 
oedema), as w e l l as i d e n t i f y i n g any breakdown of the blood 
b r a i n b a r r i e r which occurs i n tumours such as 
g l i o b l a s t o m a l l 2 . [Gd.DTPA]^- i s almost completely eliminated 
by glomerular f i l t r a t i o n , enabling abnormalities i n kidney 
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f u n c t i o n t o be diagnosed^'*' ^ ^2 _ [Gd.DOTA] " was the second 
gadolinium complex t o come i n t o widespread c l i n i c a l use i n 
1988^22^ This complex also d i s t r i b u t e s r a p i d l y i n t o the 
e x t r a c e l l u l a r i n t e r s t i t i a l spaces, and i s eliminated by 
glomerular f i l t r a t i o n i 2 2 ^  has the added advantage of 
being less t o x i c than [Gd.DTPA]^- due t o i t s slower k i n e t i c s 
of d i s s o c i a t i o n ^ O l . 
When the r e l a x a t i o n times T^ and T2 are decreased by the 
presence of a paramagnetic agent, they have the opposite 
e f f e c t on s i g n a l i n t e n s i t y . A decrease i n T^ increases the 
s i g n a l i n t e n s i t y , whereas a decrease i n T2 decreases the 
s i g n a l i n t e n s i t y . This enables images w i t h d i f f e r e n t 
c o n t r a s t s t o be constructed depending on the pulse sequences 
employed and the type of r e l a x a t i o n time measured. 
1.3.5. Relaxivity of Gadolinium Complexes. 
The presence of the paramagnetic gadolinium complex 
decreases the r e l a x a t i o n time of the protons of water 
molecules i n the v i c i n i t y . The r e l a x i v i t y of d i f f e r e n t types 
of gadolinium complexes depends on the i n t e r a c t i o n of the 
metal i o n w i t h the water protons. Water molecules which are 
coordinated d i r e c t l y t o the metal ion v i a an oxygen are 
r e f e r r e d t o as inner sphere water. Due t o t h i s close 
p r o x i m i t y , the gadolinium has most e f f e c t on the r e l a x i v i t y 
of these inner sphere waters. There i s also a d i r e c t 
r e l a x a t i o n e f f e c t on water molecules t h a t are close i n space 
but are not d i r e c t l y bound t o the complex. These are r e f e r r e d 
t o as 'outer sphere water'. For the uncomplexed ion Gd3+, 90% 
of i t s r e l a x i v i t y e f f e c t comes from inner sphere water. 
However, i n gadolinium complexes t h i s c o n t r i b u t i o n i s much 
reduced, and the c o n t r i b u t i o n from the outer sphere water 
becomes much more important. I t i s estimated t h a t one bound, 
inner sphere water c o n t r i b u t e s about as much t o the o v e r a l l 
r e l a x i v i t y as a l l of the outer sphere waters^^'H^. 
The complexation of the Gd3+ i o n i s fundamental t o i t s 
safe use i n MRI. This complexation however displaces a number 
of coordinated water molecules, and consequently reduces the 
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e f f e c t i v e r e l a x i v i t y of the Gd3+ i o n . Gadoliniiim has a t o t a l 
c o - o r d i n a t i o n number of nine, and the number of donor atoms 
i n the l i g a n d w i l l reduce the number of bound water. The 
ligands DTPA and DOTA are octadentate, thus leaving room f o r 
one bound water^^. AS the chemical s t r u c t u r e s of the ligands 
are modified t o reduce the t o x i c i t y of the complex and a l t e r 
i t s b i o d i s t r i b u t i o n and e l i m i n a t i o n , the amount of bound 
water w i l l changel23. 
Other f a c t o r s which c o n t r i b u t e t o the o v e r a l l r e l a x i v i t y 
are the c o r r e l a t i o n times. These describe the time dependence 
of motions of the metal complex on r e l a x i v i t y l l ^ . Of s p e c i f i c 
i n t e r e s t i s the r o t a t i o n a l c o r r e l a t i o n time, which i s 
dependent on the Brownian molecular r o t a t i o n of the metal 
complex. The r o t a t i o n a l c o r r e l a t i o n time increases as a 
f u n c t i o n of molecular volume and leads t o increased 
r e l a x i v i t y l l ^ . For example, the attachment of the gadolinium 
complex t o macromolecules such as p r o t e i n s can increase the 
molecular volume and thus the r o t a t i o n a l c o r r e l a t i o n time. As 
a consequence there i s a s u b s t a n t i a l (2 t o 10 f o l d ) increase 
i n r e l a x i v i t y l 2 4 . Molecular volume can be taken i n t o account 
i n the design of gadoliniiim complexes which t a r g e t s p e c i f i c 
s i t e s . 
One approach i s t o use gadolinium complexes covalently 
bound t o monoclonal antibodiesl0 9 . problems associated w i t h 
t h i s approach are f i r s t l y the d i f f i c u l t y i n d e l i v e r i n g 
s u f f i c i e n t q u a n t i t i e s of gadolinium t o the s i t e of i n t e r e s t 
( t h i s r e quires a high s a t u r a t i o n of the antigenic s i t e s and a 
lar g e number of gadolinium atoms per antibody), and secondly 
the need f o r the antibody t o be metabolised before the 
gadolinium can be e l i m i n a t e d from the body. 
A more promising approach i s the use of a simple 
gadolinium l i g a n d complex i n combination w i t h a s p e c i f i c 
c a r r i e r mediated t r a n s p o r t system. I n t h i s case binding of 
the complex t o a c a r r i e r molecule i s noncovalent, but i s 
s t i l l accompanied by an increase i n the r o t a t i o n a l 
c o r r e l a t i o n time and r e l a x i v i t y . This can be achieved by 
modifying the gadolinium complex t o be e l i m i n a t e d from the 
body by the h e p a t o b i l i a r y route. This involves the gadolinium 
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complex b i n d i n g t o c a r r i e r molecules i n the l i v e r 
hepatocytes^^'^2^, and thus increasing the molecular volume 
and r e l a x i v i t y of the complex at t h i s s p e c i f i c s i t e . Whilst 
t a r g e t i n g the hepatocytes the complex i s also en route t o 
being e l i m i n a t e d from the body without the need of 
p r e l i m i n a r y metabolism. 
With the use of contrast agents i n MRI, the i n t e n s i t y of 
the f i n a l image i s r e l a t e d t o the amount of agent present. 
However, due t o r e l a x i v i t y considerations, t h i s i s not a 
simple r e l a t i o n s h i p as i s the case i n radioisotope imaging. 
1.3.6. Hepatobiliary Imaging Contrast agents for MRI 
H e p a t o b i l i a r y c ontrast agents are s p e c i f i c a l l y targeted 
at the l i v e r and h e p a t o b i l i a r y e x c r e t i o n pathway. This 
t a r g e t i n g r e s u l t s i n an increase i n the r e l a x i v i t y of the 
water molecules, enabling imaging of the l i v e r , b i l i a r y t r e e 
and i n t e s t i n e s . Contrast i s also seen between normal and 
malignant l i v e r t i s s u e where the f u n c t i o n of the transport 
system w i t h i n the tumour c e l l s i s d i f f e r e n t from normal. 
Hepatocytes are the c e l l s i n the l i v e r which are 
responsible f o r the production of b i l e and the e l i m i n a t i o n of 
c e r t a i n x e n o b i o t i c s from the blood i n t o the b i l e ^ ^ e ^ This 
l a t t e r f u n c t i o n i s the one u t i l i s e d by MRI contrast agents. 
The hepatocytes contain d i f f e r e n t t r a n s p o r t mechanisms f o r 
the t r a n s p o r t of organic anionic, c a t i o n i c and n e u t r a l 
compounds from the blood i n t o the b i l e i 2 6 _ -phe anion 
t r a n s p o r t system appears t o be a c t i v e , and a wide range of 
compounds are e l i m i n a t e d by t h i s route, demonstrating a low 
degree of s p e c i f i c i t y . C ertain anionic compounds have been 
shoAtfn t o compete f o r t h i s carrier^^S,127_ 
W i t h i n the l i v e r , blood plasma comes i n t o d i r e c t contact 
w i t h the hepatocytes which are capable of e x t r a c t i n g 
chemicals from the blood i n one pass through the l i v e r . This 
i s c a l l e d the f i r s t pass e f f e c t ^ ^ S -phe amount of chemical 
removed per pass i s dependent on i t s e x t r a c t i o n r a t i o . I f the 
e x t r a c t i o n r a t i o i s low, then only a small amount w i l l be 
e x t r a c t e d per pass. I f the e x t r a c t i o n r a t i o i s high and the 
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c a r r i e r system i s not saturated, then the chemical may a l l be 
ex t r a c t e d i n the f i r s t pass. However, i f there are large 
amounts of chemical and the c a r r i e r system becomes saturated, 
then the r a t e of e x t r a c t i o n of the chemical from the blood 
w i l l depend on the k i n e t i c s of the c a r r i e r systeml^^,127. 
Figure 1.3. MRI Hepatobiliary Contrast Agents. 
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The MRI contrast agents [Gd.EOB-DTPA]2-, [Gd.BOPTA]^- and 
[Fe.5-Br-EHPG]"and [Fe.PGDF]" ( f i g u r e 1.3) have a l l been 
shown t o be el i m i n a t e d from the blood t o some extent by the 
h e p a t o b i l i a r y system^28-131 These contrast agents are 
d i s t r i b u t e d throughout the e x t r a c e l l u l a r spaces and undergo 
r e n a l as w e l l as h e p a t o b i l i a r y e l i m i n a t i o n . The transport 
system w i t h i n the l i v e r u t i l i s e d by these agents i s r e f e r r e d 
t o as 'the organic anion t r a n s p o r t system'^04,128^ This 
system i s based on t r a n s p o r t p r o t e i n s such as glutathione-s-
transferase^28 w i t h i n the hepatocytes and can be i n h i b i t e d by 
bromosulphophthalein (BSP)88,106,128^ Although e x h i b i t i n g 
broad s p e c i f i c i t y , t h i s c a r r i e r system requires the substrate 
t o be, ( i ) anionic, ( i i ) have some l i p o p h i l i c i t y imparted 
from an aromatic r i n g , and ( i i i ) have some h y d r o p h i l i c s i t e s 
f o r water s o l u b i l i t y . The aromatic r i n g s are thought t o be 
important i n plasma p r o t e i n binding, which shows some 
c o r r e l a t i o n w i t h h e p a t o b i l i a r y e l i m i n a t i o n , as w e l l as f o r 
bi n d i n g t o the c a r r i e r molecule w i t h i n the hepatocytes^^'^26 
S03Na 
SOaNa 
The co n t r a s t agent [Mn.DPDP] also e x h i b i t s h e p a t o b i l i a r y 
e l i m i n a t i o n , however i t i s designed t o use a d i f f e r e n t 
t r a n s p o r t system from the three complexes mentioned 
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These four c o n t r a s t agents show varying degrees of 
h e p a t o b i l i a r y uptake. Measurements of T-l r e l a x i v i t i e s show 
increased c o n t r a s t w i t h i n the l i v e r and bilel02/104,118,131-
133. The b i n d i n g t o t r a n s p o r t p r o t e i n s increases the 
r e l a x i v i t y due t o the lengthening of the r o t a t i o n a l 
c o r r e l a t i o n times. Because of t h i s e f f e c t and the s p e c i f i c 
uptake by the hepatocytes, lower doses of contrast agents 
(10-30 /xmol/kg) can be used i n comparison t o those used f o r 
t r a d i t i o n a l abdominal imaging (100 /imol/kg) 132. i f l a r g e r 
doses of co n t r a s t agents are used, s a t u r a t i o n of the 
h e p a t o b i l i a r y t r a n s p o r t system occurs leading t o higher doses 
of c i r c u l a t i n g c o n t r a s t agent. This then leads t o competition 
by the kidneys which r e s u l t s i n a l a r g e r percentage c l e a r i n g 
r e n a l l y . 
The h e p a t o b i l i a r y contrast agents studied so f a r are 
a c y c l i c compounds. The s t a b i l i t y of these compounds i n v i v o 
would be expected t o be lower than could be obtained from the 
use of macrocyclic contrast agents. The complexes [Gd.EOB-
DTPA] 2- and [Gd.BOPTA]2- both show good h e p a t o b i l i a r y imaging 
p r o p e r t i e s but possess a double negative charge. A contrast 
29 
agent w i t h a s i n g l e negative or zero charge would possess a 
lower o s m o l a l i t y and hence should give r i s e t o less pain on 
i n j e c t i o n and a reduced tendency t o crenate red blood c e l l s 
close t o the s i t e of i n j e c t i o n . 
1.4. THE SCOPE OF THIS WORK. 
The major theme of t h i s t h e s i s i s t h a t of the i n vi v o 
s t a b i l i t y and route of e l i m i n a t i o n of metal macrocycle 
complexes. 
I n chapter 2 a series of 21 12N4 macrocyclic and 4 
a c y c l i c complexes are studied w i t h a view t o t h e i r use as 
con t r a s t agents i n MRI. The e f f e c t of both charge and 
l i p o p h i l i c i t y on the pharmacokinetics and s t a b i l i t y of these 
complexes i s assessed. Measurements of i n v i t r o acid 
d i s s o c i a t i o n r ates and p a r t i t i o n c o e f f i c i e n t s of these 
complexes are compared t o the i n v i v o s t a b i l i t i e s and routes 
of e l i m i n a t i o n . 
Chapter 3 i s concerned w i t h yttrium-90 12N4 macrocycles 
f o r the l a b e l l i n g of monoclonal antibodies f o r tumour 
therapy. I n v i t r o measurements of a c i d d i s s o c i a t i o n rates and 
as s o c i a t i o n rates of both ^Oy-macrocycles and ^Oy-macrocycle-
maleimide b i f u n c t i o n a l complexing agents are examined. The i n 
v i v o s t a b i l i t y of an ^Oy-monoclonal antibody i s assessed from 
b i o d i s t r i b u t i o n and d e t a i l e d bone studies. 
I n chapter 4 g a l l i u m and indium complexes of seven 9N3 
s u b s t i t u t e d macrocycles are examined. The e f f e c t of the 
charge and l i p o p h i l i c i t y on the i n v i v o s t a b i l i t y and route 
of e l i m i n a t i o n of the complexes i s evaluated. Galliiam and 
indium 9N3 are f u r t h e r studied as possible tumour 
l o c a l i s a t i o n agents as i s a gallium-9N3-misonidazole 
conjugate. 
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CHAPTER TWO 
GADOLINIUM MACROCYCLE COMPLEXES 
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2.1 INTRODUCTION 
2.1.1. Gadolinium Complexes as Contrast Agents for Magnetic 
Resonance Imaging 
The two major MRI contrast agents i n present c l i n i c a l use 
are [Gd.DTPA]^- and [Gd.DOTA]". Both these agents r a p i d l y 
d i s t r i b u t e e x r a c e l l u l a r l y f o l l o w i n g intravenous i n j e c t i o n , 
and are subsequently e l i m i n a t e d from the body v i a glomerular 
f i l t r a t i o n ^ . This allows f o r contrast enhancement of tissues 
w i t h a high p r o p o r t i o n of f l u i d content (e.g. oedema), and 
f o r i d e n t i f i c a t i o n of any breakdown of the blood b r a i n 
b a r r i e r 2 - 4 . The e l i m i n a t i o n of [Gd.DTPA]^- and [Gd.DOTA]" by 
the r e n a l route also allows the imaging of kidney f u n c t i o n ^ . 
There i s also much i n t e r e s t i n developing contrast agents 
f o r imaging the l i v e r / g a l l bladder/ intestine^"®. This 
imaging of the h e p a t o b i l i a r y e l i m i n a t i o n route i s achieved by 
agents which are s p e c i f i c a l l y taken up by l i v e r hepatocytes 
and e l i m i n a t e d i n t o the b i l e ( s e c t i o n 1.3.6). Contrast agents 
which are being developed f o r h e p a t o b i l i a r y imaging include 
[Gd.EOB-DTPA]2- and[Gd.BOPTA]2-. Both these agents show r a p i d 
e x t r a c e l l u l a r d i s t r i b u t i o n and considerable h e p a t o b i l i a r y 
e l i m i n a t i o n along w i t h some renal e l i m i n a t i o n ^ ' l ^ . 
Factors which may in f l u e n c e the tr a n s p o r t of a given 
metal complex by hepatocytes i n t o the b i l e are i t s charge, 
l i p o p h i l i c and h y d r o p h i l i c c h a r a c t e r i s t i c s ^ ^ ' . 
2.1.2. Toxicity of Gadolinium Complexes. 
The amount of gadolinium contrast agent administered t o a 
p a t i e n t tends t o be l a r g e , t y p i c a l l y about 10 grams, (0.1 t o 
0.2 mmol per kg). Thus i t i s of paramount importance th a t the 
t o x i c i t y of any complex i s as low as possible. T o x i c i t y can 
a r i s e from three sources, ( i ) the i n t a c t metal-ligand 
complex, ( i i ) f r e e metal, and ( i i i ) f r e e l i g a n d . LD50 values 
(the dose at which 50% of the animals would die) i n mice f o r 
met a l - l i g a n d complexes are i n the order of 5 mmol/kg f o r the 
acyclic^'12,17 gadolinium complexes [Gd.DTPA]^- and 
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[Gd. BOPTA] 2 -, and 11 mmol/kg f o r the macrocyclicl'^"^ 
gadolinium complex [Gd.DOTA]'. 
The t o x i c i t y of the i n t a c t metal-ligand complex i s 
r e l a t e d t o i t s o s m o l a l i t y . This i s of p a r t i c u l a r importance 
i n MRI as large doses of 0.1 t o 0.2 mmol/kg are 
administered^^. Due t o t h e i r charged nature the complexes 
[Gd.DTPA]2- and [Gd.DOTA]' have t o be i n j e c t e d i n s o l u t i o n 
w i t h a counter i o n , u s u a l l y NMG (N-methylglucamide) . The 
l a r g e r the number of solute p a r t i c l e s (a t o t a l of 3 f o r 
NMG2[Gd.DTPA] and 2 f o r NMG[Gd.DOTA]) the greater the 
os m o l a l i t y of the i n j e c t i o n s o l u t i o n i s . I n j e c t i o n of a 
hyperosmolar s o l u t i o n causes osmotic shock t o the p a t i e n t . 
This can lead t o crenation of the blood c e l l s , shrinkage and 
s h r i v e l l i n g due t o loss of i n t e r n a l water, as w e l l as a 
red u c t i o n i n blood pressure and e l e v a t i o n of blood 
volume-'-^' 20, 21 _ 
The data l i s t e d i n t a b l e 2.1 shows t h a t the osmolality 
values f o r these co n t r a s t agents are higher than t h a t of 
blood, whose o s m o l a l i t y i s 0.3 Osmol/kg-water22. Moreover, i t 
i s c l e a r t h a t the smaller the number of counter ions needed, 
the lower the o s m o l a l i t y of the i n j e c t i o n s o l u t i o n . Hence 
[Gd.DOTA]" w i t h a s i n g l e negative charge w i l l be less t o x i c 
than [Gd.DTPA]2- w i t h i t s double negative charge. The complex 
iGd.HP-D03A] which i s n e u t r a l i n charge, i s being developed . 
as a low o s m o l a l i t y contrast agent because of these 
considerations^^. 









Figure 2.1. Chemical Structures of Gadolinium Contrast 
Agents. 
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D i s s o c i a t i o n of gadolinium contrast agent leads t o both 
f r e e metal and fr e e l i g a n d . Uncomplexed Gd3+ has an LD50 
value of between 0.3 and 0.5 mmol/kg f o r mice^^'l'^. The free 
Gd^ """ i o n i s taken up by complexing agents which are n a t u r a l l y 
present i n the serum such as c i t r a t e , albumin and 
t r a n s f e r r i n ^ l . The Gd3+ then accumulates i n the body at such 
s i t e s as the l i v e r and bone^ causing t o x i c i t y ^ O . (Gd3+ at 
about 20 [M, has been shown t o i n h i b i t Ca+ binding t o 
mammalian sarcoplasmic r e t i c u l u m ^ l ) . Equally t o x i c are any 
fr e e ligands which have LD50 values of between 0.1 and 0.5 
mmol/kg i n mice^S. T o x i c i t y of the fre e ligands i s due t o 
t h e i r a b i l i t y t o complex n a t u r a l l y occurring e s s e n t i a l metal 
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ions from the blood, such as Zn2+, Ca2+, Mg2+ and Cu2+ , and 
the subsequent loss of these metals by e l i m i n a t i o n of the 
complex from the body23. 
2.1.3. I n Vivo S t a b i l i t y of Gadolinium Complexes. 
For a gadolinium complex t o be of use as a MRI contrast 
agent i t needs t o be k i n e t i c a l l y stable i n v i v o (section 
1.2.6). I n animals the complex w i l l encounter many 
challenging environments. Amongst these are acid conditions 
as low as pH 2 i n the stomach, endogenous metal ions such as 
Zn2+, Ca2+, Mg2+ and Cu2+ i n the plasma2l,24^ as w e l l as 
n a t u r a l ligands such as c i t r a t e , albumin and 
t r a n s f e r r i n ^ ^ ' 2 1 . These components a l l compete w i t h the 
complex f o r gadolinium i o n or l i g a n d , and so c o n t r i b u t e 
towards d i s s o c i a t i o n of the complex. 
There are several thermodynamic considerations which can 
e f f e c t the s t a b i l i t y of the gadoliniiim complex^^/20,21 _ 
However, i t i s k i n e t i c considerations (the acid catalysed 
d i s s o c i a t i o n r a t es (kQ]-,g) ) which are the most relevant 
measurements24,25_ These have been shown t o c o r r e l a t e w e l l 
w i t h i n v i v o s t a b i l i t y f o r both a c y c l i c and macrocyclic 
gadolinium complexes25. Due t o the r i g i d conformational 
s t a b i l i t y of macrocyclic ligands such as DOTA, these 
complexes are much more r e s i s t a n t t o both acid and c a t i o n 
a t t a c k than the open chain a c y c l i c ligands such as DTPA. 
The macrocyclic l i g a n d complex [Gd.DOTA]" and the a c y c l i c 
l i g a n d complex [Gd.DTPA]2- are both used i n the c l i n i c as MRI 
co n t r a s t agents. However, the k i n e t i c s t a b i l i t y of [Gd.DOTA]" 
i s c l e a r l y superior t o t h a t of [Gd.DTPA]2-, the ra t e of 
d i s s o c i a t i o n at pH 1 of [Gd.DOTA]' being 1,000 times slower^^ 
than t h a t of [Gd.DTPA]2-. 
2.1.4. The use of Radioactively Labelled Gadolinium 
Complexes. 
Although these gadolinium complexes are intended f o r use 
i n MRI, nuclear magnetic resonance s i g n a l i n t e n s i t i e s are not 
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a simple f u n c t i o n of complex concentration i n vivo^S. A 
d i r e c t and s e n s i t i v e approach i s v i a the use of ra d i o a c t i v e 
l a b e l . The isotope ^^^Gd 242 days, 7 = 97-103 KeV, X 
rays = 41-47 KeV) i s e a s i l y detected by means of i t s gamma 
r a d i a t i o n . I n t h i s series of experiments a l l of the 
gadolinium complexes are l a b e l l e d w i t h a mixture of stable 
157(3^ and r a d i o a c t i v e 1^30^. 
2.1.5. The Scope of Work i n This Chapter. 
A t o t a l of 25 gadolinium complexes were studied. The 
chemical s t r u c t u r e s of these ligands are l i s t e d i n f i g u r e s 
2.2a and 2.2b, and they can be separated i n t o the f o l l o w i n g 
nine groups:-
I . H y d r o p h i l i c anionic aza-carboxylic and aza-
phosphinic acids 
I I . L i p o p h i l i c anionic aza-phosphinic acids 
I I I . N eutral monoamide aza-phosphinic acids 
IV. Neutral monoamide aza-carboxylic acids 
V. Cationic monoamide aza-phosphinic acids 
V I . Cationic monoamide aza-carboxylic acids 
V I I . Neutral 7 co-ordinate aza-phosphinic acid 
V I I I . A c y c l i c c a r b o x y l i c acids 
IX. C i t r a t e 
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Figure 2.2a. Chemical Structures of the Ligands Used to 
CoznpJejr Gadolinium. 
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I n V i t r o Measurements 
A c i d c a t a l y s e d d i s s o c i a t i o n measurements were performed 
on t h e f o l l o w i n g e i g h t complexes and t h e n r e l a t e d t o t h e i r 
k i n e t i c s t a b i l i t y i n v i v o :-
Group I , [Gd.DOTA]- and [Gd.12N4P4Me4]", h y d r o p h i l i c 
a n i o n i c . 
Group I I , [ G d . l 2 N 4 P 4 P h 4 ] [ G d . l 2 N 4 P 4 B u 4 ] - and 
[Gd.12N4P4BZ4]', l i p o p h i l i c a n i o n i c . 
Group I I I , tGd.l2N4P3Me3NBu2], [Gd.12N4P3Me3NBz2] and 
[Gd.12N4P3Bu3NMe2], n e u t r a l . 
49 
P a r t i t i o n c o e f f i c i e n t measurements were performed as a 
means o f d e t e r m i n i n g t h e r e l a t i v e l i p o p h i l i c i t i e s o f the 
g a d o l i n i u m complexes. These measurements were th e n compared 
t o t h e animal d i s t r i b u t i o n d a t a t o determine whether any 
r e l a t i o n s h i p e x i s t s between t h e l i p o p h i l i c i t y o f t h e complex 
and i t s r o u t e o f e l i m i n a t i o n f r o m t h e mouse. P a r t i t i o n 
c o e f f i c i e n t s were de t e r m i n e d f o r e l e v e n g a d o l i n i u m 
complexes:-
Group I , [Gd.DOTA]" and [Gd.l2N4P4Me4]", h y d r o p h i l i c 
a n i o n i c . 
Group I I , [Gd.l2N4P4Ph4]-, [Gd.l2N4P4Bu4]- and 
[Gd.12N4P4BZ4]•, l i p o p h i l i c a n i o n i c . 
Group I I I , [Gd.l2N4P3Me3NBu2] , [Gd.12N4P3Me3NBz2] , 
[Gd.l2N4P3Ph3NMe2] and [Gd.12N4P3Bu3NMe2] , 
n e u t r a l . 
Group IV, [Gd.DTPA]2- and [Gd.BOPTA]2-. 
I n Vivo Experiments 
B i o d i s t r i b u t i o n s o f a l l 25 g a d o l i n i i i m complexes were 
examined i n o r d e r t o assess t h e i r s u i t a b i l i t y f o r MRI. I n the 
f i r s t s t u d y a l l 25 complexes were g i v e n t o mice a t a low dose 
o f 0.1 juraol/kg t o assess t h e i n v i v o s t a b i l i t y o f t h e 
complexes and t o e s t a b l i s h t h e p r i n c i p l e r o u t e o f e l i m i n a t i o n 
o f t h e complex f r o m t h e body ( h e p a t o b i l i a r y v s . r e n a l ) . 
F o l l o w i n g on f r o m t h i s s t u d y one complex [Gd.l2N4P4Bz4] ", 
which e x h i b i t e d p r o p e r t i e s which c o u l d make i t a f a v o u r a b l e 
agent f o r use i n h e p a t o b i l i a r y imaging by MRI, was s t u d i e d i n 
g r e a t e r d e t a i l . T h i s i n c l u d e d examining n o t o n l y i t s 
b i o d i s t r i b u t i o n over an extended t i m e p e r i o d and a t h i g h e r 
doses, b u t a l s o i t s b e h a v i o u r i n another species ( r a t s ) and 
t h e e f f e c t o f c o - a d m i n i s t r a t i o n o f t h e drug 
b r o m o s u l p h o p h t h a l e i n ( s e c t i o n 1.3.6). 
The e f f e c t o f i n c r e a s i n g t h e dose a thousand f o l d t o 100 
/imol/kg, c o r r e s p o n d i n g t o t h e l e v e l s used i n t h e c l i n i c , on 
t h e r o u t e o f e x c r e t i o n and i n v i v o s t a b i l i t y o f t h r e e 
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s e l e c t e d complexes [Gd.i2N4P4Bz4]", [Gd.l2N4P4Me4]" and 
[Gd.DTPA]2- v,as a l s o s t u d i e d . 
The O v e r a l l Aims. 
The o v e r a l l aims o f t h i s s t udy were t o determine t he 
p r i n c i p l e r o u t e o f e x c r e t i o n ( h e p a t o b i l i a r y o r r e n a l ) o f t h e 
groups o f g a d o l i n i u m complexes (page 46) and t o assess t h e i r 
i n v i v o s t a b i l i t y . I t was a l s o o f p a r t i c u l a r i n t e r e s t t o 
det e r m i n e whether any chemical p r o p e r t i e s o f t h e complexes 
( i . e . c y c l i c v s . a c y c l i c , charge, l i p o p h i l i c i t y , and a c i d 
d i s s o c i a t i o n r a t e c o n s t a n t (kQ]-,g)) c o u l d be c o r r e l a t e d w i t h 
t h e i r i n v i v o s t a b i l i t y and r o u t e o f e l i m i n a t i o n . 
The two g a d o l i n i u m complexes i n common use i n MRI, 
[Gd.DOTA]- (group I ) and [Gd.DTPA]2-(group V I I I ) , were 
i n c l u d e d i n t h i s s t u d y t o i l l u s t r a t e t h e behaviour o f 
complexes whi c h a r e known t o be c l e a r e d almost e x c l u s i v e l y by 
t h e k i d n e y s ^ . The complex [ G d . C i t r a t e ] (group I X ) , i s known 
t o be u n s t a b l e i n v i v o and has been i n c l u d e d i n o r d e r t o 
p i n p o i n t t hose t i s s u e s i n which uncomplexed gadoliniiom i s 
d e p o s i t e d . 
2.2. DISSOCIATION OF GADOLINIPM MACROCYCLE COMPLEXES 
E x p e r i m e n t a l d e t a i l s a re g i v e n i n s e c t i o n 2.6. 
D i s s o c i a t i o n measurements u s i n g HPLC r a d i o m e t r y were 
c a r r i e d o u t on t h e f o l l o w i n g e i g h t g a d o l i n i u m macrocycle 
complexes:-
Group I , [Gd.DOTA] - and [Gd.l2N4P4Me4]-, h y d r o p h i l i c 
a n i o n i c . 
Group I I , [Gd.12N4P4Ph4]-, [Gd.12N4P4BU4]" and 
[Gd.12N4P4BZ4]-, l i p o p h i l i c a n i o n i c . 
Group I I I , [Gd.l2N4P3Me3NBu2], [Gd.12N4P3Me3NBz2] and 
[Gd.l2N4P3Bu3NMe2], n e u t r a l . 
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2.2.1. Stabilities of Gadoliniiun Aza-phosphinic Acid 
Macrocycles 
The r e s u l t s g i v e n i n Table 2.2 show t h a t i n t h e pH range 
1 t o 2, a l l o f these g a d o l i n i u m aza-phosphinic a c i d 
m a c r o c y c l i c complexes are between 15 and 1,000 times more 
s t a b l e t h a n [Gd.DTPA]2- (ko]3s= l . l x lO'^ s"! a t pH 1)19. 
The most s t a b l e o f t h e new [Gd.macrocycle] compounds are 
t h e n e u t r a l compounds [Gd.12lN4P3Me3NBu2], [Gd.l2N4P3Bu3NHMe] 
and [Gd.12N4P3NBZ2]. These e x h i b i t s i m i l a r s t a b i l i t i e s t o 
[Gd.DOTA]" w i t h r e s p e c t t o a c i d c a t a l y s e d d i s s o c i a t i o n . 
Indeed [Gd.l2N4P3Me3Bu2] i s more s t a b l e t h a n [Gd.DOTA]" a t pH 
1.0, as might be expected on t h e b a s i s o f coulombic 
a t t r a c t i o n . N e u t r a l complexes sh o u l d be t h e l e a s t s e n s i t i v e 
t o a c i d c a t a l y s e d d i s s o c i a t i o n and t h e i r kQ]-,g v a l u e s a l s o 
show a l e s s steep dependence on pH t h a n do t h e a n i o n i c 
complexes ( f i g u r e 2.3). 
Of t h e n e g a t i v e l y charged [Gd.macrocycles] , [Gd.DOTA]" i s 
t h e most s t a b l e w i t h [Gd.l2N4P4Me4]" n o t f a r behind f o l l o w e d 
by [Gd.l2N4P4Bz4]-, [Gd.l2N4P4Bu4]" and l a s t l y 
[Gd.12N4P4Ph4]•. These compounds a l s o f o l l o w t h e same o r d e r 
when i t comes t o s t a b i l i t y dependence on pH ( f i g u r e 2.3). For 
[Gd.12N4P4Ph4]• t h e p l o t o f kobs shows a steep slope, 
t h i s complex h a v i n g t h e g r e a t e s t i n c r e a s e i n kQ^g w i t h 
decrease i n pH. The more l i p o p h i l i c compounds appear t o be 
more s e n s i t i v e t o a t t a c k by H+ a t low pH. 
52 
Table 2.2. Dissociation Data for Gadolinium Complexes 
Gadolini\im 
con^lex 
pH kobs/ 10-6 sec-1 







































































































1.0 1.5 2 .0 
2.3. PARTITION COEFFICIENTS OF GADOLINIUM MACROCYCLE 
COMPLEXES 
E x p e r i m e n t a l d e t a i l s a re g i v e n i n s e c t i o n 2.6.3. 
The p a r t i t i o n c o e f f i c i e n t P i s a measure o f t h e amount o f 
a compound d i s s o l v e d i n one s o l v e n t phase r e l a t i v e t o another 
s o l v e n t phase under e q u i l i b r i u m c o n d i t i o n s . 
Here, t h e p a r t i t i o n c o e f f i c i e n t s between o c t a n o l and 
water, o c t a n o l and phosphate b u f f e r e d s a l i n e , pH 7.4 (PBS), 
b u t a n o l and water, and b u t a n o l and PBS are measured as a 
means o f comparing t h e l i p o p h i l i c i t i e s o f t h e g a d o l i n i u m 
complexes. PBS was used as w e l l as water as PBS i s more 
comparable w i t h p h y s i o l o g i c a l c o n d i t i o n s i . e . b u f f e r e d a t pH 
7.4. 
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A h i g h (more p o s i t i v e ) Log P v a l u e r e l a t e s t o in c r e a s e d 
l i p o p h i l i c i t y . L i p o p h i l i c compounds a r e more l i k e l y t o be 
e l i m i n a t e d f r o m t h e body v i a t h e h e p a t o b i l i a r y r o u t e t h a n t he 
r e n a l r o u t e . Hence i t was hoped t o e s t a b l i s h a c o r r e l a t i o n 
between t h e Log P v a l u e s and t h e r o u t e o f e l i m i n a t i o n from a 
mouse t h a t had been i n j e c t e d w i t h t h e co r r e s p o n d i n g 
r a d i o l a b e l l e d complex. 
Log P v a l u e s were determined f o r e l e v e n g a d o l i n i u m 
complexes:-
Group I , [Gd.DOTA]- and [Gd.i2N4P4Me4]", h y d r o p h i l i c 
a n i o n i c . 
Group I I , [Gd.l2N4P4Ph4]-, [Gd.12N4P4Bu4]- and 
[Gd.12N4P4BZ4]-, l i p o p h i l i c a n i o n i c . 
Group I I I , [Gd.l2N4P3Me3NBu2] , [Gd.12N4P3Me3NBz2] , 
[Gd.l2N4P3Ph3NMe2] and [Gd.12N4P3Bu3NMe2] , 
n e u t r a l . 
Group IV, [Gd.DTPA]2- and [Gd.BOPTA]2-, a c y c l i c a n i o n i c . 
Teible 2.3. Gadolinium Macrocycle Partition Coefficients 
Gadoliniiim Log P 
Complex Octanol/ Octanol/ Butanol/ Butan 
water PBS water PBS 
12N4P4Me4 -4. 75 -4.47 -3.03 -3.15 
DTPA -4 .18 -4.59 -3.96 -3.87 
BOPTA -3 . 63 -3 . 79 -2.50 -2 .18 
DOTA -3 .40 -4 .16 -2.39 -3.01 
12N4P3Me3NBu2 -2 . 00 -1.91 -0.05 -0.53 
l2N4P3Me3NBz2 -1.36 -1.33 -0.13 -0.15 
12N4P4Ph4 - 1 . 54 -1.14 0 .41 0.35 
12N4P4Bu4 - 1 . 09 -1.05 0.58 0 .52 
12N4P4BZ4 -0 . 66 -0 .48 0 . 71 0.61 
12N4P3Ph3NMe2 -0.36 -0.37 0 .54 0.51 
12N4P3Bu3NHMe -0.35 -0.34 0.57 0.58 
These r e s u l t s a re shown g r a p h i c a l l y i n f i g u r e 2.4, 
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The complexes [Gd.l2N4P3Bu3NHMe] and [Gd.i2N4P3Ph3NMe2] 
have t h e h i g h e s t Log P v a l u e s w i t h [Gd.l2N4P4Bz4]', 
[Gd.12N4P4BU4]- and [Gd.12N4P4Ph4]" n e x t . These complexes a l l 
have p o s i t i v e Log P v a l u e s when measured i n b u t a n o l / w a t e r 
and butanol/PBS. 
The low Log P v a l u e f o r [Gd.B0PTA]2- can be a t t r i b u t e d t o 
i t s double n e g a t i v e charge. 
For a l l t h e complexes t h e r e i s no s i g n i f i c a n t d i f f e r e n c e 
between t h e Log P v a l u e s f o r water o r PBS, showing t h a t t h e 
b u f f e r i n g a c t i o n o f t h e PBS does n o t change Log P. Complexes 
f o l l o w t h e same p a t t e r n o f s o l u b i l i t y i n o c t a n o l and b u t a n o l . 
Log P v a l u e s a r e g e n e r a l l y h i g h e r i n b u t a n o l t h a n o c t a n o l . 
F i g u r e 2.4. Log P Values for Gadolinium Con^lexes. 
4 
Log P Values for Gafinli-niniii OnmpTexes 
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2.4. BIODISTRIBUTION STUDIES. 
2.4.1. B i o d i s t r i b u t i o n of Gd Complexes a t a Dose of 0.1 
imol/)cg. 
The aims o f t h i s s t u d y were t o determine the p r i n c i p l e 
r o u t e o f e x c r e t i o n ( h e p a t o b i l i a r y o r r e n a l ) o f a l l 25 
g a d o l i n i x i m complexes and t o assess t h e i r i n v i v o s t a b i l i t y . 
P r e s e n t a t i o n of r e s u l t s 
F i g u r e s 2.5 t o 2.11 show t h e % dose i n 5 t i s s u e s a t 5 
minutes p o s t i n j e c t i o n f o r t h e groups I t o IX. These 5 
t i s s u e s a r e b l o o d , k i d n e y s , l i v e r , g a l l b l a d d e r and g u t , 
where t h e g u t r e p r e s e n t s t h e t o t a l i n t e s t i n a l t r a c t from t he 
stomach t o t h e l a r g e i n t e s t i n e i n c l u s i v e . More p r e c i s e d a t a 
f o r i n d i v i d u a l t i s s u e s a r e shown i n s e c t i o n 2.4.1.6. Fi g u r e s 
2.12 t o 2.21 each show t h e % dose f o r each o f t h e 25 
complexes i n a s i n g l e t i s s u e . 
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to F i g u r e s i n t h i s s e c t i o n . 
Nxxmber i n Group Complex 
Fi g u r e s 
1. I [Gd.DOTA]-
2 . I [Gd.l2N4P4Me4]" 
3. I [Gd.l2N4P3Me3C]' 
4 . I I [Gd.12N4P4Ph4]" 
5. I I [Gd.12N4P4BU4]" 
6. I I [Gd.12N4P4BZ4]" 
7. I I I [Gd.12N4P3Me3NHMe] 
8. I I I [Gd. 12N4P3Me3NMe2] 
9 . I I I [Gd.12N4P3Me3NBu2] 
10. I I I [Gd.12N4P3Me3N(IBu)2] 
11. I I I [Gd.12N4P3Me3NBz2] 
12 . I I I [Gd.12N4P3Ph3NHMe] 
13. I I I [Gd.12N4P3Bu3NMe2] 
14. IV [Gd.12N4C3N(IBu)2] 
15. IV [Gd.12N4C3NMeBz] 
16. V [Gd.12N4P3Me3NH(CH2)4NH3]+ 
17. V [Gd.12N4P3BU3NH(CH2)4NH3]+ 
18. V [Gd.12N4P3BZ3NH(CH2)4NH3]+ 
19. V I [Gd.12N4C3NH(CH2)4NH3]+ 
20 . V I [Gd.12N4C3NH(CH2)2NMe3]+ 
21. V I I [Gd.12N4P3Me3Bz] 
22 . V I I I [Gd.DTPA(NHBz)2] 
23 . V I I I [Gd.DTPA]2-
24. V I I I [Gd.BOPTA]2-
25. IX [ G d . C i t r a t e ] 
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2.4.1.1. B i o d i s t r i b u t i o n Data f o r the D i f f e r e n t Groups of Gd 
Conq>lexes 
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F i g u r e 2.10. Group VI. Cationic Monoamlde Aza-carboxyllc 
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2.4.1.2. Summary of the B i o d i s t r i b u t i o n of Groups I to IX a t 
a Dose of 0.1 /unol/kg. 
Group I 
The three h y d r o p h i l i c a n i o n i c a z a - c a r b o x y l i c and aza-
phosphinic a c i d s i n group I (numbers l , 2 and 3) are excreted 
r e n a l l y . ( f i g u r e 2.5). The b i o d i s t r i b u t i o n s of 
[Gd.l2N4P4Me4] - and [Gd. l2N4P3Me3C]" (numbers 2 and 3) are 
comparable a t 5 minutes to that of [Gd.DOTA]" (number l ) 
which i s known to be excreted predominantly v i a the kidneys. 
These s i m i l a r i t i e s i n d i c a t e that r e n a l e x c r e t i o n i s the main 
route of c l e a r a n c e f o r [Gd. l2N4P4Me4] " and [Gd. i2N4P3Mfe3C] " 
I n r e s p e c t of i n v i v o s t a b i l i t y , [Gd.l2N4P3Me3C]' i s l e s s 
s t a b l e than [Gd.DOTA] - and [Gd. l2N4P4Me4]". [Gd. 12N4P3Mfe3C] " 
having an e l e v a t e d r e t e n t i o n of iSSg^j i n the blood, l i v e r and 
s k e l e t o n a t 24 hours ( f i g u r e s 2.13, 12.17 and 2.19). This i s 
a c l e a r i n d i c a t i o n of the d i s s o c i a t i o n of 153Q^ from t h i s 
complex. 
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Group I I 
T h i s group o f l i p o p h i l i c a n i o n i c aza-phosphinic a c i d s 
(niimbers 4, 5 and 6) shows p r i n c i p a l l y h e p a t o b i l i a r y 
c l e a r a n c e . T h i s i s i n d i c a t e d by t h e v e r y h i g h l e v e l s , by 5 
m i nutes p o s t i n j e c t i o n , o f complex i n t h e l i v e r , g a l l b l a d d e r 
and g u t compared w i t h l e v e l s o f t h e o t h e r 22 complexes i n 
these t i s s u e s ( f i g u r e s 2.16, 2.18 and 2.20). Most o f the dose 
p r e s e n t i n t h e g u t a t 5 minutes i s i n t h e f i r s t few 
c e n t i m e t r e s o f t h e s m a l l i n t e s t i n e i n t o which the g a l l 
b l a d d e r empties. 
From f i g u r e 2.12 i t i s c l e a r t h a t t h e group I I complexes 
a r e b e i n g c l e a r e d f r o m t h e b l o o d more q u i c k l y by the l i v e r 
t h a n t h e o t h e r complexes which c l e a r by t h e k i d n e y s . 
L e v e l s o f ^^3(3(j i n t h e b l o o d , l i v e r and s k e l e t o n a t 24 
hours a r e low and comparable t o l e v e l s w i t h [Gd.DOTA]-
i n d i c a t i n g t h a t group I I complexes are s t a b l e i n v i v o . 
The d a t a i n f i g u r e 2.6 i l l u s t r a t e t h e d i f f e r e n c e s w i t h i n 
t h e group. The complex [Gd.l2N4P4Ph4]- (number 4) has t h e 
l o w e s t dose i n t h e l i v e r and t h e h i g h e s t dose i n t h e gut a t 5 
m i n u t e s . T h i s complex a l s o has t h e h i g h e s t Log P v a l u e f o r 
l i p o p h i l i c i t y ( s e c t i o n 2.3). Thus t h e r e may be some 
c o r r e l a t i o n between Log P v a l u e s o f t h e a n i o n i c macrocycle 
complexes and t h e i r r a t e o f c l e a r a n c e t h r o u g h t h e 
h e p a t o b i l i a r y system. 
Group I I I 
W i t h i n t h i s group o f seven n e u t r a l monoamide aza-
p h o s p h i n i c a c i d complexes (niombers 7 t o 13) , two complexes 
[Gd.l2N4P3Ph3NHMe] and [Gd.i2N4P3Bu3NMe2] (numbers 12 and 
13) , were found t o behave d i f f e r e n t l y f rom t h e o t h e r f i v e 
( f i g u r e 2 . 7 ) . 
Complexes [Gd.12N4P3Me3NHMe], [Gd.12N4P3Me3NMe2] , 
[Gd.l2N4P3Me3NBu2], [Gd.12N4P3Me3N(IBu)2] and 
[Gd.12N4P3Me3NBz2] (numbers 7, 8, 9, 10 and 11), are a l l 
showing p r i m a r i l y r e n a l c l e a r a n c e . A l s o , j u d g i n g by t h e low 
63 
l e v e l s o f 153(3^ i n t h e b l o o d , l i v e r and s k e l e t o n a t 24 hours 
( f i g u r e s 2.13, 2.17 and 2.19), t h e y are s t a b l e i n v i v o . 
These complexes c o u l d be u s e f u l f o r MRI imaging i n the 
same way as [Gd.DOTA]• and [Gd.DTPA]2- are used a t pr e s e n t 
w i t h t h e added advantage t h a t t h e y are n e u t r a l complexes. 
T h i s means t h a t t h e y would have a much more f a v o u r a b l e , lower 
o s m o l a l i t y . 
The complexes [Gd.l2N4P3Ph3NHMe] and [Gd.i2N4P3Bu3NMe2] 
(numbers 12 and 13) show some c l e a r a n c e by t h e h e p a t o b i l i a r y 
r o u t e . By 5 minutes a t o t a l o f 11.7% and 8.8% dose 
r e s p e c t i v e l y were p r e s e n t i n t h e combined l i v e r , g a l l b l a d d e r 
and g u t o f mice g i v e n [Gd.l2N4P3Ph3NHMe] and 
[Gd. l2N4P3Bu3N]y[e2] . These v a l u e s compare w i t h l e s s than 6% o f 
t h e i n j e c t e d dose i n t h e c o r r e s p o n d i n g t i s s u e s o f mice g i v e n 
t h e o t h e r 5 n e u t r a l complexes. A t 24 hours a f t e r i n j e c t i o n o f 
[Gd.l2N4P3Ph3NHMe] o r [Gd. l2N4P3Bu3NMe2] t h e l e v e l o f l53G(i 
i n t h e b l o o d , l i v e r and s k e l e t o n i s about t w i c e as g r e a t as 
t h e l e v e l s i n t h e r e s t o f t h e group ( f i g u r e s 2.13, 2.17 and 
2.19) . T h i s may i n d i c a t e a degree o f d i s s o c i a t i o n b u t i s more 
l i k e l y t o r e f l e c t t h e r a t h e r slower c l e a r a n c e o f these 
n e u t r a l l i p o p h i l i c complexes f r o m t h e body. 
Group IV 
The two n e u t r a l monoamide a z a - c a r b o x y l i c a c i d s (numbers 
14 and 15, f i g u r e 2.8) show s i m i l a r t i s s u e d i s t r i b u t i o n s t o 
t h e n e u t r a l monoamide aza- p h o s p h i n i c a c i d complexes (niimbers 
7 t o 11) i n group I I I ( f i g u r e s 2.7). A g ain t h e i r i s no 
s i g n i f i c a n t r e t e n t i o n o f ^^^G6. i n t h e b l o o d , l i v e r o r 
s k e l e t o n a t 24 hours ( f i g u r e s 2.13, 2.17 and 2.19) i n d i c a t i n g 
good i n v i v o s t a b i l i t y . Both complexes show p r i m a r i l y r e n a l 
c l e a r a n c e and c o u l d prove u s e f u l i n MRI f o r t h e same reasons 
as numbers 7 t o 11 i n group I I I . 
Group V 
These c a t i o n i c monoamide aza-phosphinic a c i d s (numbers 16 
t o 18) a r e a l l showing p r i m a r i l y r e n a l c l e a r a n c e ( f i g u r e 
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2.9) . Only [Gd.12N4P3Bu3NH(CH2)4NH3]+ (number 17), shows any 
i n d i c a t i o n o f d i s s o c i a t i o n w i t h a s l i g h t l y e l e v a t e d l e v e l i n 
t h e s k e l e t o n a t 24 hours o f 0.46% dose, i n comparison t o 
<0.05% f o r [Gd.DOTA]" ( f i g u r e 2.19). Complexes 
[Gd.l2N4P3Me3NH(CH2)4NH3]+ and [Gd.12N4P3Bz3NH(CH2) 4NH3] + 
appear t o be s t a b l e i n v i v o , based upon t h e l a c k of ^^^Gd 
d e p o s i t i o n i n t h e s k e l e t o n . 
Group VI 
These two c a t i o n i c monoamide a z a - c a r b o x y l i c a c i d s 
(numbers 19 and 2 0 ) , show p r i m a r i l y r e n a l c l e a r a n c e ( f i g u r e 
2.10) and no s i g n i f i c a n t r e t e n t i o n o f 153Gd a t 24 hours i n 
t h e l i v e r o r s k e l e t o n ( f i g u r e s 2.17 and 2.19) c o n s i s t e n t w i t h 
good i n v i v o s t a b i l i t y . 
Group V I I 
T h i s n e u t r a l 7 c o - o r d i n a t e aza-phosphinic a c i d (number 
2 1 ) , i s showing p r i m a r i l y r e n a l c l e a r a n c e a t 5 minutes 
( f i g u r e 2.10). However by 24 hours i t i s obvious t h a t t h i s 
complex i s h i g h l y u n s t a b l e i n v i v o w i t h l a r g e amounts of 
153Gd r e t a i n e d i n t h e l i v e r ( 8 % dose) and s k e l e t o n (10.8% 
dose) as w e l l as e l e v a t e d l e v e l s i n b l o o d and g u t ( f i g u r e s , 
2.17, 2.19, 2.13 and 2.21). 
Group V I I I 
T h i s group o f a c y c l i c c a r b o x y l i c a c i d s ( f i g u r e 2.11) 
i n c l u d e s a n e u t r a l complex, [Gd.DTPA(NHBz)2] (number 22), an 
a n i o n i c h y d r o p h i l i c complex, [Gd.DTPA]^- (number 23 ) , and a 
l i p o p h i l i c a n i o n i c complex, [Gd.BOPTA]^- (number 2 4 ) . 
A t 5 minutes [Gd.DTPA(NHBz)2] (number 2 2 ) , shows 
p r i m a r i l y r e n a l c l e a r a n c e , b u t t h e % dose i n t h e l i v e r (6.3%) 
and g u t ( 4 . 9 % ) , i s about t w i c e t h a t found i n t h e 
c o r r e s p o n d i n g t i s s u e s o f t h e mice g i v e n s t a b l e , r e n a l l y 
c l e a r e d , n e u t r a l m a c r o c y c l i c complexes (group I I I numbers 7 
t o 11) . By 24 hours t h e amount o f r a d i o l a b e l r e m a i n i n g i n the 
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l i v e r , s k e l e t o n and g u t ( f i g u r e s 2.13, 2.17, 2.19 and 2.21) 
i s about 10 ti m e s t h a t r e m a i n i n g a f t e r t r e a t m e n t w i t h one of 
t h e s t a b l e , r e n a l l y c l e a r e d , n e u t r a l complexes (group I I I 
numbers 7 t o 1 1 ) . A l t h o u g h i t i s d i f f i c u l t t o say p r e c i s e l y 
t o what e x t e n t t h i s can be accounted f o r by some 
h e p a t o b i l i a r y c l e a r a n c e as opposed t o d i s s o c i a t i o n o f t h e 
complex, i t i s c l e a r t h a t t h e complex does d i s s o c i a t e 
s i g n i f i c a n t l y . 
The complex [Gd.DTPA]^- (number 2 3 ) , i s c l e a r i n g 
p r i m a r i l y by t h e r e n a l pathway. There i s a s l i g h t e l e v a t i o n 
i n t h e % dose i n t h e s k e l e t o n a t 24 hours, and 0.3% of t h e 
i n j e c t e d dose was found t h e r e compared t o l e s s t h a n 0.05% o f 
t h e dose f o r [Gd.DOTA]". T h i s suggests t h a t [Gd.DTPA]^- i s 
more s u s c e p t i b l e t o d i s s o c i a t i o n i n v i v o t h a n [Gd.DOTA] " i n 
accordance w i t h t h e i r r e l a t i v e r a t e s o f a c i d - c a t a l y s e d 
d i s s o c i a t i o n ( s e c t i o n 2.2). 
The l i p o p h i l i c a n i o n i c complex [Gd.BOPTA]^- (nxomber 2 4 ) , 
a l s o shows h e p a t o b i l i a r y c l e a r a n c e . I n common w i t h t h e 
b e h a v i o u r o f t h e l i p o p h i l i c macrocycle complexes i n group I I , 
[Gd.B0PTA]2- c l e a r s r a p i d l y f r o m t h e b l o o d i n t o t h e l i v e r 
(22% d o se), g a l l b l a d d e r and g u t w i t h o n l y about 5% dose i n 
t h e k i d n e y s a t 5 m i n u t e s . The r a t e o f passage t h r o u g h t h e 
h e p a t o b i l i a r y system i s n o t as f a s t as f o r t h e group I I 
l i p o p h i l i c a n i o n i c a z a-phosphinic a c i d s . T h i s c o u l d be 
r e l a t e d t o t h e double n e g a t i v e charge on [Gd.B0PTA]2- and 
t h e r e f o r e i t s l o w e r Log P v a l u e . 
By 24 hours t h e % dose/g r e t a i n e d i n t h e s k e l e t o n i s 
s l i g h t l y e l e v a t e d a t 0.22% dose compared t o <0.05% dose f o r 
[Gd.DOTA]", s u g g e s t i n g t h a t [Gd.BOPTA]^- i s l e s s s t a b l e i n 
v i v o t h a n [Gd.DOTA]". 
Group IX 
[ G d . C i t r a t e ] i s known t o be h i g h l y u n s t a b l e i n v i v o . T h i s 
can be seen f r o m t h e e l e v a t e d l e v e l s i n t h e l i v e r (22% dose) 
and s k e l e t o n (52% dose) a t 24 hours ( f i g u r e s 2.17 and 2.19). 
There a r e a l s o e l e v a t e d l e v e l s i n t h e b l o o d ( f i g u r e 2.13) 
caused by t h e d i s s o c i a t e d ^^^Gd b i n d i n g t o b l o o d p r o t e i n s 
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such as t r a n s f e r r i n , and i n t h e g u t ( f i g u r e 2.21) where 
d i s s o c i a t e d ^^^Gd i s b e i n g s l o w l y e l i m i n a t e d from t h e l i v e r . 
Other t i s s u e s 
The d i s t r i b u t i o n o f these complexes was a l s o examined i n 
v a r i o u s o t h e r t i s s u e s i . e . b r a i n , f a t , l u n g s , h e a r t muscle, 
s k e l e t a l muscle, s p l e e n , s a l i v a r y glands and s k i n . 
Of p a r t i c u l a r i n t e r e s t was whether t h e l i p o p h i l i c 
complexes were c r o s s i n g t h e b l o o d / b r a i n b a r r i e r or b e i n g 
c o n c e n t r a t e d i n t h e f a t . The s a l i v a r y glands and s k i n were 
examined t o see i f t h e r e was any e x c r e t i o n o f complexes by 
these r o u t e s . There was no evidence o f a c c u m u l a t i o n of 
l i p o p h i l i c complexes i n t h e b r a i n , f a t , s a l i v a r y glands o r 
t h e s k i n . 
Some s l i g h t i n c r e a s e s i n t h e % dose i n t h e t i s s u e s l i s t e d 
below were seen f o r [ G d . C i t r a t e ] (niomber 25) and 
[Gd.12N4P3Me3Bz] (number 2 1 ) . Both o f these complexes are 
h i g h l y u n s t a b l e and are showing h i g h b l o o d l e v e l s o f ^^^Gd 
( f i g u r e 2.13). The complex no. 23 [Gd.DTPA]^-, appears t o 
have about t w i c e t h e % dose i n t h e b r a i n and l u n g as most o f 
t h e o t h e r s t a b l e complexes measured. 
(a) % Dose i n B r a i n . 
The % dose i n t h e b r a i n a t 5 minutes was l e s s t h a n 0.15% 
f o r a l l t h e g a d o l i n i u m complexes. A f t e r 24 hours a l l t h e 
complexes had l e s s t h a n 0.002% dose i n t h e b r a i n , w i t h t h e 
e x c e p t i o n s o f numbers 21 (0.006%), 23 (0.004%) and 25 
(0 . 0 2 8 % ) . 
(b) % Dose/g Pat 
The % dose/g f a t was l e s s t h a n 1% dose/g a t 5 minutes and 
l e s s t h a n 0.005% dose/g a t 24 hours f o r a l l complexes. 
(c) % Dose Lung 
67 
The % dose i n t h e l u n g was measured f o r complexes numbers 
1, 2 ,4, 5, 6, 7, 17, 18, 21, 22, 23 and 25. There was l e s s 
t h a n 1 % dose a t 5 minutes and l e s s t h a n 0.005% dose a t 24 
hours i n t h e l u n g s w i t h t h e e x c e p t i o n s o f numbers 21, 23 and 
25 w i t h 0.06, 0.01 and 0.25% dose r e s p e c t i v e l y a t 24 hours. 
(d) % Dose/g Heart Muscle 
The % dose/g o f h e a r t muscle was measured f o r complexes 
numbers 4, 5, 6, 7, 18, 21, 22 and 25. The % dose/g was l e s s 
t h a n 1.5% a t 5 minutes and l e s s t h a n 0.002% a t 24 hours f o r 
these complexes measured except f o r number 25 (2.5% a t 5 min 
and 0.98% a t 24 h r ) . 
(e) % Dose Spleen 
For t h e complexes 1, 2, 4, 6, 7, 17 ,18, 22, 23 and 25 
t h e amount o f r a d i o l a b e l i n t h e spleen was measured. The % 
dose was l e s s t h a n 0.3% f o r these complexes a t 5 minutes, and 
l e s s t h a n 0.005% a t 24 hours except f o r numbers 23 (0.02%) 
and 25 ( 0 . 0 7 % ) . 
( f ) % Dose I n the S a l i v a r y Glands. 
The dose i n t h e s a l i v a r y g lands was measured f o r 
complexes l , 2, 4, 7, 23 and 25. A l l had doses o f l e s s t h a n 
0.6% a t 5 minutes and l e s s t h a n 0.01% a t 24 hours except 
number 25 (0.14% a t 24 h r ) . 
(g) % dose/g S k i n 
The % dose/g o f s k i n was measured f o r complexes l , 2, 4, 
7, 23 and 25. The % dose/g were l e s s t h a n 0.6% a t 5 minutes 
and l e s s t h a n 0.1% a t 24 hours except f o r number 25 (0.34% a t 
24 h r ) . 
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2.4.1.3. B i o d i s t r i b u t i o n s of 25 Gadolinium Con^lexes a t 0.1 
mol/kg. 
% Dose i n Blood 
Fig u r e 2.12. % Dose ^^^Gd in Blood at 5 Minutes. 
% Dose i n Blood a t 5 min 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
F i g u r e 2.13. % Dose ^^^Gd in Blood at 24 Hours. 
% Dose i n Blood a t 24 hours 
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% Dose i n Kidneys 
Figure 2.14. % Dose ^^^Gd in Kidneys at 5 Minutes. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
F i g u r e 2.15. % Dose ^^^Gd in Kidneys at 24 Hours. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
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% Dose i n L i v e r 
F i g u r e 2.16. % Dose ^^^Gd in Liver at 5 Minutes. 
% Dose i n L i v e r a t 5 min 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
F i g u r e 2.17. % Dose ^^^Gd in Liver at 24 Hours. 
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% Dose i n G a l l Bladder. 
Figure 2.18. % Dose ^^^Gd in Gall Bladder at 5 Minutes 
% Dose i n G a l l Bladder a t 5 min 
1 — i — I — I ' ^ i 
H 1 h™+ 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
% Dose/g i n Skeleton, 
F i g u r e 2.19. % Dose ^^^Gd in Skeleton at 24 Hours. 
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% Dose i n the Gut. 
Figure 2.20. % Dose ^^^Gd in Total Gut at 5 Minutes 
% Dose i n T o t a l Gut a t 5 min 
n 40 + 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
Figure 2.21. % Dose ^^^Gd in Total Gut at 24 Hours 
% Dose i n T o t a l Gut a t 24 hours 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
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2.4.2. Further B i o d i s t r i b u t l o n Studies on the Con^lex 
[Gd.l2N4P4Bz4]-
F u r t h e r s t u d i e s a t h i g h e r doses were c a r r i e d out w i t h 
[Gd.12N4P4BZ4]• as i t was showing p r o p e r t i e s which suggested 
t h a t i t was a c a n d i d a t e f o r h e p a t o b i l i a r y imaging by MRI. 
The p r o p e r t i e s which i n f l u e n c e d t h i s c h o i c e were :-
1. A h i g h s p e c i f i c c l e a r a n c e t h r o u g h t h e h e p a t o b i l i a r y 
system ( s e c t i o n 2.4.1). 
2. I t was t h e most s t a b l e o f t h e a n i o n i c l i p o p h i l i c 
macrocycles w i t h r e s p e c t t o a c i d c a t a l y s e d d i s s o c i a t i o n 
( s e c t i o n 2.2). 
3. I t was t h e most water s o l u b l e o f t h e a n i o n i c l i p o p h i l i c 
m acrocycles. The s o l u b i l i t y 2 7 o f H3O+[Gd.12N4P4Bz4]" i s 
40 mmol dm'3. 
4. Ease o f s y n t h e s i s and p u r i f i c a t i o n ' s . 
The b i o d i s t r i b u t i o n o f [Gd.l2N4P4Bz4]" was f i r s t l y 
s t u d i e d i n more d e t a i l over 24 hours w i t h a dose o f 0. l / i 
mol/kg. T h i s i n c l u d e d 2 and 4 hour t i m e p o i n t s . Higher doses 
o f [Gd. 12N4P4BZ4] ", 2, 70 and 100 /xmol/kg were th e n s t u d i e d 
a t 5 m i n u t e , and doses o f 2, and 100 /xmol/kg a t 24 hour t i m e 
p o i n t s . These h i g h e r doses are i n l i n e w i t h doses c u r r e n t l y 
used i n t h e c l i n i c f o r [Gd.DTPA]'-. 
The b i o d i s t r i b u t i o n o f [Gd.12N4P4Bz4]" was a l s o examined 
i n two r a t s a t 10 and 20 minutes t o see i f t h e c l e a r a n c e 
p a t t e r n was s i m i l a r i n t h e two s p e c i e s . L a s t l y t h e e f f e c t of 
t h e d r u g b r o m o s u l p h o p h t h a l e i n was examined. T h i s compound 
i n h i b i t s l i v e r u p take o f t h e complex by t h e 'organic a n i o n 
t r a n s p o r t e r ' ( s e c t i o n 1.3.6). 
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2.4.2.1. B i o d i s t r i b u t i o n of [Gd.12N4P4Bz4]" a t a Dose of 0.1 
funol/kg. 
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The d a t a shown i n f i g u r e 2.22 demonstrate t h e r a p i d 
c l e a r a n c e o f [Gd.l2N4P4Bz4]" f r o m t h e b l o o d t h r o u g h the 
h e p a t o b i l i a r y system. By 5 minutes 14.3% o f t h e dose i s i n 
t h e l i v e r , 3% i n t h e g a l l b l a d d e r and 45% i s a l r e a d y p r e s e n t 
i n t h e s m a l l i n t e s t i n e . 
By 2 hours t h e r e i s l e s s t h a n 0.005% dose l e f t i n the 
b l o o d and o n l y 0.05% dose i n t h e l i v e r . 80% o f t h e dose has 
e n t e r e d t h e i n t e s t i n e and can be seen t o have moved down t h e 
i n t e s t i n e i n t o t h e caecum and l a r g e i n t e s t i n e . 
A f t e r 4 hours some complex has been e x c r e t e d i n the 
faece s , and by 24 hours t h e m a j o r i t y o f t h e complex has l e f t 
t h e mouse w i t h o n l y v e r y s m a l l amounts r e m a i n i n g i n the 
e l i m i n a t i o n pathway. 
The r o l e o f t h e k i d n e y s i n r e n a l c l e a r a n c e i s a l s o 
e v i d e n t f r o m f i g u r e 2.22. There i s a low % c l e a r a n c e by t h i s 
r o u t e , <2.5% dose b e i n g i n t h e k i d n e y s a t 5 minutes and t h i s 
amount decreases s t e a d i l y t h e r e a f t e r . However t h e % dose i n 
t h e k i d n e y s i s n o t a measure o f t h e t o t a l dose c l e a r e d 
r e n a l l y , as even by 5 minutes some dose has passed t h r o u g h 
t h e k i d n e y s and i n t o t h e u r i n e . 
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2.4.2.2. The E f f e c t on B i o d i s t r i b u t i o n of I n c r e a s i n g Doses of 
[Gd.l2N4P4Bz4]~ 
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C l e a r d i f f e r e n c e s i n t h e b i o d i s t r i b u t i o n o f 
[Gd.12N4P4BZ4]" w i t h i n c r e a s i n g dose o f complex can be seen 5 
minutes a f t e r i n j e c t i o n o f t h e complex ( f i g u r e 2.23). T h i s 
dose dependence i s c h a r a c t e r i s e d by an i n c r e a s e i n the % dose 
i n t h e b l o o d and k i d n e y s , and by a decrease i n t h e % dose i n 
t h e g a l l b l a d d e r and s m a l l i n t e s t i n e as t h e dose of 
[Gd.12N4P4BZ4]" i s i n c r e a s e d . 
The % dose o f [Gd.l2N4P4Bz4]' p r e s e n t i n t h e l i v e r a t 5 
min u t e s i s fr o m b o t h h e p a t o b i l i a r y c l e a r a n c e and l i v e r b l o o d 
c o n t e n t . T h i s t o t a l % dose does n o t v a r y much w i t h t he dose 
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o f t h e complex, o n l y d r o p p i n g from 14% dose a t 0.1 imol/kg to 
9% dose a t 100 ^mol/kg 
The % dose i n t h e caecum and t h e l a r g e i n t e s t i n e i s l e s s 
t h a n 1 % a t a l l doses. The s l i g h t l y h i g h e r amounts i n the 70 
and 100 /xmol/kg doses can be a t t r i b u t e d t o t h e i r h i g h e r % 
dose i n t h e b l o o d . 











































A l t h o u g h t h e r e a r e o n l y v e r y s m a l l amounts of 
[Gd.12N4P4BZ4]• r e m a i n i n g i n t h e e x c r e t i o n pathways a t 24 
hours, i t i s e v i d e n t t h a t t h e l a r g e r t h e dose g i v e n t o t h e 
mouse, t h e l o n g e r i t t a k e s t o c l e a r t h e complex from t h e 
body. I n s e c t i o n 2.4.3 t h e r e t e n t i o n o f [Gd.l2N4P4Bz4] " from 
78 
t h e h i g h e s t dose o f 1 0 0 /nmol/kg i s examined a t 7 days post 
i n j e c t i o n . T h i s d a t a shows t h a t t h e v a s t m a j o r i t y o f t h e 
complex has been e l i m i n a t e d by 7 days w i t h l e s s t h a n 0 . 0 5 % of 
t h e i n j e c t e d dose r e m a i n i n g i n t h e k i d n e y s , l i v e r , g u t or 
s k e l e t o n . 
The E f f e c t of Dose I n c r e a s e s 
As t h e dose o f [ G d . 1 2 N 4 P 4 B Z 4 ] ' i s i n c r e a s e d from 0. l t o 
1 0 0 /imol/kg s a t u r a t i o n o f t h e t r a n s p o r t e r s i t e s i n the l i v e r 
appears t o be o c c u r r i n g . T h i s has t h e e f f e c t o f s l o w i n g down 
t h e r a t e o f c l e a r a n c e o f t h e complex v i a t h e h e p a t o b i l i a r y 
r o u t e . T h i s has t h e added e f f e c t o f i n c r e a s i n g the % dose 
c l e a r e d by t h e r e n a l r o u t e due t o t h e h i g h e r c i r c u l a t i n g 
l e v e l s o f complex i n t h e b l o o d . 
2.4.2.3. The B i o d i s t r i b u t i o n of [Gd.12N4P4Bz4]~ i n the Rat. 
F i g u r e 2 . 2 5 i l l u s t r a t e s t h e s i m i l a r i t y i n b i o d i s t r i b u t i o n 
o f [Gd 1 2 N 4 P 4 B Z 4 ] " i n t h e mouse and t h e r a t . The p r i m a r y 
r o u t e o f e l i m i n a t i o n o f t h e complex i s v i a t h e h e p a t o b i l i a r y 
r o u t e , and t h e % dose c l e a r e d by t h i s r o u t e i s s i m i l a r i n 
b o t h s p e c i e s . 
The r a t i s a l a r g e r animal w i t h a slower m e t a b o l i c r a t e 
t h a n t h e mouse, and appears t o c l e a r t h e complex a t a 
s l i g h t l y s lower r a t e t h a n t h e mouse ( t h e % dose i n the b l o o d 
o f t h e mice a t 5 minutes i s between t h e amount i n t h e b l o o d 
o f t h e r a t s a t 1 0 and 2 0 m i n u t e s ) . 
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2.4.2.4. The E f f e c t of Bromosulphophthalein on Hepatobiliary 
Clearance. 
F i g u r e 2.26. The Effect of BSP on the Biodlstribution of 






Blood Kidney L i v e r G a l l Small Caecuin+ 
Bladder I n t e s t i n e Large 
I n t e s t i n e 
F i g u r e 2.26 shows t h e e f f e c t o f 100 mg/kg o f 
b r o m o s u l p h o p h t h a l e i n (BSP) which was a d m i n i s t e r e d i n t r a 
v e n o u s l y t o mice 2 minutes b e f o r e i n j e c t i o n o f 100 /xmol/kg 
[Gd.12N4P4BZ4]". F i v e minutes a f t e r t h e i n j e c t i o n o f 
[Gd.12N4P4BZ4]" t h e r e i s a decrease i n t h e % dose of 
[Gd.12N4P4BZ4]" p r e s e n t i n a l l t i s s u e s i n t h e h e p a t o b i l i a r y 
c l e a r a n c e r o u t e , i . e . l i v e r , g a l l b l a d d e r and i n t e s t i n e s . As 
a consequence, t h e amount o f [Gd.l2N4P4Bz4]" i n t h e b l o o d i s 
g r e a t e r and t h e r e i s an i n c r e a s e i n t h e p r o p o r t i o n o f r e n a l 
e l i m i n a t i o n . 
BSP b l o c k s t h e r e c e p t o r s i n t h e l i v e r which are 
r e s p o n s i b l e f o r t h e t r a n s p o r t o f a n i o n i c l i p o p h i l i c 
c o m p l e x e s ^ S ' . Because t h e r a t e o f passage o f 
[Gd.12N4P4BZ4]" t h r o u g h t h e l i v e r i s slowed down by BSP, i t 
can be concluded t h a t t h e same r e c e p t o r s i n t h e l i v e r are 
r e s p o n s i b l e f o r t h e t r a n s p o r t o f [Gd.12N4P4Bz4]". 
81 
2.4.3. Comparison of the B i o d i s t r i b u t i o n of [Gd.12N4P4Bz4] ", 
[Gd.l2N4P4Me4] ' and [Gd.DTPA]2- a t High (100 /unol/kg) and Low 
(0.1 fmol/kg) Doses. 
The dose o f a t y p i c a l g a d o l i n i u m c o n t r a s t agent used i n 
c l i n i c a l MRI i s o f t h e o r d e r o f 100 fimol/kg. I n t h e p r e v i o u s 
s e c t i o n 2.4.1, t h e dose l e v e l s used were o n l y O.l /iinol/kg due 
t o t h e s m a l l amounts o f these new complexes which were 
a v a i l a b l e . 
The e f f e c t o f i n c r e a s i n g t h e dose o f [Gd.l2N4P4Bz4] " on 
t h e % c l e a r e d by t h e h e p a t o b i l i a r y and r e n a l r o u t e s was 
s t u d i e d i n s e c t i o n 2.4.2. T h i s showed t h a t t h e % dose c l e a r e d 
by t h e h e p a t o b i l i a r y r o u t e decreased w i t h i n c r e a s i n g dose o f 
[Gd.l2N4P4Bz4]'. 
I n t h i s s e c t i o n comparisons are made between the 
b i o d i s t r i b u t i o n s o f t h r e e g a d o l i n i u m complexes 
[ G d . l 2 N 4 P 4 B z 4 ] [ G d . l 2 N 4 P 4 M e 4 ] " and [Gd.DTPA]2-, a t h i g h and 
low doses (100 and 0.1 ^mol/kg). As w e l l as examining changes 
i n t h e % e l i m i n a t i o n by t h e d i f f e r e n t r o u t e s , t h e l o n g term 
r e t e n t i o n o f t h e complexes i n t h e s k e l e t o n was a l s o s t u d i e d 
t o see i f t h e r e were any changes i n t h e s t a b i l i t y o f the 
complexes a t t h e h i g h e r dose. 
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B i o d i s t r i b u t i o n s 
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[Gd.l2N4P4Bz4]• 
The d a t a shown i n f i g u r e s 2.27 and 2.28 i l l u s t r a t e t h a t 
a t 5 m i n u t e s when a h i g h e r dose o f [Gd.l2N4P4Bz4]' i s g i v e n 
(100 /imol/kg v e r s u s O.l jumol/kg) , l e s s o f t h e complex c l e a r s 
t h r o u g h t h e g u t . However t h e amount o f t h e complex i n the 
i n t e s t i n e a t 5 minutes, (12.5% dose), i s s t i l l 4 times 
g r e a t e r t h a n t h a t f o r [Gd.12N4P4Me4}" o r [Gd.DTPA]2-. 
A f t e r 5 m i n u t e s , t h e % o f t h e complex found i n t h e l i v e r 
a t a h i g h dose ( 100 jLunol/kg) i s about h a l f t h a t a t a low 
dose (0.1 /xmol/kg) . A f t e r 24 hours, f o u r times as much of t h e 
complex i s i n t h e l i v e r a t t h e h i g h dose. T h i s i s as a r e s u l t 
o f t h e l o n g e r t i m e t a k e n t o c l e a r a l a r g e r amount of complex. 
The % dose i n b o t h t h e b l o o d and t h e k i d n e y s a t 5 minutes 
i s h i g h e r f r o m t h e 100 jumol/kg dose and i s o f t h e same o r d e r 
as f o r [Gd. l2N4P4Me4] " and [Gd.DTPA] 2-. A t 24 hours t h e r e i s 
s t i l l some r e n a l c l e a r a n c e f r o m t h e h i g h dose, as the % dose 
i n t h e k i d n e y s i s about 7 times t h a t from t h e low dose. 
The % dose r e t a i n e d i n t h e s k e l e t o n f r o m t h e 100 fimol/kg 
dose (0.05%) i s about t w i c e t h a t r e t a i n e d from t h e low dose 
a t 24 hours . T h i s % dose had f u r t h e r reduced t o o n l y 0.03% 
a f t e r 7 days i n d i c a t i n g t h a t [Gd.l2N4P4Bz4]" i s a h i g h l y 
s t a b l e complex i n v i v o . 
[Gd.l2N4P4He4]' 
A t 5 minutes t h e b i o d i s t r i b u t i o n o f [Gd.12N4P4Me4] ' a t 
b o t h doses i s v e r y s i m i l a r . By 24 hours t h e r e i s about t e n 
t i m e s more %[Gd.l2N4P4Me4]' i n t h e g u t and t h r e e times more 
i n t h e l i v e r f r o m t h e 100 ^ o l / k g dose. T h i s i m p l i e s t h a t a t 
th e h i g h e r dose, s m a l l amounts o f [Gd.l2N4P4Me4]" c l e a r 
t h r o u g h t h e a l t e r n a t i v e h e p a t o b i l i a r y r o u t e . 
The % dose r e t a i n e d i n t h e s k e l e t o n a t 24 hours i s 0.07% 
f r o m t h e h i g h dose and i s about t w i c e t h a t r e t a i n e d from t h e 
low dose. By 7 days t h i s has reduced t o 0.03% dose i n d i c a t i n g 
t h a t l i k e t h e analogous m a c r o c y c l i c complex [Gd.l2N4P4Bz4] ', 
t h e complex [Gd. l2N4P4]y[e4] " i s h i g h l y s t a b l e i n v i v o . 
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[Gd.DTPA]2-
The b i o d i s t r i b u t i o n o f [Gd.DTPA]^- a t 5 minutes i s v e r y 
s i m i l a r a t b o t h doses (100 and O.l ^mol/kg). 
A t 24 hours t h e r e i s about 5 times t h e % dose i n t h e gut 
fr o m t h e h i g h dose o f [Gd.DTPA]2-.This a g a i n i n d i c a t e s t h a t 
a t a h i g h dose some complex i s passed t h r o u g h t he a l t e r n a t i v e 
e x c r e t i o n pathway as t h e p r e f e r r e d r e n a l pathway becomes 
o v e r l o a d e d . 
The amount o f r a d i o l a b e l r e t a i n e d i n t h e s k e l e t o n and 
l i v e r a t 24 hours f r o m t h e h i g h dose i s 0.11% and 0.15% o f 
t h e i n j e c t e d dose compared t o 0.30% and 0.65% r e s p e c t i v e l y 
f r o m t h e low dose o f [Gd.DTPA]^-. T h i s i n c r e a s e d % r e t e n t i o n 
i n b o t h t h e l i v e r and s k e l e t o n from t h e lower dose o f 
[Gd.DTPA]2- c o u l d be due t o i t s s u s c e p t i b i l i t y t o c a t i o n 
promoted d i s s o c i a t i o n ^ ! . A t t h e low dose o f [Gd.DTPA]^-, o . l 
fimol/k.g, t h e c o n c e n t r a t i o n o f [Gd.DTPA]^- r e l a t i v e t o t h e 
c o n c e n t r a t i o n o f c a t i o n s (e.g. Zn2+ and Cu2+) i n t h e b l o o d 
would be low, so a h i g h e r p r o p o r t i o n would d i s s o c i a t e t h a n a t 
t h e h i g h dose (100 punol/kg) where t h e r e l a t i v e c o n c e n t r a t i o n 
o f [Gd.DTPA]2- t o c a t i o n s would be h i g h . 
The amount o f ^^^G6. i n t h e s k e l e t o n a t 7 days i s 0.15% of 
th e i n j e c t e d dose. U n l i k e t h e s i t u a t i o n w i t h t h e m a c r o c y c l i c 
complexes where t h e % dose reduces over 7 days, t he % dose i n 
t h e s k e l e t o n remains c o n s t a n t ( p o s s i b l y even i n c r e a s i n g a 
l i t t l e ) . T h i s i n d i c a t e s t h a t [Gd.DTPA]^- i s l e s s s t a b l e i n 
v i v o t h a n [Gd.l2N4P4Bz4]". and [Gd.l2N4P4Me4]". 
2.5. CONCLUSIONS 
The R e l a t i o n s h i p Between Acid D i s s o c i a t i o n constants and i n 
Vivo S t a b i l i t y . 
A l l t h e g a d o l i n i u m aza-phosphinic a c i d macrocycles which 
had a c i d d i s s o c i a t i o n c o n s t a n t measurements ta k e n were shown 
t o be 15 t o 1,000 ti m e s more s t a b l e t h a n [Gd.DTPA]^- i n t h e 
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range o f pH 1 t o 2 . ( t a b l e 2.2). T h i s h i g h i n v i t r o s t a b i l i t y 
i s a l s o m i r r o r e d i n v i v o as a l l o f these complexes 
demonstrate h i g h i n v i v o s t a b i l i t y i n t h e mouse as 
demonstrated by v e r y low % doses i n t h e s k e l e t o n 24 hours 
a f t e r i n j e c t i o n ( f i g u r e 2.19). 
The R e l a t i o n s h i p Between L i p o p h i l i c i t y and Hepatobiliary 
Clearance. 
F i g u r e s 2.29 t o 2.31 are p l o t s o f t h e r e l a t i o n s h i p 
between t h e g a d o l i n i u m macrocycle Log P v a l u e s f o r 
b u t a n o l / w a t e r and [A.] % Dose i n t h e I n t e s t i n e ( f i g u r e 2.29), 
[B.] % Dose i n t h e L i v e r + g a l l b l a d d e r ( f i g u r e 2.30) and 
[ C ] % Dose i n t h e I n t e s t i n e + l i v e r + g a l l b l a d d e r , 5 
minutes a f t e r an i n j e c t i o n o f O.l /xmol/kg ( f i g u r e 2.31). 
These f i g u r e s show t h e e x t e n t o f e l i m i n a t i o n o f these 
complexes by t h e h e p a t o b i l i a r y pathway i n t h e mouse. 
The a n i o n i c g a d o l i n i u m macrocycle complexes 
([Gd.12N4P4BZ4]", [Gd.12N4P4BU4]" and [Gd.l2N4P4Ph4]") have 
p o s i t i v e b u t a n o l / w a t e r Log P v a l u e s and a l l c l e a r by the 
h e p a t o b i l i a r y r o u t e . For these complexes t h e r e i s a 
c o r r e l a t i o n between a h i g h b u t a n o l / w a t e r Log P v a l u e and a 
h i g h t o t a l amount o f complex i n t h e h e p a t o b i l i a r y pathway 
( f i g u r e 2.31). 
The complexes [Gd.12N4P3Bu3NHMe] and [Gd.l2N4P3Ph3NMe2] 
which have t h e most p o s i t i v e Log P v a l u e s i n b u t a n o l / w a t e r 
b u t a r e n e u t r a l i n charge, show some e l i m i n a t i o n by the 
h e p a t o b i l i a r y r o u t e , b u t t h i s i s much l e s s t h a n t h e a n i o n i c 
l i p o p h i l i c macrocycle complexes. 
[Gd.B0PTA]2- has a low ( n e g a t i v e ) Log P v a l u e f o r 
b u t a n o l / w a t e r , b u t shows a h i g h c o n c e n t r a t i o n i n the l i v e r + 
g a l l b l a d d e r . The e l i m i n a t i o n p i c t u r e f o r t h i s a n i o n i c 
a c y c l i c complex i s d i f f e r e n t f rom t h a t o f t h e a n i o n i c 
l i p o p h i l i c macrocycles i n t h a t a t 5 minutes a f t e r i n t r a v e n o u s 
i n j e c t i o n t h e r e i s 27% i n t h e l i v e r + g a l l b l a d d e r but o n l y 
7% i n t h e i n t e s t i n e compared w i t h 17% and 47% r e s p e c t i v e l y 
f o r [Gd.l2N4P4Bz4]-.This i n d i c a t e s t h a t [Gd.B0PTA]2- i s taken 
up by t h e l i v e r b u t i s n o t passed t h r o u g h t h e g a l l b l a d d e r 
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i n t o t h e i n t e s t i n e as q u i c k l y as t h e a n i o n i c l i p o p h i l i c 
m acrocycle complexes. 
Gadoliniiim Macrocycle Complexes Suiteible f o r use as MRI 
C ontrast Agents. 
From t h e range o f g a d o l i n i u m complexes s t u d i e d the 
f o l l o w i n g macrocycle complexes a l l have p r o p e r t i e s which make 
them p o s s i b l e new c a n d i d a t e s f o r MRI c o n t r a s t agents. The 
p r o p e r t i e s which make a g a d o l i n i u m complex s u i t a b l e f o r MRI 
c o n t r a s t are :- ( i ) r a p i d e x t r a c e l l u l a r d i s t r i b u t i o n , ( i i ) 
h i g h i n v i v o s t a b i l i t y , ( i i i ) s p e c i f i c c l e a r a n c e by the 
k i d n e y s o r l i v e r , w i t h no l o n g t e r m body r e t e n t i o n , and ( i v ) 
low charge, so as t o reduce osmotic shock. 
From group I t h e complex [Gd.l2N4P4Me4]" has p r o p e r t i e s 
v e r y s i m i l a r t o [Gd.DOTA]" which would make i t a s u i t a b l e 
e x t r a c e l l u l a r c o n t r a s t agent. 
The group I I complexes a l l e x h i b i t e d r a p i d e x t r a c e l l u l a r 
d i s t r i b u t i o n and h i g h i n v i v o s t a b i l i t y w i t h a combination of 
h e p a t o b i l i a r y and r e n a l e l i m i n a t i o n . T h i s makes them s u i t a b l e 
f o r use as g e n e r a l e x t r a c e l l u l a r and s p e c i f i c l i v e r / g a l l 
b l a d d e r / i n t e s t i n e c o n t r a s t imaging. 
Groups I I I and IV, t h e n e u t r a l aza-phosphinic and aza-
c a r b o x y l i c a c i d macrocycles, a l l show r a p i d e x t r a c e l l u l a r 
d i s t r i b u t i o n , h i g h i n v i v o s t a b i l i t y and r e n a l c l e a r a n c e . 
They a l s o have t h e added advantage o f n e u t r a l charge which 
e l i m i n a t e s t h e need f o r c o u n t e r i o n s i n t h e i n j e c t i o n 
s o l u t i o n , t h u s l o w e r i n g t h e o s m o l a l i t y o f t h e s o l u t i o n . Thus 
these two groups o f g a d o l i n i u m complexes c o u l d be l e s s t o x i c 
and hence s a f e r t o use t h a n t h e p r e s e n t c o n t r a s t agents, 
[Gd.DTPA]2 - and [Gd.DOTA]'. 
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Figure 2.29. Plot of Butanol/tfater Log P Values vs. % Dose of 
Coiqpiex i n the Intestines at 5 Minutes Post Injection 
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F i g u r e 2.30. Plot of Butanol/trater Log P Values vs. % Dose of 
Complex i n t i e Liver + Gall Bladder at 5 Minutes Post 
Injection 








Figure 2.31. Plot of Butanol/Water Log P Values vs. % Dose of 
Complex In the Intestine + Liver + Gall Bladder at 5 Minutes 
Post Injection 




Oa d e l l n l u a Complex 
S u i t a b i l i t y of Gadolinium Cc»^lexes For MRI Hepatobiliary 
Imaging 
The group I I a n i o n i c l i p o p h l i c macrocycles 
[Gd.l2N4P4Ph4]-, [Gd.l2N4P4Bu4]- and [Gd.12N4P4Bz4] " a l l have 
p r o p e r t i e s making them s u i t a b l e candidates f o r MRI 
h e p a t o b i l i a r y c o n t r a s t agents. A l l have high percentage 
c l e a r a n c e s (42-65% dose a t 5 minutes) by t h i s route, and high 
i n v i v o s t a b i l i t y as i n d i c a t e d by low percentage doses 
r e t a i n e d i n the ske l e t o n a t 24 hours ( l e s s than 0.025%) and 
low a c i d d i s s o c i a t i o n r a t e v a l u e s (24-78 x 10^ s e c ' ^ a t pH 
1) . 
[Gd.12N4P4BZ4]• was the most promising complex frcxn t h i s 
group and was stu d i e d i n f u r t h e r d e t a i l . The f a c t o r s which 
con t r i b u t e d to t h i s choice were the high h e p a t o b i l i a r y 
c l e a r a n c e , s t a b i l i t y , and water s o l u b i l i t y of [Gd.l2N4P4Bz4]" 
T h i s complex was shown to be el i m i n a t e d by the same transport 
mechanism i n l i v e r hepatocytes as BSP. Th i s transport 
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mechanism can be s a t u r a t e d a t h i g h doses of complex. High 
doses o f 100 /xmol/kg were shown t o have c l e a r e d almost 
c o m p l e t e l y f r o m t h e mouse i n 7 days, i n d i c a t i n g l o n g term 
s t a b i l i t y and s a f e t y . 
The [Gd.12N4P4BZ4]" complex i s b e i n g f u r t h e r s t u d i e d by 
Dr. I . J . Rowland a t t h e Royal Marsden H o s p i t a l by d i r e c t MRI 
measurements o f r a t s . [Gd.12N4P4Bz4]" i s showing p o t e n t i a l as 
a tumour d e t e c t i o n agent when a d m i n i s t e r e d a t doses of 100-
200 /xmol/kg, and as an agent f o r cholangiography when 
a d m i n i s t e r e d a t doses as low as O.l t o 10 ^imol/kg (when l i v e r 
t r a n s p o r t s i t e s are not s a t u r a t e d ) . 
Figure 2.32. MRI Image of the Abdomen of a Rat, 6 Hours After 
Administration of 0.2 mmol/kg [Gd. 12N4P4Bz4J '. 
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F i g u r e 2.32 shows enhancement o f t h e g u t and b l a d d e r of a 
r a t . T h i s MRI image i s a f a t suppressed FLASH image taken 6 
hours a f t e r a d m i n i s t r a t i o n o f 0.2 mmol/kg [Gd.12N4P4Bz4] ". 
F i g u r e 2.32 c o u r t e s y o f I . J . Rowland. 
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2.6. GADOLINIUM EXPERIMENTAL. 
Throughout t h e f o l l o w i n g e x p e r i m e n t a l procedures, g o l d 
l a b e l q u a l i t y chemicals and m e t a l f r e e p l a s t i c ware were used 
t o reduce any m e t a l c o n t a m i n a t i o n . The s u p p l i e r s o f apparatus 
and r e a g e n t s used, t o g e t h e r w i t h t h e p u r i t y o f reagents are 
l i s t e d i n Appendix I . G a d o l i n i u m - 1 5 3 was s u p p l i e d as 
g a d o l i n i u m c h l o r i d e i n 0.IM HCl, 0 . 5 - 5 mCi/mg G d . ( 1 8 . 5 - 1 8 5 
MBq/mg Gd), t l / 2 = 2 4 2 days, 7= 9 7 - 1 0 3 KeV, x-rays= 4 1 - 4 7 Kev. 
2.6.1. Prep a r a t i o n of Gadolini\am Macrocycle Complexes for 
B i o l o g i c a l Use 
I n t h e f o l l o w i n g p r e p a r a t i o n s t h e amount o f c a r r i e r added 
was u s u a l l y 1 0 % , b u t i n o r d e r t o achieve t h e maximum 
perce n t a g e l a b e l l i n g t h e amount o f c a r r i e r was reduced i n 
some cases. T h i s was because t h e macrocycle s o l u t i o n s 
c o n t a i n e d s m a l l amounts o f c o n t a m i n a t i n g c a t i o n s . Any 
c o n t a m i n a t i n g c a t i o n s f r o m e i t h e r t h e ^^SQ^J^ tj-ie macrocycle 
p r e p a r a t i o n o r i n any o f t h e b u f f e r s o l u t i o n s used w i l l l i m i t 
t h e f i n a l y i e l d o f [Gd.macrocycle]. Hence, th r o u g h o u t , h i g h 
p u r i t y (e.g. A l d r i c h ' g o l d l a b e l ' ) chemicals and metal f r e e 
p l a s t i c s where used. 
The 153QCJ used was 0 . 5 - 5 mCi/mg Gd, i . e . a 1 0 0 /iCi sample 
o f 1 5 3 G C I c o n t a i n e d 2 0 - 2 0 0 ng ^^"^Gd ( 0 . 1 3 - 1 . 3 /xmoles) . T h i s 
compares w i t h 0 . 5 fmoles o f macrocycle i n 2 5 0 /itl o f a 2 mM 
s o l u t i o n . U s u a l l y t h e 1 5 3 Q(^ gave good l a b e l l i n g r e s u l t s > 9 0 % 
w i t h 1 0 % added c a r r i e r , s u g g e s t i n g t h a t t h e ^^^Gd was o f the 
h i g h e r p u r i t y ( i . e . 0 . 1 3 fjxaoles/lOO /xCi) . 
B e f o r e t h e r e a c t i o n m i x t u r e was s e p a r a t e d by HPLC, 
u n r e a c t e d Gd3+ was mopped up by adding DTPA. Formation of t h e 
[Gd.DTPA]2- complex n o t o n l y p r e v e n t e d c o n t a m i n a t i o n of t h e 
HPLC column w i t h '^^^Gd.^+, b u t a l s o p r o v i d e d t h e means by 
wh i c h t h e percentage l a b e l l i n g o f [Gd.macrocycle] c o u l d be 
measured a c c u r a t e l y . A 1 0 f o l d molar excess of DTPA over 
macrocycle was s u f f i c i e n t t o complex a l l u n r e a c t e d Gd^ "*" and 
any o t h e r c a t i o n s which may have been p r e s e n t . When t e s t i n g 
v e r y s m a l l amounts e.g. l ^ 1 o f 2 mM macrocycle s o l u t i o n , a 
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50 t i m e s molar excess o f DTPA over macrocycle was used 
because o f any s m a l l a b s o l u t e amounts o f c o n t a m i n a t i n g 
c a t i o n s . I t had p r e v i o u s l y been e s t a b l i s h e d t h a t the 
macrocycles were s t a b l e w i t h r e s p e c t t o t r a n s - c o m p l e x a t i o n by 
DTPA i n t h e pH range used24. 
A l l t h e g a d o l i n i u m complexes were prepared by methods 
s i m i l a r t o those employed f o r t h e p r e p a r a t i o n o f [Gd.DOTA]' 
T h i s method i s s e t o u t below w i t h any v a r i a t i o n s used i n t h e 
o t h e r p r e p a r a t i o n s l i s t e d i n t a b l e 2.4. 
The o n l y e x c e p t i o n t o t h i s was t h e p r e p a r a t i o n of 
[ G d . C i t r a t e ] . [ G d . C i t r a t e ] was p r e p a r e d by adding l53Gdci3 t o 
a s o l u t i o n c o n t a i n i n g 1.8 mg sodium c i t r a t e and 6.8 mg NaCl 
per ml. 
P r e p a r a t i o n of [Gd.DOTA]-
250 / i l Of a s o l u t i o n c o n t a i n i n g 200 mM ammonium a c e t a t e 
pH 6.5, 2 mM DOTA, 0.2 mM GdCls (10% c a r r i e r ) + 50-150 ^Ci 
^^^Gd, was i n c u b a t e d a t 310K ( 3 7 ^ 0 f o r 30-90 minutes. 
The f o r m a t i o n o f [Gd.DOTA]" and o t h e r complexes was 
measured f i r s t l y a t 30 minutes by adding l fil o f t h e r e a c t i o n 
m i x t u r e t o 50 t i m e s molar excess o f DTPA over macrocycle( 2 
1x1 o f 100 mM DTPA) . T h i s was t h e n made up t o 100 /xl w i t h HPLC 
r u n n i n g b u f f e r (0.2 M ammonium a c e t a t e pH 6.8, 10% 
a c e t o n i t r i l e w i t h AX300 column, o r 0.15 M ammoniiim a c e t a t e pH 
6.8 w i t h Poros Q/M column) and i n c u b a t e d f o r 5 minutes. The 
p e r c e n t a g e l a b e l l i n g was t h e n analysed by HPLC an i o n 
exchange. I f t h e % o f [Gd.DOTA]" o r o f t h e o t h e r complexes 
was >90% t h e r e a c t i o n m i x t u r e was quenched w i t h DTPA. I f t h e 
l a b e l l i n g was l e s s t h a n 90% t h e r e a c t i o n m i x t u r e was 
i n c u b a t e d f o r a f u r t h e r p e r i o d a t 370c and t h e percentage 
complex f o r m a t i o n re-examined. When t h e r e was no f u r t h e r 
i n c r e a s e i n complex f o r m a t i o n t h e r e a c t i o n m i x t u r e was 
quenched by a d d i n g 10 /xl o f 500 mM DTPA (10 times molar 
excess over m a c r o c y c l e ) . T h i s m i x t u r e was t h e n separated by 
HPLC, t h e [Gd.DOTA]"(or o t h e r complex) peak b e i n g c o l l e c t e d 
m a n u a l l y (dropwise i n t o a p o l y e t h y l e n e t u b e ) . 
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For [Gd.DOTA]" t h e l a b e l l i n g e f f i c i e n c y was u s u a l l y 
g r e a t e r t h a n 98%. On an AX300 a n i o n exchange coliamn r u n a t 1 
ml/min w i t h 0.2 M ammonium a c e t a t e pH 6.8, 10% a c e t o n i t r i l e 
r u n n i n g b u f f e r , [Gd.DOTA]' e l u t e s a t 4.6 min f o l l o w e d by 
[Gd.DTPA]2- a t about 12 min. 
On a Poros Q/M a n i o n exchange column r u n a t 2 ml/min w i t h 
0.15 M ammonium a c e t a t e pH 6.8 r u n n i n g b u f f e r , [Gd.DOTA]' 
e l u t e s a t 0.9 min f o l l o w e d by [Gd.DTPA]2- a t 2 t o 3 min. 
Be f o r e any p r e p a r a t i o n was used f u r t h e r , an a l i q u o t was 
c h a l l e n g e d by DTPA and checked by HPLC t o make sure t h a t i t 
was f r e e f r o m 153Q(J l a b e l l e d contaminants and uncomplexed 
l53Gd. 
0 2 4 
minutes 
Figure 2.33 
0 4 8 12 
minutes 
Figure 2.34. 
16 2 4 
minutes 
Figure 2.35. 
F i g u r e s 2.33 t o 3.35 are t y p i c a l HPLC t r a c e s from 
g a d o l i n i i a m - l a b e l l e d macrocycles. F i g u r e 2.33 i s a 
r a d i o a c t i v i t y t r a c e o f [Gd.l2N4P4Me4]' p u r i f i e d by a Poros 
Q/M a n i o n exchange column. T h i s p r e p a r a t i o n achieved 98% 
l a b e l l i n g e f f i c i e n c y , t h e s e c t i o n o f t h e peak between t h e two 
marks was t h e f r a c t i o n c o l l e c t e d f o r animal s t u d i e s . F i g u r e 
2.34 shows [Gd.l2N4P4Me4]' p u r i f i e d on an AX300 a n i o n 
exchange colvmin, i n t h i s case 95% l a b e l l i n g was achieved, and 
t h e [Gd.DTPA]2- e l u t e d much l a t e r t h a n on t h e Poros Q/M 
column. F i g u r e 2.35 i s a r a d i o a c t i v i t y t r a c e o f a 
[Gd.12N4P4BZ4]' p r e p a r a t i o n s e p a r a t e d by a Poros Q/M a n i o n 
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exchange coliimn. The s e c t i o n between t h e two marks i s t h e 
f r a c t i o n t a k e n f o r animal s t u d i e s . 








% l a b e l l i n g 
98 
E l u t i o n 
time (min) 





KOH added to 
a d j u s t pH to 6.5 
5% c a r r i e r 








12N4P4Ph4 no c a r r i e r 98 7.3 
12N4P4BZ4 90 9.0 1.57 
(with DTPA at 3.5) 
12N4P3Me3NHMe no c a r r i e r 99 3.7 
12N4P3Me3NMe2 94 4.1 
12N4P3Me3NBu2 93 3.6 
12N4P3Me3 (IBu) 2 5% c a r r i e r 98 3.6 
12N4P3Me3NBz2 1.2% c a r r i e r 92 3.6 
12N4P3Bu3NHMe 18 hour in c u b a t i o n 95 3.8 
12N4P3Ph3NMe2 80 4.7 
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Table 2.4. Part 2. Preparation of Gadolinium Complexes. 
Gadolinium 
Con^lex 




E l u t i o n 
time (min) 
AX300 Poros Q/M 
12N4C3N(IBu)2 0.5% c a r r i e r . 97 









80 4.0 0.91 
12N4P3Bz3 pH a d j u s t e d to 6.5 80 
NH(CH2)4NH3+ 
4.0 0.95 
12N4C3 20% c a r r i e r 
NH(CH2)4NH3+ 
60 3.4 
12N4C3 2% c a r r i e r 
NH(CH2) 210163 + 
65 3.4 
12N4P3Me3Bz no c a r r i e r 65 6.9 
( d i s s o c i a t e d by 50% i n 24 hours) 
DTPA(NHBz)2 not DTPA quenched 3.7 
DTPA not DTPA quenched 14.2 2.0 
BOPTA not DTPA quenched 15.2 
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2.6.2 Gadolinium L a b e l l e d Macrocycles D i s s o c i a t i o n 
Experiments 
Prep a r a t i o n of Gadolinium L a b e l l e d Macrocycles f o r 
D i s s o c i a t i o n s . 
As h i g h a l a b e l l i n g e f f i c i e n c y as p o s s i b l e was r e q u i r e d 
f o r these d i s s o c i a t i o n measurements. To achieve t h i s t h e 
amount o f non r a d i o a c t i v e GdCl3 ( c a r r i e r ) used i n these 
p r e p a r a t i o n s v a r i e d depending on t h e p u r i t y o f t h e 
macrocycles ( i . e . freedom f r o m c o n t a m i n a t i n g c a t i o n s ) . 
[Gd.DOTA]• 
250 ^ 1 o f a s o l u t i o n c o n t a i n i n g 200 mM ammonium a c e t a t e 
pH 7, 40 mM DOTA, 30 mM GdCls (75% c a r r i e r ) + 63 /xCi l^^gd, 
was i n c u b a t e d a t 333K (60°C) f o r 30 minutes. 
The f o r m a t i o n o f [Gd.DOTA] " was measured by removing 2 [il 
o f t h e above s o l u t i o n and i n c u b a t i n g w i t h 50 times molar 
excess DTPA over macrocycle i n HPLC r u n n i n g b u f f e r (0.2 M 
ammonium a c e t a t e pH 6.8, 10% a c e t o n i t r i l e w i t h AX300 column, 
o r 0.15 M ammonium a c e t a t e pH 6.8 w i t h Poros Q/M column) f o r 
5 mi n u t e s . T h i s was t h e n analysed by HPLC a n i o n exchange t o 
det e r m i n e t h e percentage o f ^ -^^ Gd i n t h e [Gd.DOTA] " and 
[Gd.DTPA]" peaks by r a d i o m e t r y ( s e c t i o n 2.6.1). 
[Gd.l2N4P4Me4]~ 
250 jul o f a s o l u t i o n c o n t a i n i n g 200 mM ammonium a c e t a t e 
pH 7, 25 mM 12N4P4, 88 fiCi ^ ^^Gd (no c a r r i e r ) and KOH t o 
a d j u s t t o pH 7 was i n c u b a t e d a t 333K (60°C) f o r 2.5 hours. 




250 IJ.1 o f a s o l u t i o n c o n t a i n i n g 200ITIM ammonium a c e t a t e pH 
6.5, 40 mM 12N4P4BU4, 4 mM GdCls (10% c a r r i e r ) + 6 5 /iCi ^ ^^Gd 
was i n c u b a t e d a t 333K (60Oc) o v e r n i g h t . 
The f o r m a t i o n o f [Gd.l2N4P4Bu4]" was t e s t e d as f o r 
[Gd.DOTA]-
[6d.l2N4P4Ph4] -
The p r e p a r a t i o n was t h e same as f o r [Gd.l2N4P4Bu4]". 
[Gd.l2N4P4Bz4]~ 
The p r e p a r a t i o n was t h e same as f o r [Gd.l2N4P4Bu4]" w i t h 
KOH h a v i n g been added t o a d j u s t t h e pH t o 7. 
[Gd.12N4P3He3NBz2] 
The p r e p a r a t i o n was t h e same as f o r [Gd.l2N4P4Bu4] " 
except o n l y 0.4 mM ( 1 % c a r r i e r ) was added. 
[Gd.l2N4P3Me3Bu2] 
The p r e p a r a t i o n was t h e same as f o r [Gd.12N4P4Bu4]". 
[Gd.12N4P3Bu3NHMel 
The p r e p a r a t i o n was t h e same as f o r [Gd.l2N4P4Bu4]". 
B u f f e r s f o r D i s s o c i a t i o n Measurements 
A s o l u t i o n o f g l y c i n e ( O . l mol dm"3) was a d j u s t e d t o pH 
1.0, 1.3, 1.5 and 2.0 w i t h HCl. The pH (+/- 0.1 u n i t s ) was 
measured by a H o r i b a pH meter on each d i s s o c i a t i o n . The same 
b u f f e r s were used t h r o u g h o u t . 
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D i s s o c i a t i o n Measurements 
An a l i q u o t o f a s t o c k s o l u t i o n o f [Gd.macrocycle] was 
added t o l.O o r 1.5 mis o f b u f f e r ( a t 310K ( 3 7 ^ 0 ) ) t o g i v e a 
f i n a l c o n c e n t r a t i o n o f 2 mM [Gd.macrocycle], (except 
[Gd.l2N4P4]" which was 1.27 mM). These were i n c u b a t e d a t 310K 
(37OC) . 
Three 35 /xl samples were removed a t each time p o i n t and 
added t o a m i x t u r e o f 7 fxl, 500 rrtM DTPA (50 times molar 
excess over macrocycle) and 59 /xl o f HPLC r u n n i n g b u f f e r (0.2 
M ammonium a c e t a t e pH 6.8, 10% a c e t o n i t r i l e w i t h AX300 
column, o r 0.15 M ammonium a c e t a t e pH 6.8 w i t h Poros Q/M 
column) t o make up t o 100 fil t o t a l volume. The m i x t u r e s were 
v o r t e x e d , c e n t r i f u g e d and t h e n f r o z e n a t 253K (-20°C) 
im m e d i a t e l y , o r r u n on t h e HPLC w i t h i n 5-20 minutes. 
S i m i l a r l y , samples were r u n on t h e HPLC w i t h i n 5-20 minutes 
o f d e f r o s t i n g . 
R a d i o m e t r i c HPLC a n a l y s i s o f [Gd.DOTA]- and [Gd.l2N4P4]-
was c a r r i e d o u t u s i n g an AX300 a n i o n exchange coliomn. A Poros 
Q/M a n i o n exchange column was used f o r a n a l y s i s o f t h e r e s t 
o f t h e g a d o l i n i u m complexes. 
C a l c u l a t i o n of ICQ^Q, 
The r a t e o f d i s s o c i a t i o n was c a l c u l a t e d by f i r s t 
m easuring t h e r e l a t i v e amounts o f complexed [Gd.macrocycle] 
and unbound Gd^ "*". Each sample t a k e n had a 50 times molar 
excess o f DTPA added t o scavenge any unbound Gd^ "*". The 
[Gd.macrocycle] and [Gd.DTPA]2- were t h e n separated by HPLC 
r a d i o m e t r y , t h e r e l a t i v e amounts o f each species b e i n g g i v e n 
by t h e areas o f t h e c o r r e s p o n d i n g peaks. 
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A t y p i c a l d a t a s e t i s g i v e n below f o r 
[Gd. 12N4P3Me3NBu2] : -
Time % [Gd. 12N4P3Me3NBu2] 
hours Run 1 Run 2 Run 3 Average 
0 89 . 05 89.35 89.30 89 .23 
1 87.32 87.44 87.37 87.38 
3 85.55 85. 70 85.84 85.70 
6.67 83.55 83.63 83.68 83 .55 
24 73.96 74 .44 74 .96 74.42 
30 71. 87 71. 85 72.18 71.97 
48 66.23 66.38 66.95 66.52 
72.86 59 . 80 59 . 68 59 . 71 59 . 73 
143.67 44 .12 44.55 44 .43 44.37 
168 40 . 04 40.70 40.46 40 .40 
192 37 . 04 36.80 37.08 36.97 
216 33 .48 33.52 33.38 33.46 
336 18.09 18 .14 17.91 18.05 
The observed r a t e o f d i s s o c i a t i o n (kQ]-,g) was c a l c u l a t e d 
f r o m t h e sl o p e o f a p l o t o f Log C^/Co v s . t i m e (seconds) 
[ p l o t s 1-8] , where CQ i s t h e c o n c e n t r a t i o n o f [Gd.macrocycle] 
a t t i m e zero and i s t h e c o n c e n t r a t i o n a t a g i v e n time 
p o i n t . 
Ct/Co was c a l c u l a t e d f r o m % [Gd.macrocycle] a t time t 
d i v i d e d by % [Gd.macrocycle] a t t = 0 . 
kobs = s l o p e X -2.303 
Assuming a f i r s t - o r d e r dependence on t h e g a d o l i n i u m 
complex, t h e h a l f l i f e o f t h e [Gd.macrocycle] i s g i v e n by:-
t l / 2 = 0.693/koj5s 
A summary o f a l l t h e g a d o l i n i u m macrocycle d i s s o c i a t i o n 
d a t a i s g i v e n i n t a b l e 2.5. F i g u r e s 2.36 t o 2.43 are t h e 
p l o t s f o r each macrocycle. The slopes were determined by 
l i n e a r r e g r e s s i o n a n a l y s i s . 
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Table 2.5. Summary of Gadolinium Dissociation Data. 
Gadolinium 
Complex 
pH Slope of 
-Log Ct/Co 





% SE Half 
l i f e 
hours 
DOTA 1 .0 1.39E-06 1 .26E-08 0 999 3.16 0 91 60.2 
1 .3 7.51E-07 6 .&3E-09 0 999 1.73 0 91 111 
1 .5 3.90E-07 1 .83E-09 1 000 0.898 1 47 214 
2 .0 2.13E-08 2 .06E-09 0 883 0.0490 9 68 3930 
12N4P4Me4 1 .0 4.52E-06 4 .43E-08 0 999 10.4 0 98 18.5 
1 .3 3.20E-06 3 .07E-08 0 999 7.37 0 96 26.1 
1 .5 3.01E-06 1 .28E-08 1 000 4.63 0 64 41.6 
2 .0 4.90E-07 1 .18E-08 0 996 1.13 2 41 171 
12N4P4Ph4 1 .0 3 .37E-05 2 .69E-07 1 000 77.6 0 80 2 .48 
1 .5 1.58E-05 1 .19E-07 1 000 36.4 0 75 5.29 
2 .0 6.38E-06 8 .88E-08 0 998 14 .7 1 39 13.1 
12N4P4BU4 1 .0 1.60E-05 2 .61E-07 0 998 36.9 1 63 5.22 
1 .5 8.72E-06 1 .17E-07 0 999 20.1 1 34 9 .59 
2 .0 3.07E-06 4 .22E-08 0 999 7.08 1 37 27.2 
12N4P4BZ4 1 .0 1.04E-05 9 .54E-07 0 937 23 .9 9 19 8.06 
1 .5 3.97E-06 3 .87E-07 0 917 9.14 9 52 21.1 
2 .0 1.22E-06 6 .16E-08 0 977 2 .81 5 05 68.5 
12N4P3Me3NBu2 1 .0 5.48E-07 1 .03E-08 0 996 1.26 1 88 152 
1 .5 2.15E-07 1 .02E-08 0 980 0.494 4 75 389 
2 .0 8.86E-08 6 .74E-09 0 956 0.204 7 61 943 
12N4P3Me3NBz2 1 .0 1.86E-06 3 .65E-08 0 995 4 .28 1 96 44 .9 
1 .5 7.10E-07 3 .97E-08 0 967 1.64 5 59 118 
2 .0 4.35E-07 2 .53E-08 0 973 1.00 5 81 192 
12N4P3Bu3NHMe 1 .0 1.80E-09 4 .OlE-08 0 996 4.14 2 23 46.5 
1 .5 6.59E-07 1 .64E-08 0 994 1.52 2 49 127 
2 .0 1.96E-07 8 .68E-09 0 954 0.451 4 43 427 
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Figure 2.36. 
D i s s o c i a t i o n of [Gd.DOTA]- a t 310K 
F i g u r e 2.37. 
400000 800000 1200000 1600000 2000000 
pH 2.0 
Time sec 
D i s s o c i a t i o n of [Gd.12N4P4Me4]- a t 310K 
Log 
Ct/Co 











200000 400000 600000 800000 1000000 1200000 1400000 
H 1 1 1 1 1 1 














pH 2. 0 




D i s s o c i a t i o n of [Gd.12N4P4Bu4] - at 310K 
20000 40000 60000 80000 100000 
0. 00 
-0.20 + pH 2. 0 
0.40 
0. 60 
Ct/Co -0. 80 
-1. 00 











50000 100000 150000 200000 250000 300000 
H 1 -0.00 
0.20 
H 2. 0 
0. 40 
0 . 60 
pH 1.5 
pH 1. 0 
Figure 2.41. 
Time sec 
D i s s o c i a t i o n of [Gd.12N4P3Me3NBu2] at 
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2.6.3 P a r t i t i o n C o e f f i c i e n t s of Gadolinixjm Complexes 
The g a d o l i n i u m macrocycle complexes were prepared as 
d e s c r i b e d i n s e c t i o n 2.6.1. 





A l l s o l v e n t s were s a t u r a t e d w i t h t h e i r p a r t n e r (e.g. 
o c t a n o l was s a t u r a t e d w i t h water, and water was s a t u r a t e d 
w i t h o c t a n o l f o r ( 1 ) . Dulbeccos A pH 7.3 phosphate b u f f e r e d 
s a l i n e (PBS) was used. 
For each o f t h e above m i x t u r e s , 3 d i f f e r e n t volume r a t i o s 
were s e t up. 
A. 0.50 ml/0.50 ml 
B. 0.75 ml/0.25 ml 
C. 0.25 ml/0.75 ml 
To each o f these 12 m i x t u r e s , 5 o r 10 ^ 1 o f r a d i o l a b e l l e d 
g a d o l i n i u m macrocycle i n 0.15 M ammonium a c e t a t e pH 6.8, was 
added. These were shaken f o r l hour on a v e r t i c a l t u r n t a b l e , 
t h e n c e n t r i f u g e d f o r 2 rain t o separate t h e phases. D u p l i c a t e 
samples (100 ^ 1) were t a k e n f r o m each phase o f each tube. 
These samples were t h e n counted f o r r a d i o a c t i v i t y u s i n g an 
LKB compugamma. 
C a l c u l a t i o n of Log P va l u e s 
The r a t i o o f t h e cpm i n t h e s o l v e n t phase t o t h e cpm i n 
water was used t o c a l c u l a t e t h e P v a l u e s 
P= cpm i n 100 fil O c t a n o l o r B u t a n o l 
cpm i n 100 /xl Water o r PBS 
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T h i s c a l c u l a t i o n i s t h e same f o r each volume r a t i o i . e . 
1:1, 3:1, o r 1:3. 
A t y p i c a l d a t a s e t i s g i v e n below f o r [Gd.l2N4P4Bz4] • 
P Log P E Log p 
Octanol/Water 0 .20 -0.70 Octanol/PBS 0. 32 -0 . 50 
0.5 ml/0.5 ml 0 .23 -0.64 0.5 ml/0.5 ml 0 . 35 -0. 45 
Octanol/Water 0 .22 -0.65 Octanol/PBS 0. 31 -0. 51 
0.75 ml/0.25 ml 0 .25 -0.61 0.75 ml/0.25 ml 0 . 32 -0 . 49 
Octanol/Water 0 .20 -0.70 Octanol/PBS 0 . 34 -0 . 46 
0.25 ml/0.75 ml 0 .21 -0.68 0.25 ml/0.75 ml 0. 36 -0. 44 
Average 0 .22 -0 . 66 Average 0. 33 -0. 48 
SD 0 . 02 0. 04 SD 0. 02 0. 03 
P Log P P Log p 
Butanol/Water 4 .99 0.70 Butanol/PBS 4 . 20 0. 62 
0.5 ml/0.5 ml 4 . 77 0 . 68 0.5 ml/0.5 ml 4 . 44 0 . 65 
Butanol/Water 3 .23 0 . 51 Butanol/PBS 2. 19 0. 34 
0.75 ml/0.25 ml 3 .51 0.55 0.75 ml/0.25 ml 2 . 26 0 . 35 
Butanol/Water 8 .23 0.92 Butanol/PBS 7 . 40 0. 87 
0.25 ml/0.75 ml 8 . 71 0.94 0.25 ml/0.75 ml 7 . 07 0 . 85 
Average 5 .57 0.71 Average 4 . 60 0 . 61 
SD 2 .35 0.18 SD 2. 26 0. 23 
Table 2.6. Summary of Gadolinium Macrocycle Partition 
Coefficient Data. 
Gadolinium Octanol\Water Octanol\PBS Butanol\Water Butanol\PBS 
Complex LOG P SD LOG P SD LOG P SD LOG P SD 
12N4P4Me4 -4. 75 0.55 -4 47 0. 77 -3 .03 0. 03 -3 .15 0. 06 
DTPA -4. 18 0.56 -4 59 0.34 -3 .96 0. 43 -3 .87 0. 49 
BOPTA -3. 63 0.36 -3. 79 0.57 -2 .50 0. 08 -2 .18 0. 03 
DOTA -3 . 40 0.26 -4. 16 0. 73 -2 .39 0.18 -3 .01 0. 04 
12N4P3Me3NBu2 -2. 00 0.38 -1. 91 0. 05 -0 .50 0. 01 -0 .53 0. 01 
12N4P3Me3NBz2 -1. 36 0. 03 -1. 33 0. 04 -0 .13 0. 04 -0 .15 0. 04 
12N4P4Ph4 -1. 54 0.15 -1. 14 0. 02 0. 41 0. 01 0. 35 0. 01 
12N4P4Bu4 -1. 09 0. 05 -1 05 0. 04 0. 58 0.17 0. 52 0.20 
12N4P4Bz4 -0. 66 0. 04 -0. 48 0. 03 0. 71 0.18 0. 61 0.23 
12N4P3Ph3NMe2 -0. 36 0. 03 -0 37 0. 02 0. 54 0. 02 0. 51 0. 02 
12N4P3Bu3NHMe -0. 35 0. 04 -0. 34 0. 03 0. 57 0. 09 0. 58 0. 09 
107 
2.6.4. B i o d i s t r i b u t i o n Studies 
B i o d i s t r i b u t i o n s t u d i e s were c a r r i e d o u t on 25 g a d o l i n i u m 
complexes whose p r e p a r a t i o n s are d e s c r i b e d i n s e c t i o n 2.6.1. 
A l l complexes had t h e i r p u r i t y checked by HPLC b e f o r e 
i n j e c t i o n i n t o a n i m a l s . 
The b i o d i s t r i b u t i o n s were conducted on c o n g e n i t a l l y 
athymic nude male mice (MFI-nu/nu/Ola/Hsd) aged 13 t o 16 
weeks w i t h an average we i g h t o f 36 g. Between t h r e e and f i v e 
mice were k i l l e d f o r each complex a t each time p o i n t . 
Gadolinium-153 complexes were a d m i n i s t e r e d i n t r a v enously 
v i a t h e t a i l v e i n a t a dose o f approx. O.l /Limol/kg, 7.5 fiCi 
^^^Gd/mouse. The dose o f [Gd. C i t r a t e ] was approx. 2 nmol/kg, 
0.8 /iCi 153Q(5/n^ouse. 
F u r t h e r s t u d i e s were unde r t a k e n w i t h [Gd.i2N4P4Me4]' and 
[Gd.DTPA]2- a t a dose o f 100 /xmol/kg, 7.5 ^ C i l53Gd/mouse and 
w i t h [Gd. 12N4P4BZ4] • a t doses o f 2, 70 and 100 ixmol/k.g, 7.5 
/xCi l^^Q^/mouse. A t these h i g h e r doses t h e i n j e c t i o n 
c o n s i s t e d o f a m i x t u r e o f r a d i o a c t i v e ( ^ ^ ^ G d ) and non 
r a d i o a c t i v e (^ '^^ Gd) complex which had been l e f t t o 
e q u i l i b r a t e f o r 24 hours. The non r a d i o a c t i v e complexes used 
were 0.5M [Gd.DTPA]^- Magnevist (Schering H e a l t h c a r e ) , and 
[Gd.l2N4P4Me4]- ( C e l l t e c h L t d . ) and [Gd.l2N4P4Bz4]" (Durham 
U n i v e r s i t y ) . 
The b i o d i s t r i b u t i o n o f [Gd.l2N4P4Bz4]' was a l s o examined 
i n two F i s c h e r r a t s (body weigh approx. 300g) a t a dose of 
0.01 ;tmol/kg, 7.5 /iCi ^^^Gd p e r r a t . 
Mice were k i l l e d a t 5 minutes p o s t i n j e c t i o n by c e r v i c a l 
d i s l o c a t i o n , and a t l a t e r t i mes by an i n t r a p e r i t o n e a l 
i n j e c t i o n o f p e n t o b a r b i t o n e . A sample o f c a r d i a c b l o o d was 
t a k e n and t h e f o l l o w i n g t i s s u e s d i s s e c t e d : - b r a i n , b o t h 
femurs, b o t h k i d n e y s , l i v e r , g a l l b l a d d e r , l u n g s , h e a r t 
muscle, s a l i v a r y g l a n d s , spleen, stomach, s m a l l i n t e s t i n e 
( f r o m t h e p y l o r i c s p h i n c t e r t o t h e s t a r t o f t h e caeciam) , 
caecum, l a r g e i n t e s t i n e , samples o f f a t , s k e l e t a l muscle and 
s k i n . 
A l l samples were weighed w i t h t h e e x c e p t i o n o f t h e g u t . 
For c a l c u l a t i o n s o f t o t a l t i s s u e dose, t h e mass o f b o t h t h e 
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b l o o d and t h e s k e l e t o n were ta k e n as 10% o f t h e body weight. 
T i s s u e samples were p l a c e d i n p o l y e t h y l e n e v i a l s and had 
t h e i r volume made up t o l ml w i t h f o r m a l s a l i n e i n ord e r t o 
keep t h e geometry c o n s t a n t f o r gamma c o u n t i n g . Larger samples 
such as l i v e r and i n t e s t i n e s were d i v i d e d between s e v e r a l 
tubes f o r a n a l y s i s . Samples were assayed f o r i53Q(j i-,y a 
Compugamma equipped w i t h a 3" w e l l t y p e N a l T l c r y s t a l . Each 
sample was counted f o r 5 o r 20 minutes depending on the l e v e l 
o f ^53Q(J p r e s e n t . The l i m i t o f d e t e c t i o n based on a 20 min 
count, was 100 cpra. T h i s i s approx. 0.0006% o f the dose 
assuming a dose o f 22 x 10^ cpm, 7.5 /iCi ^^^Q^J^ 
Rat t i s s u e s were removed and assayed as i n the mice 
expe r i m e n t s w i t h t h e e x c e p t i o n o f t h e g a l l b l a d d e r , as t h e 
r a t does n o t possess one. 
Summary t a b l e s a r e p r e s e n t e d i n Chapter 2.4 
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The a i m o f r a d i o i i r a n u n o t h e r a p y i s t o d e l i v e r a s t e r i l i s i n g 
d o s e o f r a d i a t i o n s e l e c t i v e l y t o t u m o u r c e l l s b y u s i n g t h e 
t a r g e t i n g p r o p e r t i e s o f a n t i b o d i e s w h i c h r e c o g n i s e tiomour 
s p e c i f i c a n t i g e n s . 
I n o r d e r t o a c h i e v e t h e maximum t i i m o u r k i l l i n g e f f e c t 
w i t h as l i t t l e damage t o n o r m a l t i s s u e as p o s s i b l e , a h i g h 
tixmour t o b a c k g r o u n d r a t i o i s needed. F o r t h i s t h e f o l l o w i n g 
r e q u i r e m e n t s s h o u l d be met:-
1 . An a n t i b o d y w h i c h w i l l b i n d s e l e c t i v e l y , t i g h t l y and 
q u i c k l y t o a t u m o u r s p e c i f i c a n t i g e n . 
2. R a p i d c l e a r a n c e f r o m t h e c i r c u l a t i o n o f any unbound 
a n t i b o d y . 
3. A r a d i o i s o t o p e w h i c h e m i t s p a r t i c l e r a d i a t i o n . 
4. A r a d i o i s o t o p e w i t h a h a l f l i f e w h i c h i s matched t o t h e 
t i m e s c a l e o f a n t i b o d y u p t a k e b y t h e t u m o u r and 
c l e a r a n c e o f any unbound a n t i b o d y , so t h a t t h e m a j o r 
p a r t o f t h e r a d i a t i o n dose i s d e l i v e r e d t o t h e tumour. 
5. A r a d i o i s o t o p e w h i c h i s r e a d i l y a v a i l a b l e , c a r r i e r - f r e e , 
d e c a y s t o a s t a b l e d a u g h t e r , and has c h e m i c a l p r o p e r t i e s 
w h i c h e n a b l e i t t o be a t t a c h e d t o an a n t i b o d y . 
6. The r a d i o i s o t o p e s h o u l d be bound t i g h t l y t o t h e a n t i b o d y 
so t h a t i t does n o t a c c i o m u l a t e i n t i s s u e s o t h e r t h a n 
t h o s e t o w h i c h t h e a n t i b o d y d i r e c t s i t . 
3.1.2. A n t i b o d i e s f o r T a r g e t i n g . 
I n 1957 Pressman^ f i r s t p r o p o s e d t h e use o f a n t i b o d i e s 
f o r t h e t a r g e t i n g o f r a d i o a c t i v i t y t o t u m o u r s . However, i t 
was n o t u n t i l t h e d e v e l o p m e n t o f m o n o c l o n a l a n t i b o d i e s (McAb) 
b y K o h l e r a n d M i l s t e i n ^ i n 1975 t h a t a n t i b o d i e s o f a h i g h 
e nough s p e c i f i c i t y t o a s i n g l e a n t i g e n became a v a i l a b l e t o 
make c l i n i c a l r a d i o i m m u n o t h e r a p y f e a s i b l e . McAbs a r e h i g h l y 
s p e c i f i c , h i g h a f f i n i t y a n t i b o d i e s w h i c h c an be r a i s e d 
a g a i n s t s p e c i f i c a n t i g e n s . McAbs have been r a i s e d a g a i n s t 
113 
s e v e r a l tiomour a s s o c i a t e d a n t i g e n s . These a n t i g e n s can be 
e x p r e s s e d i n h i g h l e v e l s i n t u m o u r s b u t a r e n o t u s u a l l y 
t o t a l l y t u m o u r s p e c i f i c , as t h e a n t i g e n s c an be p r e s e n t i n 
some n o r m a l t i s s u e s ^ . Two s u c h McAbs a r e B72.3 and HMFGl. 
B72.3 b i n d s t o t h e a n t i g e n TAG-72 w h i c h i s a h i g h m o l e c u l a r 
w e i g h t g l y c o p r o t e i n e x p r e s s e d i n o v e r 90% o f c o l o r e c t a l , 
g a s t r i c a nd o v a r i a n c a n c e r s , and 70% o f b r e a s t cancers'*'5. 
HMFGl McAb b i n d s t o 'human m i l k f a t g l o b u l e a n t i g e n ' w h i c h i s 
e x p r e s s e d i n n o r m a l l a c t a t i n g b r e a s t and i s a l s o f o u n d i n 
many c a n c e r s i n c l u d i n g o v a r i a n c a n c e r ^ . B o t h t h e s e McAbs have 
b e e n l a b e l l e d w i t h y t t r i u m - 9 0 and u s e d i n c l i n i c a l t r i a l s f o r 
t h e t h e r a p y o f c o l o r e c t a l ^ a nd o v a r i a n ^'^ c a n c e r s . 
One p r o b l e m w i t h t h e use o f McAbs i n humans has been t h e 
d e v e l o p m e n t o f an immunogenic r e s p o n s e b y p a t i e n t s t o t h e 
mouse McAb^'^"^, w h i c h c a n l e a d t o p o t e n t i a l l y l e t h a l serum 
s i c k n e s s . I n o r d e r t o overcome t h i s HAMA (human a n t i - m o u s e 
a n t i g e n ) r e s p o n s e , t e c h n i q u e s have been d e v e l o p e d t h r o u g h 
g e n e t i c e n g i n e e r i n g t o p r o d u c e c h i m e r i c and humanised 
a n t i b o d i e s ^ . 
A n o t h e r p r o b l e m has b e e n t h e d i f f i c u l t y e x p e r i e n c e d b y 
t h e r e l a t i v e l y h i g h m o l e c u l a r w e i g h t McAb (160,000 d a l t o n s ) 
p e n e t r a t i n g i n t o s o l i d t u m o u r s ^ ^ . A n t i b o d i e s c a n be s p l i t 
i n t o s m a l l e r f r a g m e n t s . Fab o r Fab' ( m o l e c u l a r w e i g h t 50,000) 
o r Fab'2 ( m o l e c u l a r w e i g h t 100,000) and s t i l l r e t a i n t h e i r 
a n t i g e n b i n d i n g c a p a c i t y . The s m a l l e r t h e m o l e c u l e , t h e 
e a s i e r i t i s f o r i t t o e n t e r t h e e x t r a v a s c u l a r space and f r o m 
t h e r e t o e n t e r t u m o u r s . S m a l l e r m o l e c u l e s a l s o show more 
r a p i d b l o o d c l e a r a n c e ^ . L a b e l l e d McAb f r a g m e n t s have been 
u s e d i n x e n o g r a f t s o f human c o l o n i c t u m o u r i n m i c e t o g i v e 
h i g h e r t u m o u r t o b l o o d r a t i o s t h a n have been o b t a i n e d b y 
u s i n g w h o l e M c A b ^ . However, t h i s h i g h e r tiomour t o b l o o d 
r a t i o was a t t h e ex p e n s e o f l e s s a n t i b o d y ( o r f r a g m e n t s ) i n 
t o t a l b e i n g d e l i v e r e d t o t h e tiomour. To overcome t h e p r o b l e m 
o f t h e p e n e t r a t i o n o f McAbs i n t o t u m o u r s o r any h e t e r o g e n e i t y 
o f a n t i g e n e x p r e s s i o n w i t h i n t h e tumour ^ ^ ^ an i s o t o p e 
e m i t t i n g b e t a p a r t i c l e r a d i a t i o n c a p a b l e o f d e l i v e r i n g a 
s t e r i l i s i n g dose o v e r many c e l l d i a m e t e r s c a n be u s e d . 
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3.1.3 Y t t r i u m i n Radioimmunotherapy. 
A r a n g e o f r a d i o i s o t o p e s and t h e i r d e c a y c h a r a c t e r i s t i c s 
f o r p o s s i b l e u s e i n r a d i o i m m u n o t h e r a p y use have been 
d i s c u s s e d i n s e c t i o n 1.2.3. The most w i d e l y u s e d i s o t o p e f o r 
r a d i o i m m u n o t h e r a p y i s i o d i n e - 1 3 1 13-17^ f o l l o w e d b y y t t r i i a m -
90 18-24_ I o d i n e -131 i s n o t an i d e a l i s o t o p e f o r t h e r a p y as 
i t has a h i g h y i e l d o f gamma r a d i a t i o n , a r a t h e r l o n g h a l f 
l i f e (193 h o u r s ) a n d a t e n d e n c y t o d e h a l o g e n a t e f r o m t h e McAb 
i n v i v o . Y t t r i u m - 9 0 i s more s u i t e d t o r a d i o i m m u n o t h e r a p y due 
t o b e i n g a p u r e b e t a - e m i t t e r w i t h a b e t t e r s u i t e d h a l f l i f e 
o f 64 h o u r s . The y t t r i u m - 9 0 b e t a p a r t i c l e has a mean r a n g e o f 
3.9 mm i n t i s s u e , m a k i n g i t s u i t a b l e f o r t h e t r e a t m e n t o f 
t u m o u r masses where t o t a l a nd u n i f o r m p e n e t r a t i o n can be 
d i f f i c u l t ^ O ' 1 2 _ 9 0Y i s a l s o r e a d i l y a v a i l a b l e f r o m a 
s t r o n t i u m - 9 0 g e n e r a t o r i n c a r r i e r f r e e f o r m , s u i t a b l e f o r 
l a b e l l i n g o f b i f u n c t i o n a l c o m p l e x i n g a g e n t s . 
S e v e r a l t r e a t m e n t s w i t h ^^y-McAbs o f human c o l o n i c 
c a n c e r l 8 - 2 i ^ lymphoma's, hepatoma'S and g l i o m a ' ^ x e n o g r a f t s 
h a v e r e s u l t e d i n i n h i b i t i o n o f t u m o u r g r o w t h and i n some 
c a s e s c o m p l e t e r e m i s s i o n . F o l l o w i n g on f r o m t h e s e s u c c e s s e s 
i n a n i m a l s t u d i e s , ^^Y-McAbs have been u s e d i n c l i n i c a l 
t r i a l s o n p a t i e n t s w i t h B c e l l lymphoma's, b r e a s t c a n c e r ' ^ 
a n d o v a r i a n c a n c e r ^ ' 8 / 2 7 , 2 8 _ -pj^g s u c c e s s o f ^^Y-McAhs i n 
c l i n i c a l t h e r a p y has b e e n l i m i t e d b y bone marrow t o x i c i t y 
( m y e l o s u p p r e s s i o n ) w i t h ^^Y doses b e i n g l i m i t e d t o l e s s t h a n 
20 t o 25 mCi p e r p a t i e n t ^ " ^ ' . T h i s has been due t o t h e 
r e l e a s e o f f r e e y t t r i u m - 9 0 f r o m t h e McAb. Uncomplexed y t t r i u m 
i s known t o be a bone s e e k e r and t o d e p o s i t on bone 
s u r f a c e s ' ^ ' 3 0 w h ere i t c a n i r r a d i a t e t h e bone marrow t h e r e b y 
c a u s i n g m y e l o s u p p r e s s i o n . The p r o b l e m o f i r r a d i a t i o n o f t h e 
bone m a r r o w f r o m y t t r i u m - 9 0 on t h e bone s u r f a c e i s worse i n 
humans t h a n has b e e n s u g g e s t e d f r o m p r e - c l i n i c a l s t u d i e s i n 
m i c e , b e c a u s e more o f t h e r a d i a t i o n dose i s a b s o r b e d i n t h e 
m a r r o w o f l a r g e r s p e c i e s . I n o r d e r t o m i n i m i s e t h i s bone 
m a r r o w t o x i c i t y , b i f u n c t i o n a l c o m p l e x i n g a g e n t s need t o be 
d e v e l o p e d w i t h h i g h i n v i v o s t a b i l i t i e s w i t h r e s p e c t t o m e t a l 
r e l e a s e . 
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3.1.4. B i f u n c t l o n a l Complexing Agents. 
A b i f u n c t i o n a l c o m p l e x i n g a g e n t has t h e d u a l p r o p e r t i e s 
o f b i n d i n g a m e t a l i o n and a t t a c h i n g t o an a n t i b o d y . T h i s 
b i f u n c t i o n a l c o m p l e x i n g a g e n t p l a y s a c r i t i c a l r o l e i n t h e i n 
v i v o s t a b i l i t y a nd hence e f f e c t i v e n e s s i n t h e r a p y o f t h e 
r a d i o i m m u n o c o n j u g a t e . The b i f u n c t i o n a l c o m p l e x i n g a g e n t 
s h o u l d f u l f i l t h e f o l l o w i n g c r i t e r i a : -
1 . The a t t a c h m e n t o f t h e b i f u n c t i o n a l c o m p l e x i n g a g e n t t o t h e 
McAb s h o u l d n o t a l t e r i t s i m m u n o r e a c t i v i t y . T h i s u s u a l l y 
means a maximum o f 3 c o m p l e x i n g a g e n t s p e r McAb^^. 
2. The m e t a b o l i s m o f t h e McAb s h o u l d n o t be a l t e r e d b y t h e 
l a b e l l i n g p r o c e d u r e . Thus any l a b e l l i n g s h o u l d be p e r f o r m e d 
i n aqueous s o l u t i o n b e t w e e n pH 4 and 8 a t no g r e a t e r t h a n 
3 7 O C . 
3 . F o l l o w i n g t h e c a t a b o l i s m o f t h e McAb, t h e b i f u n c t i o n a l 
c o m p l e x i n g a g e n t s h o u l d h e l p t o c l e a r t h e r a d i o m e t a l f r o m 
t h e body. The c o m p l e x e s [Y.DOTA]" and [Y.DTPA]2- and t h e i r 
b i f u n c t i o n a l c o m p l e x i n g a g e n t s a r e a l l c l e a r e d r a p i d l y f r o m 
t h e b o d y v i a t h e k i d n e y s 3 2 . 
4. The c o m p l e x i n g a g e n t s h o u l d n o t r e l e a s e t h e r a d i o m e t a l i n 
v i v o . 
The most, common f a i l u r e o f t h e b i f u n c t i o n a l c o m p l e x i n g 
a g e n t i s t h a t i t does n o t h o l d t h e r a d i o m e t a l s e c u r e l y enough 
i n v i v o w h i c h l e a d s t o t h e p r e m a t u r e r e l e a s e o f ^^Y and 
c o n s e q u e n t bone marrow t o x i c i t y ^ ' 2 7 _ 
3.1.5. I n V i v o S t a b i l i t y o f Y t t r i \ j m Complexes. 
I n e x p e r i m e n t s o n t h e s t a b i l i t y o f y t t r i u m - m a c r o c y c l e 
c o m p l e x e s y t t r i i m - 8 8 i s sometimes u s e d i n s t e a d o f y t t r i u m - 9 0 . 
T h i s i s b e c a u s e ^^Y has a r e l a t i v e l y s h o r t h a l f l i f e o f 64 
h o u r s , and i s d e t e c t e d b y m e a s u r i n g t h e B r e m s s t r a u h l u n g 
r a d i a t i o n f r o m i t s ^ - e m i s s i o n . Y t t r i u m - 8 8 has a l o n g e r h a l f 
l i f e o f 107 d a y s and e m i t t s g a m m a - r a d i a t i o n ( 0 . 5 1 and 3.62 
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MeV) w h i c h i s e a s i e r t o d e t e c t t h a n B r e m s s t r a u h l u n g 
r a d i a t i o n . 
Y t t r i u m -90 was f i r s t l i n k e d t o McAbs b y u s i n g DTPA 
c y c l i c a n h y d r i d e (CaDTPA) w h i c h was l i n k e d t o t h e McAb v i a 
one o f i t s c a r b o x y l i c a c i d g r o u p s 3 3 , 3 4 _ y t t r i u m has a co-
o r d i n a t i o n momber o f 8 a n d t h u s needs an o c t o d e n t a t e 
l i g a n d - ^ ^ . The l o s s o f one c a r b o x y l i c a c i d g r o u p f r o m t h e DTPA 
l i g a n d f o r l i n k i n g t o t h e a n t i b o d y l e a d s t o l o s s i n t h e 
s t a b i l i t y o f t h e y t t r i u m - D T P A c o m p l e x . T h i s was seen as:- t h e 
l o s s o f 8 t o 9% o f 9 0Y p e r day36 f r o m t h e ^Oy-caDTPA-McAb 
c o m p l e x i n s e r i i m s t a b i l i t y e x p e r i m e n t s ; t h e a c c u m u l a t i o n i n 
bone o f 13% o f t h e i n j e c t e d y t t r i u m dose p e r gram a t 3 days 
( 9 0 Y ) 3 7 ^ 1 1 t o 12% a t 5 d a y s ( 8 8Y ) 3 8 , 3 9 ^nd 9% a t 8 days 
( 9 0 Y ) 3 2 p o s t i n j e c t i o n ; and as bone marrow t o x i c i t y i n 
t h e r a p y t r i a l s w i t h ^^Y-McAbs b o t h i n m i c e ^ ^ ' ^ ^ ' ^ ^ and 
p a t i e n t s ' ^ ' 27, 
F i g u r e 3.1. Bifunctional Complexing Agents Based on DTPA. 
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CaDTPA SCN-Bz-DTPA MX-DTPA CHX-A-DTPA 
I n o r d e r t o i m p r o v e on t h e i n v i v o s t a b i l i t y o f CaDTPA 
l a b e l l e d McAbs, b a c k b o n e s u b s t i t u t e d d e r i v a t i v e s o f DTPA were 
s y n t h e s i s e d . The d e r i v a t i v e s i n f i g u r e 3.1 use an 
i s o t h i o c y a n a t e g r o u p f o r a n t i b o d y l i n k a g e , l e a v i n g a l l t h e 
DTPA c a r b o x y l i c a c i d g r o u p s a v a i l a b l e f o r t h e c o - o r d i n a t i o n 
o f y t t r i u m . A l t e r n a t i v e l y a N H 2 g r o u p has be u s e d i n p l a c e o f 
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t h e S C N g r o u p 3 7 o f S C N - B Z - D T P A and M X - D T P A , o r a m a l e i m i d e 
l i n k e r g r o u p has b e e n a t t a c h e d t o t h e D T P A backbone i n p l a c e 
o f t h e b e n z y l i s o t h i o c y a n a t e g r o u p o f SCN-Bz - D T P A t o g i v e t h e 
b i f u n c t i o n a l c o m p l e x i n g a g e n t C T - D T P A . 
Y t t r i u m - l a b e l l e d McAbs made w i t h t h e s e backbone 
s u b s t i t u t e d D T P A d e r i v a t i v e s a l l showed i n c r e a s e d s t a b i l i t y 
o v e r t h o s e made w i t h CaDTPA. I n seriam s t a b i l i t y s t u d i e s SBy-
MX - D T P A l o s t 6.6% and 8 8 Y - C H X - A - D T P A 4.2% o f ^Oy o v e r 17 
d a y s ' ^ i . I n a n i m a l s t u d i e s l e s s y t t r i i o m a c c i a m u l a t e d i n t h e 
b o ne. O n l y a b o u t 3% d o s e / g was f o u n d i n t h e bone o f m i c e 
g i v e n Y-McAbs l a b e l l e d v i a t h e b a c k b o n e s u b s t i t u t e d D T P A 
d e r i v a t i v e s ( 5 0 Y ) 3 2 , 3 7 ( 8 8 Y ) 3 8 , 3 9 , 4 1 compared t o b e t w e e n 9 
a n d 13% d o s e / g i n bone f r o m Y-Ca-DTPA l a b e l l e d McAbs a t 3 t o 
7 d a y s p o s t i n j e c t i o n . The n a t u r e o f t h e c h e m i c a l l i n k a g e 
b e t w e e n t h e b a c k b o n e s u b s t i t u t e d DTPA and t h e McAb d i d n o t 
a p p e a r t o a l t e r t h e ^ ^ y bone u p t a k e 3 7 . The h i g h e r i n v i v o 
s t a b i l i t y o f t h e b a c k b o n e s u b s t i t u t e d DTPA c o n j u g a t e s was 
s i m p l y a r e s u l t o f a l l f i v e c a r b o x y l i c a c i d g r o u p s on t h e 
DTPA b e i n g a v a i l a b l e f o r c o m p l e x i n g t h e y t t r i u m . I n t h e r a p y 
s t u d i e s w i t h ^^Y-MX-DTPA-McAbs i n b o t h m i c e l ^ ' 2 1 and hiimans^, 
l e s s bone m a r r o w t o x i c i t y was seen. 
A l t h o u g h t h e s e b a c k b o n e - s u b s t i t u t e d DTPA l a b e l l e d McAbs 
a r e more s t a b l e i n v i v o t h a n t h e o r i g i n a l c y c l i c a n h y d r i d e 
l i n k e d DTPA McAbs, t h e r e i s s t i l l a m e a s u r a b l e l o s s o f 
y t t r i u m . I t i s w e l l e s t a b l i s h e d t h a t m a c r o c y c l i c l i g a n d s s u c h 
as DOTA f o r m much more s t a b l e m e t a l c o m p l e x e s i n vivo'*2 
( s e c t i o n 1.3.6) t h a n a c y c l i c l i g a n d s s u c h as DTPA. The r a t e 
o f t r a s m e t a l l a t i o n o f DTPA m e t a l c o m p l e x e s w i t h endogenous 
m e t a l i o n s i n t h e p l a s m a i s high'^3, whereas [Y.DOTA] " shows 
no m e a s u r a b l e l o s s o f ^^Y o v e r 18 d a y s i n c u b a t i o n i n serum^"^. 
[Y.DOTA]" i s a l s o l e s s s u s c e p t i b l e t o a c i d c a t a l y s e d 
d i s s o c i a t i o n s h o w i n g no l o s s o f s t a b l e y t t r i u m o v e r 3 months 
a t pH 3.6^5, o r 9 0Y o v e r 10 d a y s a t pH >2.6, 370c46. Even a t 
pH v a l u e s as l o w as l.O t h e l o s s o f '^^ Y f r o m [Y-DOTA] ' i s 
s t i l l o n l y 50% o v e r 12.8 hours^"^. T h i s h i g h k i n e t i c i n e r t n e s s 
o f [Y.DOTA]' w h i c h i s an a d v a n t a g e i n r e d u c i n g t h e l o s s o f 
^^Y i n v i v o , a l s o r e s u l t s i n a s l o w e r r a t e o f f o r w a r d b i n d i n g 
o f y t t r i i i m w i t h DOTA t h a n w i t h DTPA^^^ However, t h e r a t e o f 
118 
f o r w a r d b i n d i n g o f y t t r i u m b y DOTA i s s t i l l s u f f i c i e n t l y 
r a p i d ( 8 4 % u p t a k e i n 30 m i n u t e s a t pH 5.5, 37°C, at 5 fM 
DOTA)'^^ f o r e f f i c i e n t r a d i o l a b e l l i n g o f McAbs. 
When b i f u n c t i o n a l c o m p l e x i n g a g e n t s b a s e d on t h e 
m a c r o c y c l e DOTA ( f i g u r e 3.2) a r e u s e d t o l i n k y t t r i u m - 9 0 t o 
McAbs, t h e h i g h i n v i v o k i n e t i c s t a b i l i t y a s s o c i a t e d w i t h 
[Y.DOTA]' was r e t a i n e d . I n serum s t a b i l i t y s t u d i e s t h e l i g a n d 
p - n i t r o b e n z y l DOTA showed no m e a s u r a b l e l o s s o f ^ ^Y o v e r 18 
days'*'*, 2 B - D 0 T A showed no l o s s o f ^ ^Y o v e r 17 days"*^, and BAD 
showed no l o s s o f ^ ^Y o v e r 25 d a y s ^ ^ . A n i m a l s t u d i e s on bone 
u p t a k e o f y t t r i u m f r o m Y-McAb c o n j u g a t e d w i t h t h e l i g a n d s 2B-
DOTA and DOTA-Mal gave o n l y 2 . 1 % i n j e c t e d d ose/g (^^Y) a t 5 
days'*! and 1.5% i n j e c t e d d o s e / g (^Oy) a f t e r 8 d a y s ^ ^ 
r e s p e c t i v e l y . When ^^Y-BAD-McAb and ^ ^y.^^.^TPA-McAb were 
u s e d i n t o x i c i t y e x p e r i m e n t s ( L D 5 0 ) i n m i c e , ^^Y-MX-DTPA-McAb 
was shown t o be more t o x i c a nd b y i m p l i c a t i o n t h e l e s s s t a b l e 
o f t h e t w o . The L D S Q ' S were 220 fiCi o f ^ OY-MX-DTPA-McAb and 
307 fiCi of^Oy-BAD-McAb^O. 
F i g u r e 3.2. Bifunctlonal Complexing Agents Based on DOTA. 
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F u r t h e r e v i d e n c e o f t h e i m p r o v e d i n v i v o s t a b i l i t y o f 
y t t r i u m - D O T A c o n j u g a t e d McAbs o v e r y t t r i u m - D T P A c o n j u g a t e d 
McAbs comes f r o m s t u d i e s on t h e d i s t r i b u t i o n o f y t t r i i i m 
w i t h i n t h e mouse f e m u r . F r e e y t t r i u m i s known t o c o n c e n t r a t e 
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i n c o r t i c a l bone29/30, and s t u d i e s b y b o t h Camera e t . a l ^ l and 
H a r r i s o n e t . a l 3 2 h a ve shown t h a t s u b s t a n t i a l l y more y t t r i u m 
i s f o u n d i n t h e c o r t i c a l bone o f t h e f e m u r t h a n i n t h e bone 
m a r r o w o f m i c e g i v e n y t t r i u m - D T P A c o n j u g a t e d McAbs as opposed 
t o y t t r i u m - D O T A c o n j u g a t e d McAbs. T h i s c l e a r l y d e m o n s t r a t e s 
t h e g r e a t e r i n v i v o s t a b i l i t y o f ^ ^ Y - i m m u n o c o n j u g a t e s w h i c h 
h a v e b e e n l a b e l l e d v i a a m a c r o c y c l i c DOTA l i g a n d o v e r t h a n o f 
9 0 Y - i m m u n o c o n j u g a t e s l a b e l l e d v i a t h e a c y c l i c DTPA l i g a n d . 
B ecause l e s s y t t r i u m - 9 0 i s b e i n g r e l e a s e d f r o m ^Oy.DOTA-McAbs 
t h a n f r o m ^^Y-DTPA-McP>hs, t h e use o f t h e DOTA l i g a n d s h o u l d 
r e s u l t i n l e s s bone marrow t o x i c i t y t o p a t i e n t s u n d e r g o i n g 
r a d i o i m m u n o t h e r a p y . 
3.1.6. The Scope o f t h e Work i n T h i s C h a p t e r . 
I n t h i s c h a p t e r , t h e a c i d d i s s o c i a t i o n c o n s t a n t s a r e 
m e a s u r e d f o r t h r e e t e t r a a z a - p h o s p h i n i c a c i d m a c r o c y c l e s and 
t w o b i f u n c t i o n a l c o m p l e x i n g a g e n t s , DOTA-maleimide and an 
a z a - p h o s p h i n i c a c i d - m a l e i m i d e . These a c i d d i s s o c i a t i o n 
m e asurements a r e t h e n compared t o t h o s e o f g a d o l i n i u m 
l a b e l l e d m a c r o c y c l e s f r o m c h a p t e r 2. The a s s o c i a t i o n r a t e s 
f o r a r a n g e o f 9 a n i o n i c , n e u t r a l , and c a t i o n i c aza-
c a r b o x y l i c and a z a - p h o s p h i n i c a c i d s a r e a l s o measured 
F i n a l l y t h e McAb B72.3 i s r a d i o l a b e l l e d w i t h 90y v i a t h e 
b i f u n c t i o n a l c o m p l e x i n g a g e n t s DOTA-maleimide o r 12N4P3Me3-
m a l e i m i d e . The b i o d i s t r i b u t i o n s o f t h e s e l a b e l l e d McAbs i n 
n o r m a l m i c e a r e m e a s u r e d t o a s s e s s t h e i r i n v i v o s t a b i l i t i e s . 
The b o n e s o f t h e s e m i c e a r e e x a m i n e d i n d e t a i l t o a s s e s s t h e 
amounts o f ^ ^ y d e p o s i t e d i n t h e bone as opposed t o ^^Y i n t h e 
bone m a r r o w f r o m c i r c u l a t i n g ^^y.^oAb. 
3.2. DISSOCIATION OF YTTRIUM MACROCYCLE COMPLEXES. 
E x p e r i m e n t a l d e t a i l s a r e g i v e n i n s e c t i o n 3.5. 
D i s s o c i a t i o n measurements u s i n g HPLC r a d i o m e t r y were 
c a r r i e d o u t on one a n i o n i c y t t r i u m a z a - p h o s p h i n i c a c i d 
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c o m p l e x [Y.l2N4P4Me4]", and t w o n e u t r a l y t t r i u m aza-
p h o s p h i n i c a c i d c o m p l e x e s [Y.12N4P3Me3NBu2] and 
[Y.12N4P3Me3NBz2]. 
D i s s o c i a t i o n measurements were a l s o p e r f o r m e d on two 
y t t r i i i m l a b e l l e d b i f u n c t i o n a l c o m p l e x i n g a g e n t s [Y.DOTA-Mal] 
and [ Y . l 2 N 4 P 3 M e 3 - M a l ] . 
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3.2.1. S t a b i l i t y o f y t t r i i i m m a c r o c y c l e s . 
A summary o f t h e r e s u l t s o f t h e a c i d c a t a l y s e d 
d i s s o c i a t i o n c o n s t a n t s f o r t h e y t t r i i m i l a b e l l e d m a c r o c y c l e s 
i s g i v e n i n t a b l e 3 . 1 . The t w o n e u t r a l y t t r i u m complexes 
[Y.12N4P3Me3NBu2] and [Y.12N4P3Me3NBz2] a r e more s t a b l e i n 
a c i d s o l u t i o n t h a n t h e a n i o n i c [Y.l2N4P4Me4]", as w o u l d be 
e x p e c t e d o n t h e b a s i s o f c o u l o m b i c a t t r a c t i o n . The k Q ^ g 
v a l u e s o f t h e n e u t r a l c o m p l e x e s a l s o show a l e s s s t e e p 
d e p e n d e n c e on pH t h a n t h e a n i o n i c c o m p l e x [Y.l2N4P4Me4] '. 
However, c o n s i d e r i n g t h a t t h e p h y s i c a l h a l f l i f e o f y t t r i i o m -
90 i s o n l y 64 h o u r s , e v e n [Y.l2N4P4Me4]' i s s t a b l e f o r t w i c e 
t h i s amount o f t i m e a t pH 2. 
The t w o b i f u n c t i o n a l c o m p l e x i n g a g e n t s b o t h show h i g h 
s t a b i l i t y u n d e r a c i d c o n d i t i o n s , [Y.DOTA-Mal]" b e i n g more 
s t a b l e t h a n [ Y . i 2 N 4 P 3 M e 3 - M a l ] . T h i s a u g u r s w e l l f o r t h e i r use 
i n a n t i b o d y l a b e l l i n g f o r i n v i v o u s e . 
T a b l e 3.1. Dissociation Data for Yttrium Complexes. 
y t t r i u m pH ^oha/ * TSLalt L i f e 
complex 10"^ s e c " ^ Hours 
12N4P4Me4 1.0 13.9 13.8 
1.5 5.74 33.6 
2.0 1.67 116 
12N4P3Me3NBu2 1.0 1.89 102 
1.5 0.699 276 
2.0 0.267 721 
12N4P3Me3NBz2 1.0 1.33 145 
1.5 0.507 379 
2.0 0.195 989 
DOTA-Mal 1.0 2.72 70.8 
1.5 0.758 254 
2.0 0.141 1370 
12N4P3Me3-Mai 1.0 6.56 29.3 
1.5 2.11 91.2 
2.0 0.520 370 
* Standard e r r o r s a r e l i s t e d i n t a b l e 3 . 5 
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1.0 IS 2j0 
pH 
3.2.2. Comparison o f A c i d C a t a l y s e d D i s s o c i a t i o n C o n s t a n t s 
f o r Y t t r i u m and G a d o l i n i i u n C o n ^ l e x e s . 
T a b l e 3.2 l i s t s t h e a c i d d i s s o c i a t i o n c o n s t a n t s f o r t h e 
y t t r i u m c o m p l e x e s t o g e t h e r w i t h t h o s e o f t h e i r c o r r e s p o n d i n g 
g a d o l i n i u m c o m p l e x e s . Y t t r i u m and g a d o l i n i u m have i o n i c r a d i i 
o f 1.02 a n d 1.05 A r e s p e c t i v e l y ^ ! , and b o t h have t r i p o s i t i v e 
i o n s w h i c h f o r m o c t o d e n t a t e c o m p l e x e s . 
The y t t r i u m c o m p l e x o f DOTA i s n o t as r e s i s t a n t t o a c i d 
c a t a l y s e d d i s s o c i a t i o n as [Gd.DOTA]". The y t t r i u m complexes 
[Y.l2N4P4Me4]- a n d [Y.l2N4P3Me3NBu2] a r e a l s o a l i t t l e l e s s 
s t a b l e t h a n t h e c o r r e s p o n d i n g g a d o l i n i u m c o m p l e x e s , b u t 
[Y.l2N4P3Me3NBz2] w h i c h i s t h e most s t a b l e o f t h e y t t r i u m 
c o m p l e x e s i s more s t a b l e t h a n t h e c o r r e s p o n d i n g g a d o l i n i u m 
c o m p l e x . A l l o f t h e n e u t r a l c o m p l e x e s show l e s s a c i d 
c a t a l y s e d d i s s o c i a t i o n t h a n t h e a n i o n i c c o m p l e x e s as w e l l as 
a l e s s s t e e p dependence o f k o b s pH-
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T a b l e 3.2. Acid Dissociation Rates of Yttrium and Gadolinium 
Macrocycles 
^ o b s / l O " ^ H a l f l i f e hours 
pH 1.0 1.5 2.0 1.0 1.5 2.0 
[Gd.DOTA]" 3.16 0.898 0.049 60.2 214 3930 
*[Y.DOTA]- 15.0 1.88 0.33 12.8 102 583 
[Y.DOTA-Mal]" 2.72 0.758 0.141 70.8 254 1370 
[Gd.l2N4P4Me4]" 10.4 4.63 1.13 18.5 41.6 171 
[Y.12N4P4Me4] " 13.9 5.74 1.67 13.8 33.6 116 
[Y.12N4P3-Mal] 6.56 2.11 0.520 29.3 91.2 370 
[Gd.l2N4P3Me3NBu2] 1.26 0.494 0.204 152 389 943 
[Y.12N4P3Me3NBu2] 1.89 0.699 0.267 102 276 721 
[Gd.l2N4P3Me3NBz2] 4.28 1.64 1.00 44.9 118 192 
[Y.12N4P3Me3NBz2] 1.33 0.507 0.195 145 379 989 
* Data from K.P.Pulukkody e t a l * " ^ . 
The t w o b i f u n c t i o n a l c o m p l e x i n g a g e n t s [Y.DOTA-Mal]" and 
[Y.l2N4P3Me3-Mal] have h i g h e r s t a b i l i t y t h a n t h e i r non 
f u n c t i o n a l i s e d a n i o n i c p a r e n t c o m p l e x e s [Y.DOTA]' and 
[Y.12N4P4Me4]•. 
A l l o f t h e y t t r i u m a nd g a d o l i n i u m m a c r o c y c l e complexes 
l i s t e d a bove have much b e t t e r r e s i s t a n c e t o a c i d c a t a l y s e d 
d i s s o c i a t i o n t h a n t h e a c y c l i c c o m p l e x [Gd.DTPA]2-. Even t h e 
k o b s o f 1-39 x l O ' 5 f o r [Y.l2N4P4Me4]- i s t w o o r d e r s o f 
m a g n i t u d e g r e a t e r t h a n t h e k o b s °f ^-^ ^ ^^'^ [Gd.DTPA]2-
a t pH i 5 2 . 
I n c o n c l u s i o n , t h e a c i d c a t a l y s e d d i s s o c i a t i o n r a t e s o f 
t h e y t t r i u m m a c r o c y c l e c o m p l e x e s measured a r e much l o w e r t h a n 
t h o s e o f a c y c l i c c o m p l e x e s . T h i s s h o u l d c o r r e s p o n d t o h i g h i n 
v i v o s t a b i l i t i e s f o r a l l o f t h e above m a c r o c y c l e c o m p l e x e s . 
P r o t e i n s l a b e l l e d w i t h t h e m a c r o c y c l i c b i f u n c t i o n a l 
c o m p l e x i n g a g e n t s [Y.DOTA-Mal]' and [Y.l2N4P3Me3-Mai] , s h o u l d 
h a v e much h i g h e r i n v i v o s t a b i l i t y t h a n t h o s e l a b e l l e d w i t h 
b i f u n c t i o n a l DTPA, l e a d i n g t o l e s s r e l e a s e o f f r e e ^^Y and 
c o n s e q u e n t l y l e s s t o x i c i t y . 
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3.3, KINETICS OF YTTRIUM ASSOCIATION WITH MACROCYCLES 
E x p e r i m e n t a l d e t a i l s a r e g i v e n i n s e c t i o n 3.5.2. 
The u s e o f ^ ' ^ Y - l a b e l l e d a n t i b o d i e s f o r r a d i o i m m u n o t h e r a p y 
r e q u i r e s a q u i c k a nd r e l i a b l e l a b e l l i n g p r o t o c o l . To t h i s 
end, t h e c o m p l e x i n g a g e n t w h i c h i s t o be a t t a c h e d t o t h e 
a n t i b o d y s h o u l d u n d e r g o e f f i c i e n t and r a p i d r a d i o l a b e l l i n g 
u n d e r c o n d i t i o n s w h i c h w i l l n o t cause d e n a t u r a t i o n o f t h e 
a n t i b o d y . I n t h e s e e x p e r i m e n t s l o w c o n c e n t r a t i o n s o f l i g a n d 
(5 fjiM.) were u s e d t o r e f l e c t t h e c o n c e n t r a t i o n o f m a c r o c y c l e 
w h i c h w o u l d be e x p e c t e d when l a b e l l i n g c o n j u g a t e d a n t i b o d y . 
The ^Oy u s e d was o f h i g h p u r i t y , e s s e n t i a l l y c a r r i e r f r e e , 
a n d r e l a t i v e l y f r e e o f o t h e r m e t a l i o n s . A t t h e s e l o w 
c o n c e n t r a t i o n s a n y s m a l l amount o f c o n t a m i n a t i n g m e t a l i o n s 
w i l l s e v e r e l y a l t e r t h e l a b e l l i n g e f f i c i e n c y . 
3.3.1. R a t e s o f Y t t r i u m Uptake. 
A s s o c i a t i o n k i n e t i c s were c a r r i e d o u t on t h e f o l l o w i n g 
m a c r o c y c l e s ( s e e f i g u r e 3.6) w i t h r e s p e c t t o y t t r i u m - 9 0 
u p t a k e : -
a n i o n i c c o m p l e x e s : DOTA, l2N4P4Me4, l2N4P3Me3C, 
12N4P4BZ4. 
n e u t r a l c o m p l e x e s : l2N4P3NHMe, l2N4P3Me3NBu2, 
1 2 N 4 C 3 ( I B u ) 2 . 
c a t i o n i c c o m p l e x e s : 12N4P3Me3NH(CH2)4NH3+, 
12N4C3NH(CH2)4NH3+. 
T a b l e 3.3 a n d f i g u r e 3.6 siammarise t h e d a t a f o r y t t r i u m 
u p t a k e b y t h e r a n g e o f m a c r o c y c l e s p i c t u r e d i n f i g u r e 3.5 a t 
c o n c e n t r a t i o n s o f 5 /iM. DOTA has t h e f a s t e s t r a t e o f ^ °Y 
u p t a k e , a c h i e v i n g 80% u p t a k e w i t h i n 2 m i n u t e s . T h i s l e v e l o f 
u p t a k e ( 8 0 % ) i s a c h i e v e d w i t h i n 5 m i n u t e s f o r 
12N4P3Me3NH(CH2)4NH3+; 10 m i n u t e s f o r 12N4P4Me4; 15 m i n u t e s 
f o r 12N4P4BZ4 and l2N4P3Me3NBu2; 30 m i n u t e s f o r l2N4P3Me3C 
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F i g u r e 3.5. Chemical Structures of the Ligands Used for 
Yttrium Uptake 
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and 12N4C3NH{CH2)4NH3+; and 60 m i n u t e s f o r 12N4P3NHMe. The 
l i g a n d l 2 N 4 C 3 ( I B u ) 2 shows v e r y l i t t l e u p t a k e o f y t t r i u m 
w i t h i n 60 m i n u t e s a t a c o n c e n t r a t i o n o f 5 T h i s i s 
p r o b a b l y due t o m e t a l i o n c o n t a m i n a t i o n o f t h e sample 
e x a m i n e d r a t h e r t h a n a l a c k o f a f f i n i t y o f t h e l i g a n d f o r 
y t t r i u m . 
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T a b l e 3.3. Summary of Percentage ^^Y Uptake @ 5 fiM 





















1 54 36 8. 83 5. 55 5. 46 2. 01 5. 91 0 28 17 36 3 . 40 
2 80 51 18 .26 11 .43 14 .86 4 . 11 11 .97 0 39 36 18 8. 86 
5 98 49 55 .15 29 .03 43 .37 12 .64 35 . 17 0 48 78 54 23 .62 
10 99 67 85 .27 51 . 74 68 .59 24 .67 61 .08 0 60 90 19 42 .82 
15 99 59 87 . 11 66 .01 82 .32 35 . 78 78 .65 0 68 97 35 59 .88 
20 99 76 92 .55 73 .40 83 .53 45 .38 86 . 77 0 78 90 31 67 .55 
30 99 30 93 .35 84 .22 88 . 17 58 .38 90 .23 0 93 95 91 81 .25 
60 99 02 95 .05 94 .67 87 .22 79 .75 82 .97 1 54 95 11 91 .78 
F i g u r e 3.6. Percentage ^^Y Uptake With Time. 












10 20 30 
Time minutes 
40 50 60 
The f i v e m a c r o c y c l e s w h i c h t a k e l e s s t h a n 15 m i n u t e s t o 
r e a c h 80 % y t t r i i i m u p t a k e ( i . e . DOTA, l2N4P3Me3NH(CH2) 4NH3 + , 
l2N4P4Me4, 12N4P4BZ4 a n d l2N4P3Me3NBu2) w o u l d a l l be s u i t a b l e 
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t o a t t a c h t o m o n o c l o n a l a n t i b o d i e s v i a a b i f u n c t i o n a l g r o u p 
f o r l a b e l l i n g w i t h ^Oy f o r i m m u n o t h e r a p y e x p e r i m e n t s . 
3.3.2. Y t t r i i o m M a c r o c y c l e s f o r Which Both t h e K i n e t i c s of 
A s s o c i a t i o n and D i s s o c i a t i o n Have Been Measured. 
T a b l e 3.4. Kinetics of association and Dissociation of 
Yttrium Macrocycles. 
M a c r o c y c l e Time t a k e n 
f o r 80% Y 
u p t a k e 
D i s s o c i a t i o n 
h a l f l i f e 
( h r ) a t 
pH 1.0 
D i s s o c i a t i o n 
h a l f l i f e 
( h r ) a t 
pH 2.0 
[Y.DOTA]• 2 12.8 583 
[Y. 12N4P4Me4] " 10 13 . 8 116 
[Y. 12N4P3Me3NBu2] 15 102 721 
A l l t h r e e y t t r i u m m a c r o c y c l e c o m p l e x e s ( t a b l e 3.4) 
e x h i b i t h i g h r a t e s o f y t t r i u m u p t a k e and l o w r a t e s o f 
d i s s o c i a t i o n a t a c i d pH. The n e u t r a l c o m p l e x 
[Y.l2N4P3Me3NBu2] has t h e h i g h e s t s t a b i l i t y i n a c i d b u t t h e 
r a t e o f y t t r i u m u p t a k e i s s l i g h t l y s l o w e r , b o t h t h e s e r a t e s 
w i l l be d e p e n d e n t o n e l e c t r o s t a t i c c h a r g e s f o r o p p o s i n g 
r e a s o n s . The b i f u n c t i o n a l c o m p l e x e s d e r i v e d f r o m DOTA and 
l2N4P4Me4 (DOTA-Mal and i2N4P3Me3-Mai) have a l s o been shown 
t o h a ve h i g h s t a b i l i t y i n a c i d c o n d i t i o n s ( s e c t i o n 3.2.1) 
I n c o n c l u s i o n , [ Y . D O T A ] [ Y . l 2 N 4 P 4 M e 4 ] " and 
[Y.l2N4P3Me3NBu2] s h o u l d p r o v e s u i t a b l e f o r ^ Oy l a b e l l i n g o f 
a n t i b o d i e s f o r r a d i o i m m u n o t h e r a p y . 
3.4. YTTRIUM MACROCYCLE MALEIMIDE LINKED MONOCLONAL 
ANTIBODY. 
3.4.1. L a b e l l i n g o f Monoclonal Antibody. 
The m o n o c l o n a l a n t i b o d y B72.3 i s a mouse i g G ^ t y p e 
a n t i b o d y w i t h a h i g h a f f i n i t y f o r t u m o u r - a s s o c i a t e d 
g l y c o p r o t e i n (TAG-72) f o u n d i n human c o l o n i c and b r e a s t 
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cancers'*'5. L a b e l l i n g of t h i s antibody w i t h y t t r i u m was 
achieved by means of the b i f u n c t i o n a l complexing agents DOTA-
Mal and 12N4P3Me3-Mai ( f i g u r e 3.3). These two b i f u n c t i o n a l 
complexing agents have a macrocyclic group f o r binding 
y t t r i i o m and a maleimide group f o r attachment t o the antibody. 
The maleimide group combines w i t h t h i o l groups on a p r o t e i n 
t o form a st a b l e linkage between the macrocycle and the 
antibodyS^. As the B72.3 has no fre e t h i o l groups, Traut's 
reagent {2-iminothiolane) was used t o introduce t h i o l groups 
by r e a c t i o n w i t h l y s i n e £-amino groups. The macrocycle 
maleimide was then conjugated t o the antibody by re a c t i o n 
w i t h these t h i o l groups ( f i g u r e 3.7). 
Figure 3.7. Labelling of Antibody With Bifunctional Ligand. 
NH, 2 S 





Mac = Macrocycle 
Any unreacted t h i o l s were capped w i t h N-ethylmaleimide 
before p u r i f i c a t i o n of the antibody conjugate by gel 
f i l t r a t i o n . The antibody was then incubated w i t h yttrium-90 
f o r 15 minutes a t 370c (310K) i n 0.IM ammonium acetate b u f f e r 
pH 6. A f t e r the a d d i t i o n of DTPA t o complex any unbound ^Oy, 
the ^Oy-labelled antibody was p u r i f i e d by means of size 
exclusion HPLC. This separated any high molecular weight 
p r o t e i n aggregates and any low molecular weight [Y-DTPA]2-
from the l a b e l l e d antibody. Both DOTA-B72.3 and l2N4P3Me3-
B72.3 showed l a b e l l i n g e f f i c i e n c i e s of 30 % w i t h ^^y^ Figures 
3.8 and 3.9 show the e l u t i o n p r o f i l e s of ^ Oy.ial^eiied B72.3 
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antibody from HPLC. The sections marked were the f r a c t i o n s of 
the eluents taken f o r use i n b i o d i s t r i b u t i o n studies (section 
3.4.2) . The nxamber of t h i o l s estimated t o have been 
introduced per antibody was 2.2, so the number of macrocycles 
per antibody w i l l have been less than t h i s . 
The macrocycles DOTA-Mal and i2N4P3Me3-Mal have already 
shown high s t a b i l i t y under a c i d conditions, and f a s t rates of 
y t t r i u m uptake (sections 3.2 and 3.3) i n v i t r o . The 
attachment of these macrocycles t o the antibody B72.3 enables 
the i n v i v o s t a b i l i t y of these y t t r i i a m macrocycle conjugates 
t o be assessed. 






A s o l u t i o n of the monoclonal antibody B72.3 l a b e l l e d w i t h 
^Oy v i a e i t h e r a DOTA or l2N4P3Me3 macrocycle was i n j e c t e d 
i n t r a v e n o u s l y i n t o mice. A general t i s s u e b i o d i s t r i b u t i o n was 
performed f o r both types of l a b e l l e d antibody t o assess the 
i n v i v o s t a b i l i t y of the whole conjugate. A more d e t a i l e d 
b i o d i s t r i b u t i o n of ^^ Y i n the bone was also performed t o 
a s c e r t a i n i f there had been any release of fr e e '^^Y from the 
macrocycle antibody conjugate. 
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Figure 3.9. HPLC Elution Profile of ^ 0Y-12N4P3Me3-B72.3. 
^ 





3.4.2. Biodistribution of ^Oy-Labelled Monoclonal Antibody 
Tissue d i s t r i b u t i o n s are given i n f i g u r e s 3.10 t o 3.13 as 
% dose/g and % dose per t i s s u e f o r both 90Y-DOTA-B72.3 and 
^0Y-12N4P3Me3-B72.3. These r e s u l t s are the mean values taken 
from f i v e mice f o r each conjugate at 48 hours post i n j e c t i o n . 
A l l the t i s s u e s examined contain less 50Y-DOTA-B72.3 than 
^0Y-i2N4P3Me3-B72.3, due t o the more r a p i d e x c r e t i o n of the 
former. The o v e r a l l p a t t e r n of d i s t r i b u t i o n between the 
ti s s u e s i s s i m i l a r from both conjugates. The higher excretion 
r a t e by the DOTA-B72.3 group was probably due t o the 
i n c l u s i o n of some [^^Y.DTPAJ^- i n the i n j e c t i o n dose ( f i g u r e s 
3.8 and 3.9 show t h a t there was less separation between the 
^Oy-antibody and [^OY.DTPA]^- i n the ^ ^Y-D0TA-B12.3 than i n 
the 90Y.i2N4P3Me3-B72.3 HPLC separation) or from a less 
s a t i s f a c t o r y conjugation of the ^ Oy-DOTA-Mal t o the antibody. 
Any 90Y-macrocycle-maleimide which i s released during 
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metabolism of the antibody conjugate would be excreted very 
q u i c k l y (greater than 98% e x c r e t i o n i n 24 hours)^2 as would 
any [Y.DTPA]2-. 
The r e s u l t s of the bone analysis are presented as % 
dose/g ( f i g u r e s 3.12 and 3.14), % dose ( f i g u r e s 3.11 and 
3.15) and as t i s s u e t o blood r a t i o s ( f i g u r e s 3.14 and 3.16). 
For a l l animals the r i g h t and l e f t femurs were analysed 
separately. The femurs each had t h e i r ends (epiphyses) cut 
o f f and the bone marrow washed from the shaft t o give three 
separate samples ( i ) the shaft - bone only, ( i i ) the marrow -
no bone, and ( i i i ) the epiphyses - both bone and marrow. From 
the data i n f i g u r e s 3.12 and 3.14 i t can be seen tha t there 
i s very l i t t l e d i f f e r e n c e between the l e f t and r i g h t femur 
samples, but t h a t there i s more ^"^Y dose i n a l l the bone 
tis s u e s from ^Oy.i2N4P3Me3-B72.3 than from 50Y.DOTA-B72.3. 
When the data are presented as t i s s u e t o blood r a t i o s ( f i g u r e 
3.16) , the higher amount of ^ Oy.i2N4P3Me3-B72.3 i n the blood 
i s taken i n t o account, and there i s very l i t t l e d i f f e r e n c e 
between the two samples. Free ^Oy i g known t o concentrate i n 
bone tissue29f30^ so any concentration of ^ ^Y i n the femur 
s h a f t over t h a t of c i r c u l a t i n g ^^Y-B72.2 would be an 
i n d i c a t i o n of d i s s o c i a t i o n of ^ ^Y from the macrocycle. The % 
dose of y t t r i u m i n the femur shaft i s less than 0.01% from 
both preparations. The r a t i o of y t t r i u m i n the shaft t o th a t 
i n the marrow i s 0.27 from ^^Y-D0TA-B72.2 and 0.24 from 90Y-
l2N4P3Me3-B72.3. These low r a t i o s compare favourably w i t h 
those measured by Harrison et al32, of 0.24 f o r stable ^ Oy. 
DOTA-B72.3 and 3.5 f o r the less stable ^ ^ Y - c y c l i c anhydride 
DTPA-B72.3. The y t t r i i a m dose i n the bone marrow i s from 
c i r c u l a t i n g l a b e l l e d antibody. The conc e n t r a t i o n ( % dose/g) of 
^*^Y i n the epiphyses i s s i m i l a r t o t h a t i n the whole femur 
because the epiphyses consist of both bone and marrow. 
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Figure 3.10. % Dose/g of ^^Y-D0TA-B72.3 at 48 Hours. 
DOTA-B72.3 
CO ^ 6 o 
Blood Kidney Liver Lungs Spleen Brain Femur Skel 
muse. 
Figure 3.11. % Dose of ^(^Y-DOTA-B72.3 at 48 Hours. 
DOTA-B72.3 
Blood Kidney Liver Lungs Spleen intesline Brain Femur Skel 
muse. 
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"ST VI o D 2 
0 
Blood Kidney Liver Lungs Spleen Brain Femur Skel 
muse. 




Blood Kidney Liver Lungs Spleen Intestine Brain Femur Skel 
muse. 
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• DOT A-B723 Right 
• DOT A-B723 Left 
• 12N4P3Me3-B72.3 Right 
• 12N4P3Me3-B72.3Left 
Whole lemur shaft epiphyses marrow 
Figure 3.15. % Doae in Bone Tiaauea at 48 Houra. 
• DOT A-B723 Right 
• DOT A-B723 Left 
• 12N4P3Me3-B72.3 Right 
• 12N4P3Me3-B72.3Left 
S 0.05 
Whole femur shaft epiphyses marrow 
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Tissue to blood ratios at 48 hours 
• DOT A-B723 Right 
• DOT A-B7Z3 Left 
• 12N4P3Me3-B72.3 Right 
H 12N4P3Me3-B72.3Left 
Whole femur shaft epiphyses marrow 
I n conclusion, the amounts of c i r c u l a t i n g antibody are 
gre a t e s t from 90Y-l2N4P3Me3-B72.3 w i t h 26.4% dose i n the 
blood at 48 hours compared t o 18.7% dose f o r 50Y-DOTA-B72.3. 
Both of the l a b e l l e d antibody preparations, 50Y-DOTA-B72.3 
and 90Y-i2N4P3Me3-B72.3, are h i g h l y stable i n v i v o as 
i n d i c a t e d by the very low y t t r i u m doses i n bone t i s s u e at 48 
hours post i n j e c t i o n . 
3 . 5 . YTTRIUM EXPERIMENTAL. 
Throughout the f o l l o w i n g experimental procedures, gold 
l a b e l q u a l i t y chemicals and metal f r e e p l a s t i c ware were used 
t o reduce any metal contamination. The suppliers of apparatus 
and reagents used, together w i t h the p u r i t y of reagents are 
l i s t e d i n Appendix I . Yttrium-90 was supplied as yttrium-90 
c h l o r i d e i n 0.02 M HCl {t^/2= 64 hours, /3" average energy 
0.935 MeV),.and was e s s e n t i a l l y c a r r i e r f r e e . A l l ^^ Y-
l a b e l l e d macrocycles or conjugates were p u r i f i e d by HPLC 
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before use. P r i o r t o p u r i f i c a t i o n by HPLC, a l l mixtures were 
incubated w i t h DTPA t o complex any unreacted ^ ° Y i n order t o 
prevent contamination of the HPLC column and also t o provide 
a means by which the percentage l a b e l l i n g could be monitored. 
I t has p r e v i o u s l y been established t h a t Y - l a b e l l e d 
macrocycles are stab l e w i t h respect t o transcomplexation by 
DTPA i n the pH range used^^. 
3.5.1. Y t t r i u m L a b e l l e d Macrocycles D i s s o c i a t i o n Experiments 
P r e p a r a t i o n of Yt t r i u m L a b e l l e d Macrocycles 
[Y.12N4P4Me4]" 
250 /xl of a s o l u t i o n c ontaining 200 mM ammonium acetate 
pH 6.5, 40 mM i2N4P4Me4, 4 mM Y C I 3 (10% c a r r i e r ) + 500 ^xCi 
90Y and KOH t o adju s t t o pH 6.5, was incubated at 333K (60°C) 
f o r 1 hour. 
The formation of [Y.12N4P4Me4]- was measured by removing 
2 fil of the above s o l u t i o n and incubating w i t h 50 times molar 
excess DTPA over macrocycle i n HPLC running b u f f e r (0.15 M 
ammonium acetate pH 6.8) f o r 5 minutes. This was then 
analysed by HPLC anion exchange using a Poros Q/M coliimn w i t h 
0.15 M ammonium acetate pH 6.8 b u f f e r run at 2 ml/min, t o 
determine the p r o p o r t i o n of ^ ° Y i n the macrocycle peak by 
radiometry . 
[Y.12N4P3Me3NBu2], [Y.12N4P3Me3NBz2]• , [Y.DOTA-Mal] and 
[Y.12N4P3Me3-Mai] 
The method of pr e p a r a t i o n of these complexes was the 
same as f o r [Y.l2N4P4Me4]" except t h a t no KOH was added. 
B u f f e r s f o r D i s s o c i a t i o n Measurements 
A s o l u t i o n of g l y c i n e (O.l mM) was adjusted t o pH i.O, 
1.5 and 2.0 w i t h HCl. The pH (+/- O.l u n i t s ) as measured by 
137 
Horiba pH meter on each d i s s o c i a t i o n . The same b u f f e r s were 
used throughout. 
Dissociation Measurements 
A 75 fil a l i q u o t of the 40 mM stock s o l u t i o n of 
[Y.macrocycle] was added t o 1.5 mis of each b u f f e r t o give a 
f i n a l concentration of 2 mM [Y.macrocycle]. These were 
incubated at 310K ( 3 7 0 c ) . 
Three samples (20 or 35 /xl) were removed at each time 
p o i n t and added t o a mixture of 50 times molar excess DTPA 
over macrocycle (4 or 7 /xl of 500 mM) and HPLC running b u f f e r 
(0.15 M ammoniiom acetate pH 6.8) t o make up t o 100 fjLl t o t a l 
volume. The mixtures were vortexed, c e n t r i f u g e d and then 
frozen at 253K (-20°C) immediately, or run on the HPLC w i t h i n 
5-20 minutes. S i m i l a r l y , d e f r o s t e d samples were run on the 
HPLC w i t h i n 5-20 minutes. 
Radiometric HPLC analysis was performed w i t h a Poros Q/M 
anion exchange column run at a speed of 2 ml/min w i t h 0.15 M 
ammonium acetate pH 6.8 b u f f e r . Figures 3.17 and 3.18 show 
t y p i c a l HPLC rad i o m e t r i c analysis traces from SOy-
macrocycles. Figure 3.17 i s a HPLC trace of ^^Y.l2N4P3Me3NBz2 
showing 14% d i s s o c i a t i o n a f t e r 212 hours incubation at pH 
2.0, 310K (37 ^ 0 . Figure 3.18 i s a HPLC trace of ^Oy-
12N4P3Me3-Mal showing 30% d i s s o c i a t i o n a f t e r 18 hours at pH 
1.0. 
O 1 2 3 4 
minutes 
Figure 3.17. 
I — I — I — I — I 




C a l c u l a t i o n of kobs 
The r a t e of d i s s o c i a t i o n was ca l c u l a t e d by measuring the 
r e l a t i v e amounts of complexed [Y.macrocycle] and unbound Y3+. 
Each sample taken had a 50 times molar excess of DTPA added 
t o scavenge any unbound Y3+. The [Y.macrocycle] and 
[Y.DTPA]2- were then separated by HPLC anion exchange using a 
Poros Q/M column w i t h 0 .15 M ammonium acetate pH 6.8 b u f f e r 
run a t 2 ml/min, the r e l a t i v e amounts of each species being 
given by the areas of the corresponding peaks. 
The observed r a t e of d i s s o c i a t i o n (kQj^g) was cal c u l a t e d 
from the slope of a p l o t of Log Ct/Co vs. time (seconds), 
where Co i s the concentration of [Y.macrocycle] at time zero 
and Ct i s the concentration at a given time p o i n t ( f i g u r e s 
3.19-3.23). 
Ct/Co was c a l c u l a t e d from % [Y.macrocycle] at time t 
d i v i d e d by % [Y.macrocycle] at t=0. 
kQbs = slope X -2.303 
The d i s s o c i a t i o n h a l f l i f e of the [Y.macrocycle] i s given 
by:-
t l / 2 = 0.693/kobs 
A t y p i c a l data set i s given below f o r [Y.l2N4P4Me4] 
Time % [Y.12N4P4Me4]• 
hours Run 1 Run 2 Run 3 Average 
0 100 100 100 100 
1 95. 96 96 .06 95. 94 95 .99 
3 88. 04 87 . 87 87. 96 87 .96 
20 . 75 35 . 02 35 .06 35 . 40 35 .16 
24 30 . 03 29 . 78 29 . 69 29 . 83 
27.25 25. 97 25 .70 25. 97 25 .88 
46.08 9. 89 10 . 05 9. 83 9 .92 
116.5 0. 32 0 .31 0. 25 0 .29 
A summary of a l l the y t t r i u m macrocycle d i s s o c i a t i o n data 
i s given i n t a b l e 3.5. Figures 3.19 t o 3.23 are the p l o t s f o r 
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each macrocycle. The slopes were determined by l i n e a r 
regression a n a l y s i s . 
F i g u r e 3.19. 
D i s s o c i a t i o n of [Y.12N4P4Me4]- at 310K 




Ct/Co 1. 50 
-2 . 00 
•2.50 
•3. 00 
pH 1. 0 
pH 2. 0 
Time sec 
Table 3.5. Summary of Yttrium Dissociation Data. 
Y t t r i u m 
Complex 
pH Slope of 
-Log Ct/Co 







% SE Half 
l i f e 
hours 
12N4P4Me4 1 0 6 05E-•06 1 27E •08 1 000 13 .9 0 21 13.8 
1 .5 2 .49E-•06 8 . 67E •08 1 000 5 . 74 0 35 33.6 
2 0 7 24E- 07 4 37E--08 1 000 1 .67 0 60 116 
12N4P3Me3NBu2 1 0 8 21E- 07 1 l l E - 08 0 998 1 .89 1 35 102 
1 5 3 03E- 07 8 77E- 09 0 993 0. 699 2 89 276 
2 0 1 16E- 07 3 99E^ 09 0 989 0. 267 3 44 721 
12N4P3Me3NBz2 1 0 5 76E- 07 1 14E- 08 0 996 1 .33 1 98 145 
1 5 2 20E- 07 7 74E- 09 0 989 0. 507 3 51 379 
2 0 8 45E- 08 3 08E- 09 0 988 0. 195 3 65 989 
DOTA-Mal 1 0 1 18E- 06 2 83E- 08 0 997 2 .72 2 40 70.8 
1 5 3 29E- 07 9 69E- 09 0 995 0. 758 2 95 254 
2 0 6 l l E - 08 2 89E- 09 0 987 0. 141 4 73 1370 
12N4P3Me3-Mal 1 0 2 85E- 06 6 24E- 08 0 997 6 .56 2 19 29.3 
1 5 9 17E- 07 1 96E- 08 0 997 2 .11 2 14 91.2 
2 0 2 26E- 07 9 27E- 09 0 990 0. 520 4 10 370 
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Figure 3.20, 
D i s s o c i a t i o n of [Y.12N4P3Me3NBu2] at 
310K 









pH 2. 0 
pH 1. 0 
Figure 3.21. 
Time sec 
D i s s o c i a t i o n of [Y.12N4P3Me3NBz2] at 
310K 










pH 1. 5 
pH 1. 0 
Time sec 
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F i g u r e 3.22. 
D i s s o c i a t i o n of [Y.DOTA-Mal 1- at 310K 







pH 1. 0 
F i g u r e 3.23. 
Time sec 
D i s s o c i a t i o n of [Y.12N4P3Me3-Mai] a t 
310K 
100000 200000 300000 400000 500000 600000 
H 2.0 
pH 1. 5 
H 1. 0 
Time sec 
142 
3.5.2. Yttrium Uptake Experiments. 
A 1 /JLI a l i q u o t of ^ Y^ (70 iiCi) was added t o a s o l u t i o n 
c o n t a i n i n g 25 / i l of a 50 /xM s o l u t i o n of macrocycle; 125 fil of 
400 mM NH4OAC pH 6.5; and 99 [JLI H2O, which had been warmed t o 
37OC (310K). This 5 fM s o l u t i o n of macrocycle i n 200 mM 
NH4OAC pH 6.5 was incubated at 370c (310K) . Duplicate 10 /xl 
samples were removed at time i n t e r v a l s of up t o 1 hour and 
added t o a s o l u t i o n of 5 fil 500 /M DTPA w i t h 85 (xh 0.15 M 
NH4OAC pH 6.8, vortexed and spun down. The 50 f o l d excess of 
DTPA bound any uncomplexed y t t r i i j m w h i l s t leaving any 
yttrium-macrocycle complex i n t a c f * ^ . These samples were 
analysed by anion exchange HPLC using a Poros Q/M column w i t h 
0.15 M NH4OAC pH 6.8 running b u f f e r at 2 ml/min. 
A l l samples were run w i t h i n 5 t o 40 minutes of sampling. 
The p r o p o r t i o n of ^ ^Y i n the macrocycle peak was determined 
by radiometry. The yttrium-macrocycle complex elu t e d at about 
1 min w i t h [Y.DTPA]" e l u t i n g a t about 3 min. 
3.5.3. Biodistribution Studies 
B i o d i s t r i b u t i o n studies were c a r r i e d out on ^Oy-DGTA-
B72.3 and 90Y-l2N4P3Me3-B72.3 as described i n section 3.4.2. 
The b i o d i s t r i b u t i o n s were conducted on c o n g e n i t a l l y athymic 
nude male mice (MFI-nu/nu/Ola/Hsd) aged 13 t o 16 weeks w i t h 
an average weight of 37.6 g. 
Y t t r i u m complexes were administered i n t r a venously v i a 
the t a i l v e i n a t a dose of 10 t o 15 ixCi and 10 t o 15 fig 
antibody per mouse. Five mice were used per complex and were 
k i l l e d a t 48 hours by an i n t r a - p e r i t o n e a l i n j e c t i o n of 
pentobarbitone. A sample of cardiac blood was taken and the 
f o l l o w i n g t i s s u e s dissected:- b r a i n , both femurs, both 
kidneys, l i v e r , lungs, spleen, stomach, small i n t e s t i n e (from 
the p y l o r i c sphincter t o the s t a r t of the caecum), caecum, 
la r g e i n t e s t i n e , and a sample of s k e l e t a l muscle. For a l l 
animals the r i g h t and l e f t femurs were analysed separately. 
The femurs each had t h e i r ends (epiphyses) cut o f f and the 
bone marrow washed from the shaft t o give three separate 
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samples ( i ) the shaft - bone only, ( i i ) the marrow - no bone, 
and ( i i i ) the epiphyses - both bone and marrow. 
A l l samples were weighed w i t h the exception of the gut. 
For c a l c u l a t i o n s of t o t a l t i s s u e dose, the mass of both the 
blood and the skeleton were taken as 10% of the body weight. 
Large t i s s u e s were d i v i d e d i n t o 0.5g or less f r a c t i o n s . 
Tissues were minced i n the v i a l i n which they were weighed 
and had t h e i r voliime made up t o l ml w i t h formol s a l i n e . The 
weighed epiphyses and femur shafts were placed i n i n d i v i d u a l 
2 ml quartz thimbles and ashed i n a muffle furnace at 600°C 
f o r three hours. This ashed bone was then dissolved i n 100 fil 
IM HCl and t r a n s f e r r e d t o a counting v i a l , then made up t o l 
ml. A t t e n t i o n was pai d t o the even d i s t r i b u t i o n of ti s s u e i n 
1 ml of l i q u i d f o r consistent counting of the Bremsstrahlung 
r a d i a t i o n from ^^Y. An LKB Compugamma w i t h a 3'' w e l l type 
NalTl c r y s t a l was used t o assay the t i s s u e samples f o r ^ Oy. 
Summary tables are presented i n section 3.4.2. 
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CHAPTER FOUR 
GALLIUM AND INDIUM MACROCYCLE COMPLEXES, 
149 
4.1. INTRODUCTION 
4.1.1. Radioisotopes of Gallium and Indium. 
There has been c o n s i d e r a b l e i n t e r e s t i n t h e a p p l i c a t i o n o f 
s e v e r a l g a l l i u m and i n d i u m i s o t o p e s i n n u c l e a r medicine . The 
d i f f e r e n t p h y s i c a l c h a r a c t e r i s t i c s o f each r a d i o i s o t o p e 
d e t e r m i n e i t s u s e f u l n e s s i n d i f f e r e n t n u c l e a r medicine 
a p p l i c a t i o n s ( t a b l e 4.1). Gallium-67 has a h a l f l i f e o f 78 
hours which i s co n v e n i e n t f o r m u l t i - s t e p p r e p a r a t i o n s . T h i s 
h a l f l i f e a l s o a l l o w s i n v i v o s t u d i e s t o be c a r r i e d out over 
s e v e r a l days. I n d i u m - i l l has a s i m i l a r h a l f l i f e o f 67 hours, 
i m p a r t i n g i t w i t h t h e same advantages as g a l l i u m - 6 7 . Both o f 
thes e i s o t o p e s a re c y c l o t r o n - p r o d u c e d e n a b l i n g them t o be 
o b t a i n e d e s s e n t i a l l y c a r r i e r - f r e e . The f a v o u r a b l e energies o f 
t h e i r 7 photons make them i d e a l i s o t o p e s f o r d e t e c t i o n by 
s i n g l e p h o t o n e m i s s i o n tomography (SPECT). The absence o f any 
p a r t i c l e emissions f r o m these i s o t o p e s keeps t h e r a d i a t i o n 
dose t o t h e p a t i e n t t o a minimum. 
Two s h o r t e r l i v e d , c a r r i e r f r e e , g e n e r a t o r produced 
i s o t o p e s a r e ^ ^ ^ m j ^ and ^ ^Ga w i t h h a l f l i v e s o f 100 and 68 
minu t e s r e s p e c t i v e l y . The s h o r t h a l f l i v e s makes these 
i s o t o p e s s u i t a b l e f o r q u i c k scanning methods, and t h e 
g e n e r a t o r system has t h e advantage o f p r o d u c i n g t h e i s o t o p e s 
on s i t e . G a l l i u m - 6 8 , a p o s i t r o n e m i t t e r , i s s u i t a b l e f o r use 
w i t h p o s i t r o n e m i s s i o n tomography (PET). I t s 511 keV 
a n n i h i l a t i o n photons a r e e m i t t e d a t 180° t o each o t h e r 
e n a b l i n g a much sharper image t o be o b t a i n e d w i t h PET t h a n 
w i t h SPECT. However t h e s h o r t h a l f l i f e o f g a l l i u m - 6 8 l i m i t s 
i t s use t o those r a d i o p h a r m a c u t i c a l s which do n o t r e q u i r e 
l e n g t h y p r e p a r a t i o n s o r i n v i v o t a r g e t i n g t i m e s . 
Gallium-72 ( h a l f l i f e o f 14.1 hours) was t h e f i r s t g a l l i i i m 
r a d i o i s o t o p e t o be i n v e s t i g a t e d i n man^ b u t i s not a t a l l 
s u i t a b l e as an imaging agent due t o i t s /3" em i s s i o n and h i g h 
energy gamma r a y s which a r e t o o e n e r g e t i c f o r e f f i c i e n t 
d e t e c t i o n by an Anger camera. Gallium-69 o r -71, s t a b l e 
i s o t o p e s o f g a l l i u m , have p o t e n t i a l f o r use i n n u c l e a r 
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magnetic resonance imaging due t o t h e i r n u c l e i possessing a 
magnetic moment. 
Table 4.1. Isotopes of Gallium and Indium^'^. 
I s o t o p e H a l f l i f e Method o f Maximum P r i n c i p l e Method o f 
decay p a r t i c l e gamma p r o d u c t i o n 
energy e n e r g i e s / 
MeV i n t e n s i t i e s 
MeV (%) 
^^Ga 78 h r E.G. none 0.093(38%) S8zn(p, 2n) 
0.185(21%) c y c l o t r o n 
0.300(17%) 
68Ga 68 min ^+(90%) 1. 83 0.511(178%) ^^Ge generator. 
E.G.(10%) 1.077(3%) Parent h a l f 
l i f e 272 days 
72Ga 14.1 h r 0- 3 . 99 0.630(25%) 7lGa(n,7) 
2.201(26%) nuclear r e a c t o r 
2.508(13%) 
l l l l n 67 h r E.C. none 0.171(91%) mcd(p,n) 
0.245(94%) c y c l o t r o n 
113min 100 min I .T. none 0.392(64%) •'•^ S^n generator 
0.364(29%) Parent h a l f 
l i f e 115 days. 
E.C.= O r b i t a l e l e c t r o n capture 
I.T.= I s o m e r i c t r a n s i t i o n from upper to lower isomeric s t a t e . 
4.1.2. Gallium. 
I n v e s t i g a t i o n s i n t o t h e use o f r a d i o g a l l i u m i n medicine 
began i n 1949 when s t u d i e s by Dudley and Maddox^ showed "^^Ga 
( g i v e n as g a l l i u m l a c t a t e ) d e p o s i t e d i n bone. Gallium-72 
14 h r , I3~ and 7 ) , was produced i n a n u c l e a r r e a c t o r from 
s t a b l e "^ G^a and co n s e q u e n t l y c o n t a i n e d c o n s i d e r a b l e amounts o f 
s t a b l e c a r r i e r . When t h e c y c l o t r o n produced, e s s e n t i a l l y 
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c a r r i e r - f r e e "^^ Ga ( t i / 2 78 h r , E.C. 7 ) was administered"*, a 
d i f f e r e n t b i o d i s t r i b u t i o n was found. When c a r r i e r f r e e 
[^"^Ga.Citrate] was a d m i n i s t e r e d alone, low bone uptake was 
observed^ a l o n g w i t h h i g h e r r e t e n t i o n i n o t h e r t i s s u e s such as 
l i v e r . But, when s t a b l e g a l l i u m was a d m i n i s t e r e d along w i t h 
t h e [^"^Ga.Citrate] t o i n c r e a s e t h e t o t a l dose o f g a l l i u m , t h e 
r a d i o i s o t o p e was t a k e n up by t h e bone as had been observed 
w i t h '^^Ga. T h i s b i o d i s t r i b u t i o n o f c a r r i e r - f r e e [^"^Ga.Citrate] 
was found t o be due t o t h e b i n d i n g o f ^ "^ Ga t o b l o o d p r o t e i n s ^ . 
The g a l l i u m I I I i o n resembles t h e f e r r i c i o n i n i o n i c r a d i u s 
and charge, and b i n d s s t r o n g l y t o i r o n - b i n d i n g 
macromolecules^. These i n c l u d e t r a n s f e r r i n , l a c t o f e r r i n " ^ , 
f e r r i t i n and sid e o p h o r e s ^ ( t h e i r o n - b i n d i n g p r o t e i n o f 
b a c t e r i a ) . A t t r a c e r l e v e l s i n b l o o d , g a l l i u m i s e x c l u s i v e l y 
bound t o and t r a n s p o r t e d by t r a n s f e r r i n ^ . 
I t was i n 19 69 t h a t Edward and Hayes f i r s t d e s c r i b e d t h e 
l o c a l i s a t i o n o f ^ "^ Ga i n human tumours^^ a f t e r i n t r a v e n o u s 
i n j e c t i o n o f [^"^Ga.Citrate] . Since t h e n [^"^Ga.Citrate] has 
been shown t o accumulate i n a wide v a r i e t y o f tumours as w e l l 
as i n areas o f i n f lammation^^'^2 _ -phe mechanism by which t h i s 
a c c u m u l a t i o n o f g a l l i u m t a k e s p l a c e i s c o n t r o v e r s i a l ^ . 
However, i t i s c l e a r t h a t t r a n s f e r r i n p l a y s an i m p o r t a n t r o l e 
i n t h e g a l l i u m u ptake o f tumours, a l t h o u g h o t h e r mechanisms o f 
uptake c o u l d be a t work i n d i f f e r e n t tumours. Suggestions such 
as t h e g a l l i u m b e i n g t r a n s f e r r e d f r o m t r a n s f e r r i n i n the b l o o d 
t o l a c t o f e r r i n i n t h e tumour have been made. A l s o s t u d i e s on 
h y p o t r a n s f e r r i n e m i c mice^3 suggest t h a t a l t h o u g h t r a n s f e r r i n 
may mediate t h e uptake o f g a l l i u m by most normal s o f t t i s s u e s , 
t r a n s f e r r i n independent f a c t o r s can c o n t r i b u t e towards t he 
uptake o f g a l l i u m by bone and some tumours. The most g a l l i u m -
a v i d tumours a r e t h e lymphomas and these tumours are known t o 
possess h i g h l e v e l s o f t r a n s f e r r i n r e c e p t o r s ^ ^ . The most 
p o p u l a r t h e o r y a t p r e s e n t i s t h a t g a l l i u m g a i n s access t o t h e 
tumour v i a t r a n s f e r r i n and t r a n s f e r r i n r e c e p t o r s on t h e 
tumour13 ^  
[^"^Ga-Citrate] i s used w i d e l y f o r imaging tumours and 
abscesses by SPECT. T h i s i s o f p a r t i c u l a r use i n t h e 
management o f t h e t r e a t m e n t o f p a t i e n t s w i t h tumours such as 
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lymphomas. I n these cases t h e [^'''Ga-Citrate] complex a c t s as a 
v i a b i l i t y agent f o r t h e d e t e c t i o n o f r e s i d u a l tumour, as 
f i b r o t i c o r n e c r o t i c t i s s u e s do not accumulate t h e ^"^ Ga 
l a b e l ' - " - ^ . The a c t i o n o f g a l l i u m - c i t r a t e as an imaging agent 
i s dependent on t h e f a c t t h a t t h e g a l l i u m - c i t r a t e complex i s 
u n s t a b l e and t h a t g a l l i u m - t r a n s f e r r i n i s formed v e r y q u i c k l y 
i n v i v o . I n t h e development o f any f u r t h e r g a l l i u m l a b e l l e d 
p h a r m a c e u t i c a l s f o r imaging i t i s o f g r e a t importance t h a t 
t h ese g a l l i i m i complexes a r e s t a b l e i f these p h a r m a c e u t i c a l s 
a r e t o d i r e c t t h e p h a r m a c o k i n e t i c s o f t h e l a b e l . 
G a l l i u m l a b e l l e d drugs c u r r e n t l y under i n v e s t i g a t i o n f o r 
c l i n i c a l use i n c l u d e : - ^^Qg. [oegfej-rioxamine B-Succinyl-
( D ) P h e ^ ] - O c t r o e t i d e , a s o m a t o s t a t i n analogue, f o r t h e imaging 
o f s o m a t o s t a t i n p o s i t i v e tiamours^^; ^^Ga l a b e l l e d I r o n 
h y d r o x i d e c o l l o i d as a l i v e r imaging agent^"^; ^^Ga-oxine 
l a b e l l e d r e d c e l l s and p l a t e l e t s f o r imaging b l o o d p o o l s and 
as s e s s i n g areas o f p l a t e l e t a c c u m u l a t i o n ^ ^ ; s e v e r a l ^^Ga 
l a b e l l e d m y o c a r d i a l imaging a g e n t s l ^ ' 2 2 . ^^d ^ "^ Ga l a b e l l e d 
a n t i b o d i e s 2 3 . o t h e r complexes o f ^ "^ Ga which form h i g h l y s t a b l e 
complexes i n v i v o , such as Ga-HBED, Ga-PLED, Ga-EHPG24-26 and 
complexes based on 9N327-30 ^ r e b e i n g i n v e s t i g a t e d as 
p o t e n t i a l imaging agents f o r r e n a l o r h e p a t i c c l e a r a n c e and 
p o s s i b l y f o r b r a i n imaging. 
4.1.3. Indium. 
L i k e g a l l i u m , i n d i u m has two i s o t o p e s s u i t a b l e f o r use i n 
n u c l e a r m e d i c i n e . Indium-111 o r indium-113"^ a d m i n i s t e r e d as 
t h e c h l o r i d e o r c i t r a t e complex i s r a p i d l y t a k e n up by 
t r a n s f e r r i n i n t h e b l o o d ^ ^ as w i t h g a l l i u m . As such, i n d i u m 
has been used f o r tumour l o c a l i s a t i o n and bone marrow 
imaging^2_ i n d i u m l a b e l l e d c o l l o i d a l f e r r i c h y d r o x i d e has been 
used f o r lymph node scanning^^' and l a r g e r aggregates used f o r 
l u n g s c i n t i g r a p h y ^ ^ . m i n - D T P A i s used f o r s t u d y i n g c e r e b r a l 
s p i n a l f l u i d dynamics^^^ -p^e l i p i d s o l u b l e ^ ^ ^ I n - o x i n e complex 
i s used t o l a b e l c e l l u l a r b l o o d components'^, 36 f o j - j-he 
d e t e c t i o n o f a v a r i e t y o f d i s o r d e r s , m i n - l e u k o c y t e s 
accumulate i n abscesses'"^, ^ I n - p l a t e l e t s i n areas o f 
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thrombosis-^^, and m i n - r e d b l o o d c e l l s are used t o image t he 
b l o o d p o o l o f t h e l i v e r and spleen32. 
C e r t a i n l i g a n d s used t o complex g a l l i u m a r e a l s o b e i n g 
used w i t h i n d i u m and t h e s t a b i l i t y o f these complexes i s b e i n g 
e v a l u a t e d . These i n c l u d e m i n - o c t r e o t i d e ^ S , 4 0 ^ lUln-HBED, 
m i n - P L E D , min-EHPG24-26 ^nd m i n - m a c r o c y c l e s based on 
9N327-29_ However, t h e m a j o r i t y o f p r e s e n t i n t e r e s t i n m i n 
i n n u c l e a r m e d i c i n e i s c e n t r e d around t h e use of m i n 
l a b e l l e d a n t i b o d i e s ^ l . Monoclonal a n t i b o d i e s which have been 
l a b e l l e d w i t h m i n v i a DTPA have proved s u c c e s s f u l i n imaging 
p a t i e n t s w i t h m e t a s t a t i c melanoma'*^^ c o l o r e c t a l cancer'*^ ^ nd 
m e t a s t a t i c b r e a s t cancer^^. B i s p e c i f i c monoclonal a n t i b o d y 
m ediated t a r g e t i n g o f an m i n - D T P A dimer has a l s o been used 
t o image t h y r o i d " * ^ and c o l o r e c t a l ^ ^ cancers. min-DTPA 
l a b e l l e d p o l y c l o n a l human IgG has been s u c c e s s f u l as an agent 
f o r d e t e c t i n g s i t e s o f i n f e c t i o n and i n f l a m m a t i o n i n 
p a t i e n t s ' * " ^ ' . Because o f t h e importance o f th e c h e l a t e 
s t a b i l i t y o f m i n l a b e l l e d a n t i b o d i e s , new b i f u n c t i o n a l 
c h e l a t i n g agents u s i n g macrocycles are b e i n g developed^^, 50,28 
f o r t h e i r l a b e l l i n g . 
4.1.4. Comparative S t a b i l i t y of Ga3+, i n ^ * and Fe^* Complexes. 
The i n v i v o s t a b i l i t y o f any m e t a l - l i g a n d complex i s o f 
paramount importance as t h e l o s s o f me t a l l a b e l can l e a d t o 
t o x i c e f f e c t s . T h i s i s o f p a r t i c u l a r importance where 
r a d i o a c t i v e m e t a l s a re i n v o l v e d , as once t h e m e t a l has l o s t 
t h e t a r g e t s p e c i f i c i t y i m p a r t e d on i t by t h e l i g a n d , i t w i l l 
go elsewhere i n t h e body. T h i s w i l l r e s u l t i n a r a d i a t i o n dose 
t o normal t i s s u e and a l s o g i v e h i g h background n o i s e i n 
imaging. 
As a l r e a d y d i s c u s s e d i n s e c t i o n 1.2.6, m e t a l - l i g a n d 
complexes a r e s u b j e c t t o a t t a c k f r o m H"*", and c e r t a i n a n i o n i c 
complexes a r e s e n s i t i v e t o a t t a c k from endogenous metal i o n s 
such as Zn2+, Ca2+, Mg2+ and Cu2+- Some complexes may a l s o be 
u n s t a b l e w i t h r e s p e c t t o d i s s o c i a t i o n f o l l o w i n g b i n d i n g t o 
n a t u r a l l i g a n d s such as c i t r a t e and t r a n s f e r r i n . The meta l 
i o n s Ga3+ and In3+ resemble t h e f e r r i c i o n i n s i z e , charge and 
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c h a r a c t e r . As such they tend to form s t a b l e complexes with 
n a t u r a l l y o c c u r r i n g ligands which are produced to complex Fe'"*" 
i n the body. By f a r the most important of these n a t u r a l 
l i g a n d s i s t r a n s f e r r i n , which occurs at a concentration of 
0.25 mg/lOO ml i n blood'^. The s t a b i l i t y constants for 
t r a n s f e r r i n with the metal ions Ga'"*", I n ' ^ and Fe'"*" are 
l i s t e d i n t a b l e 4.2 together with the metal ions i o n i c r a d i i . 
Indium and i r o n e x h i b i t high s t a b i l i t y constants with 
t r a n s f e r r i n , whereas g a l l i u m forms a weaker complex with 
t r a n s f e r r i n . T h i s means that indium i s more l i k e l y than 
g a l l i u m to undergo t r a n s c h e l a t i o n to t r a n s f e r r i n from a 
complex i n v i v o . 
Table 4.2. Stability Constants (Log K) of Ga^+, In^* and Fe^+ 
Complexes. 
S t a b i l i t y Constant (Log K, 298K, 1=0.1) 
Complex Ga3 + In3 + Fe3 + 
Transferrin23 23 . 7 30.5 30.3 
DTPA23 25.5 29 . 0 28.6 
EDTA24 21. 7 24.9 25.0 
PLED25 36.35 36. 89 36.91 
HBED24 39 . 57 39 . 66 39 . 68 
P-HBED23 33 . 6 33.0 33.9 
EHPG24 33 . 6 33 . 0 33.9 
9N351 30.98 26.2 28.3 
I o n i c r a d i u s ^ 0 . 62 0 . 80 0 . 65 
The s t a b i l i t y constants f o r some other complexes are a l s o 
l i s t e d i n t a b l e 4.2. The most commonly used c h e l a t e s , DTPA and 
EDTA, have lower s t a b i l i t y constants with indium than does 
t r a n s f e r r i n . The most common method of a t t a c h i n g ^ I n to 
p r o t e i n s such as antibodies f o r imaging i s v i a a b i f u n c t i o n a l 
DTPA complexing a g e n t ^ ' ' ^ 2 , 53 _ Gallium-DTPA has a 
s i m i l a r s t a b i l i t y constant to g a l l i u m - t r a n s f e r r i n . However, 
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s t u d i e s on t h e i n v i t r o and i n v i v o s t a b i l i t y o f b o t h g a l l i u m 
and i n d i u m l a b e l l e d DTPA-albumin ( i n v o l v i n g an amide-linkage 
t o t h e p r o t e i n ) have shown l o s s e s o f 9% per day of r a d i o m e t a l 
t o t r a n s f e r r i n i n v i t r o , and 6% l o s s t o t r a n s f e r r i n i n v i v o 
w i t h i n 3 I / 2 hours54_ 
I t i s c l e a r t h a t more s t a b l e complexes f o r b o t h g a l l i u m 
and i n d i u m need t o be developed. C u r r e n t approaches b e i n g 
i n v e s t i g a t e d are w i t h l i g a n d s based on two d i f f e r e n t chemical 
backbones, ( l ) , t h e a c y c l i c l i g a n d N,N'-bis[2-
h y d r o x y b e n z y l ] e t h y i e n e d i a m i n e - N , N ' - d i a c e t i c a c i d (HBED), and 
( 2 ) , t h e m a c r o c y c l i c l i g a n d l , 4 , 7 - t r i a z a c y c l o n o n a n e t r i a c e t a t e 
(9N3). 
4.1.5. HBED and Rela t e d Ligands. 
M a t h i a s , Welch e t a l are d e v e l o p i n g l i g a n d s based on t h e 
HBED backbone as c h e l a t i n g agents f o r g a l l i u m and indium^^-
26,55,56_ F i g u r e 4.1 l i s t s t h e s t r u c t u r e s o f HBED, P-HBED 
( p r o p i o n i c acid-HBED), t - b u t y l HBED, PLED EHPG and TMPHPG. 
These l i g a n d s f o r m complexes w i t h Ga3 + , In3+ and Fe^ "*" which 
have h i g h e r s t a b i l i t y c o n s t a n t s t h a n t h e m e t a l - t r a n s f e r r i n 
complexes ( t a b l e 4.2). However, t h e i n v i v o s t a b i l i t y o f a 
complex i s n o t s i m p l y a r e f l e c t i o n o f t h e thermodynamic 
s t a b i l i t y c o n s t a n t , b u t r e l i e s much more on t h e k i n e t i c 
p r o p e r t i e s o f t h e complex. T h i s i s demonstrated by t h e i n 
v i t r o and i n v i v o s t a b i l i t y o f these a c y c l i c complexes. [ i n . P -
HBED] l o s e s a l l o f i t s i n d i u m w i t h i n 2 hours^^ when i n c u b a t e d 
i n human serum w i t h e q u i m o l a r Fe3+. Under s i m i l a r c o n d i t i o n s 
[Ga.P - H B E D ] s u r r e n d e r s 6.6% o f i t s g a l l i u m over 48 hours. I n 
v i v o t h i s i s seen as sl o w e r b l o o d c l e a r a n c e o f t h e l a b e l ^ ^ . 
T h i s s l o w e r b l o o d c l e a r a n c e i s a l s o seen f o r g a l l i u m and 
i n d i u m complexes o f EHPG26 and T M P H P G ^ ^ , w i t h t h e i n d i u m 
complexes l o s i n g more m e t a l t o t r a n s f e r r i n t h a n t h e g a l l i u m 
complexes. B i o d i s t r i b u t i o n s t u d i e s on g a l l i u m and in d i u m 
complexes o f H B E D show more b l o o d r e t e n t i o n from t h e i n d i u m 
complex t h a n t h e g a l l i u m complex a t l hour^^^ a l t h o u g h no 
r e t e n t i o n s t u d i e s were c a r r i e d o u t t o assess l o n g e r t e r m 
complex s t a b i l i t y . Serum s t a b i l i t y s t u d i e s on [Ga . H B E D ] show a 
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l o s s o f 2.7% o f t h e g a l l i u m i n 24 hours24. The indi u m and 
g a l l i u m complexes o f PLED show h i g h e r b l o o d l e v e l s a t i hour 
t h a n t h e HBED complexes i n d i c a t i n g t h a t t h e y a re l e s s s t a b l e 
i n v i v o t h a n t h e HBED complexes^^. 
Figure 4.1. Chemical Structures of HBED Related Ligands. 
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By a l t e r i n g t h e r i n g s u b s t i t u e n t s on HBED, s t r u c t u r a l l y 
r e l a t e d l i g a n d s w i t h a range o f l i p o p h i l i c i t i e s have been 
produced. The e f f e c t o f these changes on t h e ph a r m a c o k i n e t i c s 
o f t h e complexes have been e v a l u a t e d . For i n s t a n c e , t h e 
l i p o p h i l i c l i g a n d t-butyl-HBED shows h e p a t o b i l i a r y e x c r e t i o n 
r a t h e r t h e n t h e r e n a l e x c r e t i o n shown by t h e l e s s l i p o p h i l i c 
l i g a n d s 2 4 . i t had been hoped t h a t these s m a l l ( m o l e c u l a r 
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w e i g h t s 450-650), n e u t r a l , l i p o p h i l i c complexes would cross 
t h e b l o o d - b r a i n b a r r i e r t o enable them t o be used i n SPECT 
imaging o f t h e b r a i n . A l t h o u g h t h e c u t o f f p o i n t f o r c r o s s i n g 
t h e b l o o d - b r a i n b a r r i e r had been e s t i m a t e d t o be i n the range 
o f 400 t o 600 d a l t o n s , none o f these HBED analogues crossed 
t h e b l o o d - b r a i n b a r r i e r ^ ^ . 
4.1.6. 9N3 and Related Ligands. 
The second approach t o d e v e l o p i n g s t a b l e i n d i u m and 
g a l l i u m complexes has been w i t h m a c r o c y c l i c l i g a n d s ( f i g u r e s 
4.2 and 4 . 3 ) . The major advantage o f me t a l complexes w i t h 
macrocycles over t h e l i g a n d s d i s c u s s e d p r e v i o u s l y (pages 155-
6 ), i s t h e i r h i g h k i n e t i c s t a b i l i t y . As was discuss e d i n 
s e c t i o n 1.2 .6 f o r t h e s t a b i l i t y o f g a d o l i n i u m macrocycles, 
m e t a l macrocycle complexes are h i g h l y i n e r t , k i n e t i c a l l y , t o 
a c i d o r c a t i o n promoted a t t a c k . These metal - 9 N 3 complexes are 
expected t o be even more r e s i s t a n t t o a c i d o r c a t i o n a t t a c k 
t h a n metal-D0TA(12N4) complexes as t h e y have a n e u t r a l charge. 
The thermodynamic s t a b i l i t y c o n s t a n t s l i s t e d i n t a b l e 4.2 show 
h i g h v a l u e s f o r t h e 9N3 complexes, b u t t h e s t a b i l i t y c o n s t a n t s 
f o r PLED, HBED and EHPG are h i g h e r . However, i n v i v o , due t o 
t h e i r k i n e t i c i n e r t n e s s , t h e m a c r o c y c l i c 9N3 complexes are 
more s t a b l e t h a n t h e HBED ty p e a c y c l i c l i g a n d s . 
When t h e a c i d - c a t a l y s e d d i s s o c i a t i o n o f [Ga .9N3] was 
measured i n 6M HNO3 by "^ G^a NMR, no d i s s o c i a t i o n was observed 
by 60 days^"^. T h i s h i g h s t a b i l i t y i s r e f l e c t e d i n t h e i n v i v o 
s t u d i e s ^ S . [ i n . 9 N 3 ] i s a l s o r e s i s t a n t t o a c i d - c a t a l y s e d 
d i s s o c i a t i o n , b u t n o t as much as [Ga . 9 N 3 ] . When mon i t o r e d by 
^ ' c NMR i n t h e pH range 0 t o -0.7, [ I n . 9 N 3 ] d i s s o c i a t e d w i t h a 
second o r d e r r a t e constant^"^ o f 1.8 x 10"'* dm' mol'^ s"^. I n 
v i v o s t u d i e s have shown t h a t [ I n . 9 N 3 ] i s e n t i r e l y c l e a r e d from 
t h e body i n a few hours^^. The s t r u c t u r a l l y r e l a t e d g a l l i u m 
and i n d i u m 9N3P3Me3 and 9N3C3Me3 complexes a l s o d i s p l a y h i g h 
r e s i s t a n c e t o i n v i t r o a c i d - c a t a l y s e d d i s s o c i a t i o n ' s , 5 8 ^ 
T h i s h i g h k i n e t i c s t a b i l i t y o f t h e m e t a l macrocycle 
complexes i s due t o t h e compact arrangement o f the donor 
oxygen and n i t r o g e n atoms around t h e c e n t r a l l y l o c a t e d 
158 
t r i v a l e n t i o n , and t h e o v e r a l l r i g i d i t y o f t h e s t r u c t u r e . The 
s t a b i l i t y o f t h e complex i s dependent on t h e f i t o f the metal 
i o n i n t h e macrocycle c a v i t y . Two parameters which p l a y an 
i m p o r t a n t r o l e i n t h i s a r e t h e size-match s e l e c t i v i t y and t h e 
s t e r i c e f f i c i e n c y o f t h e l i g a n d ^ ^ . Size-match d e p i c t s t h e s i z e 
o f m e t a l i o n which i s b e s t matched t o t h e macrocycles c a v i t y 
and hence forms t h e most s t a b l e complex^O"^^_ s t e r i c 
e f f i c i e n c y i s when t h e s t e r i c s t r a i n on t h e l i g a n d i s kept t o 
t h e minimum w h i l s t c o n f o r m i n g t o t h e p r e f e r r e d c o - o r d i n a t i o n 
geometry o f t h e m e t a l i o n . 
The g a l l i u m i o n has a s m a l l e r r a d i u s t h a n indiiom and 
adopts a p p r o x i m a t e l y o c t a h e d r a l c o - r o r d i n a t i o n w i t h t h e l i g a n d s 
9N356 and 9N3P3Ph327. i n d i u m adopts t h e geometry o f a 
d i s t o r t e d t r i g o n a l p r i s m i n t h e complex w i t h t h e l i g a n d 
9N3Me3C3^8 and a pentag o n a l b i p y r a m i d a l geometry i n the hepta 
c o - o r d i n a t e c h l o r o i n d i u m complex o f 9N3. Thus t h e f a v o u r a b l e 
i o n i c s i z e and c o - o r d i n a t i o n geometry o f g a l l i u m w i t h these 
9N3 t y p e macrocycles c o n t r i b u t e s t o t h e i r h i g h e r s t a b i l i t y 
o ver t h e i n d i u m complexes. 
The h i g h i n v i v o s t a b i l i t y o f these g a l l i u m and indi u m 9N3 
complexes has l e a d t o t h e development o f f u n c t i o n a l i s e d 
l i g a n d s f o r t h e attachment t o monoclonal a n t i b o d i e s f o r use i n 
tiomour d e t e c t i o n ' s , 4 9 - 5 1 . 
Two f u r t h e r 9N3 analogues b e i n g s t u d i e d are TX-TACN and 
TS-TACN by Moore, Welch a t al30,63,64 ( f i g u r e 4.2). The 
g a l l i u m complexes o f b o t h these l i g a n d s e x h i b i t s l i g h t l y 
d i s t o r t e d o c t a g o n a l geometry s i m i l a r t o t h a t r e p o r t e d by 
Parker e t a l f o r t h e o t h e r 9N3 analogues^^''"^ • The l i p o p h i l i c 
i n d i u m complex o f TX-TACN shows h i g h l i v e r and b l o o d r e t e n t i o n 
i n v i v o ^ 3 i n d i c a t i n g p o s s i b l e h e p a t o b i l i a r y c l e a r a n c e and 
i n s t a b i l i t y o f t h i s complex. I n v i v o s t u d i e s on th e g a l l i u m 
complexes, wh i c h a r e l i k e l y t o be more s t a b l e , have not y e t 
been r e p o r t e d . The l i g a n d TS-TACN has been designed t o be 
s m a l l e r t h a n TX-TACN w h i l s t r e m a i n i n g l i p o p h i l i c i n th e hope 
t h a t i t can c r o s s t h e b l o o d - b r a i n b a r r i e r ^ " * . 
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4.1.7. The Scope of the Work i n T h i s Chapter. 
I n t h i s c h a p t e r a s e r i e s o f seven s t r u c t u r a l l y r e l a t e d 
l i g a n d s ( f i g u r e 4.3) are s t u d i e d as complexes w i t h g a l l i u m o r 
i n d i i i m . The e f f e c t o f t h e d i f f e r e n t s u b s t i t u e n t s added t o t h e 
9N3 core i s e v a l u a t e d . The i n v i v o s t a b i l i t y and r o u t e s o f 
e x c r e t i o n a r e examined, as w e l l as t h e o v e r a l l 
b i o d i s t r i b u t i o n s o f t h e complexes. P a r t i t i o n c o e f f i c i e n t s are 
measured f o r t h e i n d i u m complexes t o t r y and c o r r e l a t e changes 
i n l i p o p h i l i c i t y o f t h e complexes t o changes i n t h e i r 
p h a r m a c o k i n e t i c s . G a l l i u m and i n d i u m 9N3 complexes are f u r t h e r 
s t u d i e d as p o s s i b l e tumour l o c a l i s a t i o n agents, as i s a 
g a l l i u m - 9 N 3 - m i s o n i d a z o l e c o n j u g a t e . The g a l l i u m - 7 1 complex of 
9N3 i s a l s o i n v e s t i g a t e d f o r i t s s u i t a b i l i t y i n NMR imaging. 
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Figure 4 . 3 . Chemical Structures of the Llgands Used to Complex 
Gallium and Indium 
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4 . 2 . B I O D I S T R I B U T I O N OF GALLIUM C O M P L E X E S . 
The aims o f t h i s s t u d y were t o determine t h e p r i n c i p l e 
r o u t e o f e x c r e t i o n ( h e p a t o b i l i a r y o r r e n a l ) o f t h e 7 g a l l i u m 
complexes and t o assess t h e i r i n v i v o s t a b i l i t y . 
P r e s e n t a t i o n of R e s u l t s 
The g a l l i u m complexes have been d i v i d e d i n t o two groups 
f o r t h e b i o d i s t r i b u t i o n s t u d i e s . Group I are a z a - c a r b o x y l i c 
a c i d s , and group I I a r e aza-phosphinic a c i d s . 
F i g u r e s 4.4 and 4.5 show t h e % dose i n 5 t i s s u e s a t l hour 
p o s t i n j e c t i o n f o r t h e groups I and I I . These 5 t i s s u e s are 
b l o o d , k i d n e y s , l i v e r , g a l l b l a d d e r and g u t , where t h e g u t 
r e p r e s e n t s t h e i n t e s t i n a l t r a c t ( w i t h c o n t e n t s ) from t h e 
stomach t o t h e l a r g e i n t e s t i n e i n c l u s i v e . F i g u r e s 4.6 and 4.7 
show t h e % dose i n t h e t i s s u e a t 24 hours p o s t i n j e c t i o n f o r 
these groups. However a t t h i s t i m e t h e % dose i n t h e g a l l 
b l a d d e r was t o o low t o be d e t e c t e d , b u t t h e % Dose i n the 
s k e l e t o n i s shown. More p r e c i s e d a t a f o r i n d i v i d u a l t i s s u e s 
a r e g i v e n i n f i g u r e s 4.8 t o 4.17, these f i g u r e s each show t h e 
% dose f o r each o f t h e 7 complexes i n a s i n g l e t i s s u e . 
to F i g u r e s i n t h i s S e c t ion. 
Number i n Group Complex 
Fi g u r e s 
1. I [Ga.9N3] 
2 . I [Ga.9N3Me3C3] 
3 . I [Ga.9N3C3Ph3] 
4. I I [Ga.9N3P3Me3] 
5. I I [Ga.9N3P3iPr3] 
6. I I [Ga.9N3P3Ph3] 
7. I I [Ga.9N3P3Bz3] 
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4 . 2 . 1 . B i o d i s t r i b u t i o n Data f o r the Two Groups of Gallium 
Complexes. 
Figu r e 4 . 4 . Biodistribution of Group I Aza-carboxylic Acids at 
1 Hour, 
Group ! 
















F i g u r e 4 . 5 , Biodistribution of Group II Aza-phosphinic Acids 




















F i g u r e 4 . 6 . Biodistribution of Group I Aza-carboxylic Adda at 
24 Houra. 
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F i g u r e 4 . 7 . Biodistribution of Group II Aza-phosphinic Adda 
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% Dose of "^^ Ga i n Blood. 
Figure 4 . 8 . % Dose ^"^Ga in Blood at 1 Hour. 
% Dose in Blood at 1 hour 
F i g u r e 4 , 9 . % Dose ^"^Ga in Blood at 24 Hours. 
% Dose in Blood at 24 hours 
° 0.6 
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% Dose "^^ Ga i n Kidneys 
Figure 4.10. % Dose ^"^Ga in Kidneys at 1 Hour. 
% Dose in Kidney at 1 hour 
10 
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F i g u r e 4.11. % Dose ^"^Ga in Kidneys at 24 Hours. 
% Dose in Kidney at 24 hours 
o 1.0 
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% Dose S'^ Ga i n L i v e r 
F i g u r e 4,12. % Dose ^"^Ga in Liver at 1 Hour. 
% Dose in Liver at i hour 
F i g u r e 4,13. % Dose ^"^Ga in Liver at 24 Hours 







% Dose ^"'oa i n G a l l Bladder. 
Figure 4.14. % Dose ^"^Ga in Gall Bladder at 1 Hour. 
% Dose in Gail Bladder at 1 hour 
0 1.0 
% Dose S'^ Ga i n Skeleton, 
F i g u r e 4.15. % Dose ^"^Ga in Skeleton at 24 Hours 
% Dose DO Skeleton at 24 hours 
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% Dose S'^ Ga i n the Gut. 
Figure 4.16. % Dose ^"^Ga in Total Gut at 1 Hour 
% Dose in Total Gut at 1 hour 
Figure 4.17, % Dose ^"^Ga in Total Gut at 24 Hours 
% Dose in Total Gut at 24 hours 
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other T i s s u e s 
The % dose/g was a l s o measured i n t h e f o l l o w i n g t i s s u e s : -
b r a i n , l u n g , h e a r t muscle, s k e l e t a l muscle, s a l i v a r y glands 
and s p l e e n . When t h e % dose/g i n these t i s s u e s was compared t o 
t h a t o f b l o o d , t h e r e was some c o n c e n t r a t i o n of t h e complexes 
[Ga.9N3], [Ga.9N3Me3C3] and [Ga.9N3P3Me3] i n t h e l u n g , 
s a l i v a r y g l a n d s and s p l e e n a t 24 hours. A l t h o u g h t h e r e was 2 
t o 10 t i m e s t h e c o n c e n t r a t i o n o f g a l l i u m i n these t i s s u e s i n 
comparison t o t h e b l o o d , t h e y were v e r y low a b s o l u t e amounts. 
There was no c o n c e n t r a t i o n o f g a l l i i a m from any o f t h e 
macrocycles measured i n t h e b r a i n , h e a r t muscle o r s k e l e t a l 
muscle. 
4.2.2. Summary of the Gallium B i o d i s t r i b u t i o n Data. 
Clearance Pathways 
Group I 
F i g u r e 4.4 g i v e s t h e o v e r a l l v i e w o f t h e b i o d i s t r i b u t i o n 
o f t h ese n e u t r a l g a l l i u m a z a - c a r b o x y l i c a c i d s a t 1 hour. 
The complex [Ga.9N3] (number 1) i s b e i n g c l e a r e d 
e x c l u s i v e l y by t h e r e n a l system. The r a t e o f c l e a r a n c e i s such 
t h a t t h e m a j o r i t y o f t h e complex has a l r e a d y l e f t t h e body by 
1 hour, ( u n l i k e complexes which are c l e a r e d v i a t h e 
h e p a t o b i l i a r y pathway which a r e s t i l l p r e s e n t i n t h e gut a t l 
h o u r ) . 
The complex [Ga.9N3Me3C3] (number 2) i s a l s o c l e a r e d v i a 
t h e r e n a l system. A l t h o u g h t h e r e i s l i t t l e evidence o f t h i s 
complex i n t h e g u t , t h e r e i s a 4% dose i n t h e l i v e r ( f i g u r e 
4.12) a t 1 hour. As t h i s l i v e r dose has been c l e a r e d by 24 
hours ( f i g u r e 4.13), i t i s l i k e l y t o r e p r e s e n t a s m a l l amount 
o f h e p a t o b i l i a r y h a n d l i n g r a t h e r t h a n d e p o s i t i o n o f 
uncomplexed g a l l i u m . 
The l i p o p h i l i c complex [Ga.9N3C3Ph3] (number 3) i s b e i n g 
c l e a r e d p r i m a r i l y by t h e h e p a t o b i l i a r y system. T h i s i s 
a p parent f r o m t h e h i g h (53%) dose i n t h e g u t a t l hour ( f i g u r e 
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4.16) . A l r e a d y by 1 hour t h e r e i s l i t t l e o f t h e complex l e f t 
i n t h e l i v e r ( f i g u r e 4.12), a l t h o u g h t h e r e i s s t i l l some i n 
t h e g a l l b l a d d e r on i t s way t o t h e g u t . 
Group I I 
F i g u r e 4.5 g i v e s t h e o v e r a l l p i c t u r e o f t h e 
b i o d i s t r i b u t i o n o f these n e u t r a l g a l l i u m aza-phosphinic a c i d s 
1 hour p o s t i n j e c t i o n . 
The complex [Ga.9N3P3Me3] (number 4) i s t h e o n l y complex 
i n t h i s group w h i c h e x h i b i t s e x c l u s i v e l y r e n a l c l e a r a n c e . The 
s l i g h t l y more l i p o p h i l i c complex [Ga.9N3P3iPr3] (number 5) has 
5% dose i n t h e g u t a t l hour ( f i g u r e 4.16), b u t i s s t i l l b e i n g 
c l e a r e d p r i m a r i l y v i a t h e r e n a l pathway. 
The two l i p o p h i l i c complexes [Ga.9N3P3Ph3] and 
[Ga.9N3P3BZ3] (numbers 6 and 7) a r e b o t h c l e a r e d 
p r e f e r e n t i a l l y v i a t h e h e p a t o b i l i a r y pathway w i t h 36% and 38% 
dose r e s p e c t i v e l y i n t h e g u t a t l hour ( f i g u r e 4.16). The 
amount o f dose f r o m these complexes p r e s e n t i n t h e l i v e r a t l 
hour was n o t v e r y h i g h ( f i g u r e 4.12) w i t h o n l y [Ga.9N3P3Bz3] 
h a v i n g any dose s t i l l i n t h e g a l l b l a d d e r ( f i g u r e 4.14). These 
two l i p o p h i l i c g a l l i u m complexes, l i k e t h e complex 
[Ga.9N3C3Ph3], ar e t r a n s p o r t e d t h r o u g h t h e h e p a t o b i l i a r y 
system and i n t o t h e g u t by l hour p o s t i n j e c t i o n . 
I n Vivo S t a b i l i t y of Gallium Macrocycles 
Group I 
F i g u r e 4.6 g i v e s t h e o v e r a l l p i c t u r e o f t h e 24 hour 
b i o d i s t r i b u t i o n s o f t h e a z a - c a r b o x y l i c a c i d s . 
The complex [Ga.9N3] (number 1) demonstrates v e r y l i t t l e 
o v e r a l l r e t e n t i o n a t 24 hours w i t h o n l y 0.05% dose r e m a i n i n g 
i n t h e s k e l e t o n ( f i g u r e 4.15) and l e s s t h a n 0.002% dose i n t h e 
b l o o d ( f i g u r e 4.9) . T h i s i s c o n s i s t e n t w i t h a h i g h i n v i v o 
s t a b i l i t y . 
[Ga.9N3Me3C3] (number 2) a l s o has v e r y l i t t l e o v e r a l l 
r e t e n t i o n a t 24 hours. A l t h o u g h t h e r e i s a h i g h e r r e t e n t i o n i n 
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t h e s k e l e t o n t h a n f o r [Ga.9N3] (0.35% compared t o 0.05% dose) 
t h i s complex s t i l l e x h i b i t s good o v e r a l l s t a b i l i t y . 
[Ga.9N3C3Ph3] (number 3) has t h e h i g h e s t o v e r a l l r e t e n t i o n 
o f t h e complexes i n t h i s group. The s k e l e t a l v a l u e of 0.85% 
dose and b l o o d v a l u e o f 0.37% dose a t 24 hours i s i n d i c a t i v e 
o f a low l e v e l o f d i s s o c i a t i o n . 
Group I I 
F i g u r e 4.7 g i v e s t h e o v e r a l l p i c t u r e o f t h e 24 hour 
b i o d i s t r i b u t i o n s o f t h e g a l l i u m aza-phosphinic a c i d s . 
The r e n a l l y e x c r e t e d complex [Ga.9N3P3Me3] (number 4) 
shows t h e l e a s t r e t e n t i o n o f a l l t h e complexes i n t h i s group 
a t 24 hours. The v e r y low s k e l e t a l (0.06%) and b l o o d (0.004%) 
doses ( f i g u r e s 4.15 and 4.9) are i n d i c a t o r s o f t h e h i g h i n 
v i v o s t a b i l i t y o f t h i s complex. 
The complex [Ga.9N3P3iPr3] (number 5) has h i g h l e v e l s o f 
r e t e n t i o n a t 24 hours, p a r t i c u l a r l y i n t h e b l o o d and s k e l e t o n , 
i n d i c a t i n g t h a t t h i s complex i s d i s s o c i a t i n g i n v i v o . 
Complex number 7, [Ga.9N3P3Bz3], has 1.6% dose i n the 
s k e l e t o n a t 24 hours and e l e v a t e d doses i n t h e b l o o d and 
l i v e r . A l t h o u g h t h e r e s t i l l appears t o be some h e p a t o b i l i a r y 
c l e a r a n c e o c c u r r i n g a t 24 hours ( f i g u r e 4.7), t h e r e i s c l e a r l y 
some i n v i v o d i s s o c i a t i o n o f t h i s complex. 
[Ga.9N3P3Ph3] (number 6) appears t o be t h e most s t a b l e o f 
a l l o f t h e h e p a t o b i l i a r y c l e a r e d complexes from b o t h groups. 
W i t h o n l y 0.15% dose i n t h e s k e l e t o n and 0.07% dose i n t h e 
b l o o d a t 24 hours. T h i s makes [Ga.9N3P3Ph3] t h e most p r o m i s i n g 
o f t hese n e u t r a l g a l l i u m complexes f o r f u r t h e r s t udy of 
h e p a t o b i l i a r y h a n d l i n g . 
4 . 3 . B I O D I S T R I B U T I O N OF INDIUM C O M P L E X E S . 
The b i o d i s t r i b u t i o n o f 7 i n d i u m complexes was examined i n 
o r d e r t o assess t h e i r p r i n c i p l e r o u t e o f e x c r e t i o n 
( h e p a t o b i l i a r y o r r e n a l ) and i n v i v o s t a b i l i t y . These were t h e 
same groups o f a z a - c a r b o x y l i c and aza-phosphinic a c i d s as were 
s t u d i e d i n s e c t i o n 4.2 complexed w i t h g a l l i u m . 
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P r e s e n t a t i o n of R e s u l t s 
The i n d i u m complexes have been d i v i d e d i n t o t h e same two 
groups as t h e g a l l i u m complexes ( s e c t i o n 4.2) f o r the 
b i o d i s t r i b u t i o n s t u d i e s . Group I are a z a - c a r b o x y l i c a c i d s , and 
group I I a r e a z a - p h o s p h i n i c a c i d s . 
F i g u r e s 4.18 and 4.19 show t h e % dose i n 5 t i s s u e s a t 1 
hour p o s t i n j e c t i o n f o r t h e groups I and I I . These 5 t i s s u e s 
a r e b l o o d , k i d n e y s , l i v e r , g a l l b l a d d e r and g u t , where t h e g u t 
r e p r e s e n t s t h e i n t e s t i n a l t r a c t ( w i t h c o n t e n t s ) from t h e 
stomach t o t h e l a r g e i n t e s t i n e i n c l u s i v e . F i g u r e s 4.20 and 
4.21 show t h e % dose i n 5 t i s s u e s a t 24 hours p o s t i n j e c t i o n 
f o r these groups. However a t t h i s t i m e t h e % dose i n t h e 
s k e l e t o n i s shown and n o t t h e g a l l b l a d d e r . More p r e c i s e d a t a 
f o r i n d i v i d u a l t i s s u e s a r e g i v e n i n f i g u r e s 4.22 t o 4.31, 
th e s e f i g u r e s each show t h e % dose f o r each o f t h e 7 complexes 
i n a s i n g l e t i s s u e . 
Key to F i g u r e s i n t h i s S e c t i o n . 
Number i n 












I I [In.9N3P3Me3] 
I I [In.9N3P3iPr3] 
I I [In.9N3P3Ph3] 
I I [In.9N3P3Bz3] 
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4 . 3 . 1 . B i o d i s t r i b u t i o n Data f o r the Two Groups of Indium 
Coo^lexes. 
F i g u r e 4 . 1 8 . Blodiatribution of Group I Aza-carboxylic Adda 
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F i g u r e 4 . 1 9 . Biodistribution of Group II Aza-pboapbinic Adda 
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F i g u r e 4 . 2 0 . Biodistribution of Group I Aza-carboxylic Adda 
at 24 Hours. 
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F i g u r e 4 . 2 1 . Biodistribution of Group II Aza-phosphinic Adda 
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% Dose of ^ ^ ^ i n i n Blood. 
Fig u r e 4.22. % Dose ^^^In in Blood at 1 Hour. 
% Dose in Blood at 1 hour 
CO 
J? 
F i g u r e 4.23. % Dose ^^^In in Blood at 24 Hours. 
% Dose in Blood at 24 hours 
o 0.6 
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% Dose of •'•^^In i n Kidneys 
Figure 4.24. % Dose ^^^In in Kidneys at 1 Hour, 
% D o s e in Kidney at 1 liour 
10^ 
H I • I I 
Figure 4,25. % Dose ^^^In in Kidneys at 24 Hours. 









% Dose of ^ ^ I n i n Liver 
Figure 4 . 2 6 . % Dose ^^^In in Liver at 1 Hour. 
% D o s e in Liver at 1 houir 
40.50% 
Figure 4 . 2 7 , % Dose ^^^In in Liver at 24 Hours 
% Dose m Liver at 24 hours 
24.30% 
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% Dose of l ^ ^ l n i n Gall Bladder. 
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% D o s e in GaiS Bladder at 1 hour 
% Dose of ^ ^ ^ I n i n Skeleton. 
Figure 4.29. % Dose ^^^In in Skeleton at 24 Hours 
% D o s e in SkeSeton at 24 hours 
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% Dose of l l ^ l n i n the Gut. 
Figure 4 . 3 0 . % Dose ^^^In in Total Gut at 1 Hour 
% D o s e In Total G o t at 1  ooor 
Figure 4 . 3 1 . % Dose ^^^In in Total Gut at 24 Hours 
% D o s e in TotaB Got at 24 hours 
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other Tissues 
The % dose/g was also measured i n the f o l l o w i n g tissues:-
b r a i n , lung, heart muscle, s k e l e t a l muscle, and spleen. When 
the % dose/g i n these t i s s u e s was compared t o t h a t of the 
blood, there was about twice the concentration of indium i n 
the lung and spleen a t 24 hours from a l l the complexes. There 
was no concentration of indium i n the b r a i n , heart muscle or 
s k e l e t a l muscle from any of the complexes measured. 
4.3.2 S\]mmary of Biodistribution Data for Indium Macrocycles . 
Clearance Pathways 
Group I 
Figure 4.18 gives the o v e r a l l view of the b i o d i s t r i b u t i o n 
of the n e u t r a l indium aza-carboxylic acids at 1 hour post 
i n j e c t i o n . 
The complex [In.9N3] (number l ) i s being cleared e n t i r e l y 
by the r e n a l system. A f t e r l hour the m a j o r i t y of the complex 
has already been cleared from the body v i a the renal system. 
[In.9N3Me3C3] (number 2) i s showing some h e p a t o b i l i a r y 
clearance, 10% at l hour ( f i g u r e 4.30). Nevertheless the 
m a j o r i t y of t h i s complex i s s t i l l being handled by the renal 
system. 
The t h i r d complex [In.9N3C3Ph3] has very high doses i n 
both the l i v e r (41%) and gut (32%) at l hour. This i n d i c a t e s a 
high amount of h e p a t o b i l i a r y clearance, however a t 24 hours 
( f i g u r e 4.27) there i s s t i l l 24% dose i n the l i v e r . This 
suggests the accumulation of decomplexed indium i n the l i v e r 
(see next page : - i n v i v o s t a b i l i t y of indium macrocycles). 
Group I I 
The b i o d i s t r i b u t i o n of the n e u t r a l indium aza-phosphinic 
acids at l hour post i n j e c t i o n are given i n f i g u r e 4.19. 
181 
The complex [in.9N3P3Me3] (number 4) has very l i t t l e dose 
i n the gut a t l hour i n d i c a t i n g t h a t i t i s eliminated v i a the 
r e n a l pathway. 
The other 3 complexes i n t h i s group [In.9N3P3iPr3] , 
[In.9N3P3Ph3] and [In.9N3P3Bz3] (numbers 5, 6 and 7) 
demonstrate in c r e a s i n g doses i n the gut at l hour of 14, 36 
and 42% r e s p e c t i v e l y . The more l i p o p h i l i c the phosphorus 
s u b s t i t u e n t on the complex the more h e p a t o b i l i a r y clearance i s 
shown by the indium complex. 
I n Vivo S t a b i l i t y of Indium Complexes. 
Group I 
Figure 4.20 gives the o v e r a l l view at 24 hours f o r the 
aza-carboxylic a c i d complexes. 
The % dose i n the skeleton at 24 hours i s very low f o r a l l 
three complexes (<0.5% dose). The % dose i n the blood i s also 
low, less than 0.01% f o r [In.9N3] and [In.9N3Me3C3] (numbers l 
and 2 ) , and 0.1% f o r [In.9N3C3Ph3] (number 3). This together 
w i t h the low l i v e r r e t e n t i o n f o r the complexes [ln.9N3] and 
[In.9N3Me3C3] i s an i n d i c a t o r of high i n v i v o s t a b i l i t y f o r 
these two complexes. The % dose i n the l i v e r f o r the complex 
[In.9N3C3Ph3] i s however very high, 24% at 24 hours. Although 
there i s s t i l l a l i t t l e gut clearance of 3% dose, t h i s l e v e l 
of l i v e r d e p o s i t i o n i s i n d i c a t i v e of d i s s o c i a t i o n of t h i s 
p a r t i c u l a r complex. 
Group I I 
Figure 4.21 gives the o v e r a l l view at 24 hours f o r the 
indium aza-phosphinic acids. 
The only complex i n t h i s group t o show low t i s s u e 
r e t e n t i o n at 24 hours i s number 5 [In.9N3P3iPr3] . This indiiam 
complex appears t o be s t a b l e i n v i v o . 
The other 3 complexes, [In.9N3P3Me3], [In.9N3P3Ph3] and 
[In.9N3P3BZ3] (numbers 4, 6 and 7) a l l show high t i s s u e 
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r e t e n t i o n at 24 hours. This i s p a r t i c u l a r l y evident from the % 
doses i n the skeleton of 2.1, 1.2 and 1.9% r e s p e c t i v e l y . Even 
i f the high blood dose i s taken i n t o account, the skeleton has 
at l e a s t twice as much dose/g as the blood. A l l three 
complexes [In.9N3P3Me3], [In.9N3P3Ph3] and [In.9N3P3Bz3] are 
d i s s o c i a t i n g i n v i v o . 
From the indium macrocycles studied here, the only 
complexes which are stab l e i n v i v o are number l [In.9N3], 
number 2 [In.9N3Me3C3] and number 5 [In.9N3P3iPr3]. Of these 
[ln.9N3] i s cleared s o l e l y by the renal pathway. [In.9N3Me3C3] 
and [In.9N3P3iPr3] show l i m i t e d h e p a t o b i l i a r y clearance of 10 
and 14% dose r e s p e c t i v e l y at l hour post i n j e c t i o n . 
4.4 PARTITION COEFFICIENTS OF INDIDM MACROCYCLE 
COMPLEXES 
Log P values were determined f o r 6 of the 7 indium 
complexes st u d i e d i n v i v o ( s e c t i o n 4.3.). The complex 
[In.9N3C3Ph3] was h i g h l y unstable i n v i v o and was omitted. 
A high (more p o s i t i v e ) Log P value i s c o r r e l a t e d w i t h 
increased l i p o p h i l i c i t y . L i p o p h i l i c compounds are more l i k e l y 
t o be e l i m i n a t e d from the body v i a the h e p a t o b i l i a r y route 
than the r e n a l route. Therefore i t was hoped t o e s t a b l i s h a 
c o r r e l a t i o n between the Log P value of the complex and i t s 
route of e l i m i n a t i o n from a mouse. 
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a) PBS i s phosphate-buffered s a l i n e , pH 7 . 4 . 
Figure 4.32. Log P values for Indium Complexes. 
o 
Log P Values for indium Compiexes 
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Figure 4.33. Plot of Butanol/Water Log P Values vs. % Dose of 
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For a l l the indium complexes there i s no s i g n i f i c a n t 
d i f f e r e n c e between the Log P values i n water or PBS 
(phosphate-buffered s a l i n e ) , i n d i c a t i n g t h a t the b u f f e r i n g 
a c t i o n of the PBS has no great e f f e c t on the Log P value. The 
complexes f o l l o w the same p a t t e r n of s o l u b i l i t y i n both 
octanol and butanol, w i t h g e n e r a l l y higher Log P values i n 
butanol. The two complexes [In.9N3P3Ph3] and [ln.9N3P3Bz3] 
both have p o s i t i v e Log P values. These same two complexes are 
those which e x h i b i t the highest percentage h e p a t o b i l i a r y 
clearance i n mice. A p l o t of the r e l a t i o n s h i p between the Log 
p value i n butanol/water and the % dose i n the t o t a l gut at i 
hour post i n j e c t i o n f o r the s i x indium macrocycles ( f i g u r e 
4.33.) reveals a c o r r e l a t i o n (R2 by l i n e a r regression) of 
0.89. Thus f o r these n e u t r a l indium complexes the higher t h e i r 
l i p o p h i l i c i t y the greater the h e p a t o b i l i a r y clearance. This 
agrees w i t h the p a t t e r n seen f o r the gadolinium complexes 
( s e c t i o n 2.5). However, i t would be expected t h a t these 
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n e u t r a l indium complexes are using a d i f f e r e n t t r a n s p o r t e r 
s i t e i n the hepatocytes from the 'anionic t r a n s p o r t e r ' used by 
BSP and [Gd.12N4P4BZ4]-. 
4.5. COMPARISON OF CLEARANCE PATHWAY AND I N VIVO 
STABILITY OF GALLIUM AND INDIUM MACROCYCLE COMPLEXES. 
The 7 macrocycles l i s t e d below were complexed w i t h e i t h e r 
g a l l i u m ( I I I ) or indium ( I I I ) . The f u l l b i o d i s t r i b u t i o n data 
f o r these complexes has been given i n sections 4.2 and 4.3. 
Here only the t o t a l gut dose at 1 hour and the blood, l i v e r 
and s k e l e t a l doses at 24 hours are examined. Figures 4.34 t o 
4.37 give the comparative % doses i n these tissues f o r both 
the g a l l i u m and indium complexes. 
Key to Figures i n t h i s Section. 









From f i g u r e s 4.34 t o 4.37 and t a b l e 4.4 i t can be seen 
t h a t the amount of complex which clears v i a the h e p a t o b i l i a r y 
pathway f o l l o w s a s i m i l a r p a t t e r n f o r both the g a l l i u m and 
indium complexes. 
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Figure 4.37. Comparison of the % Dose in the Skeleton at 24 
Hours. 
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Table 4.4. Svamnary of In Vivo Clearance and Stability of 
Gallium and Indium Complexes. 
Complex Hepatobiliary In Vivo 
Number Clearance S t a b i l i t y 
Ga In Ga In 
1. 9N3 0 0 +++ +++ 
2. 9N3Me3C3 0 + +++ +++ 
3. 9N3C3Ph3 +++ + + + -
4. 9N3P3Me3 0 0 +++ 
5. 9N3P3iPr3 + + +++ 
6. 9N3P3Ph3 + + + + + + +++ 
7. 9N3P3BZ3 + + + + + + 
The i n v i v o s t a b i l i t y measurements show t h a t the g a l l i u m 
and indium complexes w i t h the ligands 9N3 and 9N3Me3C3 are 
st a b l e i n v i v o . [Ga.9N3C3Ph3] shows some d i s s o c i a t i o n i n v i v o 
but i s more st a b l e than the [in.9N3C3Ph3] complex. 
[Ga.9N3P3Me3] and [Ga.9N3P3Ph3] are both stable i n v i v o 
whereas the corresponding indium complexes are not. Both the 
g a l l i u m and indiiim complexes of 9N3P3Bz3 are unstable i n v i v o . 
These i n v i v o measurements agree w e l l w i t h previous i n 
v i t r o measurements (see s e c t i o n 4.1.6). [Ga.9N3], [In.9N3], 
[Ga.9N3P3Me3] and [Ga.9N3Me3C3] having shown high resistance 
t o acid-catalysed dissociation ' s ,57,60_ The general trend t h a t 
g a l l i u m forms more stab l e complexes w i t h 9N3 type ligands than 
indium (see sections 4.1.4 t o 4.1.6) also holds w i t h the 
exception of 9N3P3iPr3. 
I n conclusion, the complexes [Ga.9N3], [Ga.9N3Me3C3] , 
[Ga.9N3P3Me3], [in.9N3] and [In.9N3Me3C3] are a l l stable 
n e u t r a l complexes w i t h p o t e n t i a l f o r i n v i v o imaging. The 
complex [Ga.9N3P3Ph3] i s the most promising candidate f o r 
h e p a t o b i l i a r y imaging w i t h a high i n v i v o s t a b i l i t y . "^^ Ga or 
^ ^ I n l a b e l l e d complexes are p o t e n t i a l l y u s e f u l w i t h SPECT, 
^^Ga w i t h PET or ^iQa i n NMR imaging. 
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4.6. TUMOUR LOCALISATION OF GALLIUM AND INDIUM 
MACROCYCLE COMPLEXES. 
4.6.1. Introduction 
I n t h i s s e c t i o n the b i o d i s t r i b u t i o n and tumour uptake of 
g a l l i u m and indium macrocycle complexes are examined i n mice 
bearing xenografts of the h;aman melanotic melanoma HX118. 
The 7- e m i t t i n g isotopes of galliiam and indiiim {^^Ga and 
m m ) u t i l i s e d here f o r the determination of b i o d i s t r i b u t i o n s 
have the p o t e n t i a l of tumour imaging i n v i v o by SPECT. There 
i s also the p o s s i b i l i t y of using other isotopes of g a l l i u m f o r 
a l t e r n a t i v e imaging techniques. For example, r a d i o a c t i v e ^^Ga 
f o r PET, or s t a b l e "^ G^a f o r nuclear magnetic resonance 
imaging. 
For the v i s u a l i s a t i o n of tumour t i s s u e by any of these 
imaging techniques i t i s the contrast between the 
concentration of the l a b e l l e d complex i n the tumour t o t h a t of 
the surrounding t i s s u e s ( p a r t i c u l a r l y blood) which i s 
important, r a t h e r than j u s t the t o t a l amount of tumour uptake. 
To t h i s end i t i s the % dose/g of t i s s u e and p a r t i c u l a r l y the 
r a t i o of the tumour % dose/g t o the blood % dose/g which i s of 
s i g n i f i c a n c e i n t h i s study. 
The b i o d i s t r i b u t i o n and tumour uptake of the g a l l i u m 9N3 
complex i s studied at l, 2, 4, 8, and 24 hours post i n j e c t i o n 
( f i g u r e s 4.38 and 4.39). The corresponding indium 9N3 complex 
i s s t udied at l , 2 and 4 hours post i n j e c t i o n ( f i g u r e s 4.40 
and 4.41). B i o d i s t r i b u t i o n and tumour uptake of two f u r t h e r 
g a l l i u m complexes, [Ga.9N3P3Me3] and [Ga.9N3C3Ph3], together 
w i t h [Ga.Citrate] are also examined at 4 hours post i n j e c t i o n 
( f i g u r e s 4.42 and 4.43). 
A comparison of the tumour t o blood r a t i o s f o r a l l 5 
complexes i s given i n f i g u r e 4.44. F i n a l l y a comparison of 
[Ga.9N3] b i o d i s t r i b u t i o n i n both normal and HX118 tumour 
bearing mice i s made ( f i g u r e 4.45). 
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4.6.2. Biodistribution of Complexes i n HXllS Txjmour Bearing 
Mice. 
[Ga.9N3] 
The b i o d i s t r i b u t i o n of [Ga.9N3] i n HXllS tumour bearing 
mice i s given i n f i g u r e s 4.38 and 4.39. The f a s t e s t drop i n % 
dose/g of t i s s u e w i t h time i s f o r the blood. The slower r a t e 
of loss of [Ga.9N3] from the tiomour t i s s u e leads t o a high 
tumour t o blood r a t i o ( f i g u r e 4.44.). Between 2 and 24 hours 
post i n j e c t i o n the tumour t o blood r a t i o f o r [Ga.9N3] i s i n 
excess of 12, peaking t o a value of 22 at 4 hours and then 
slowly d e c l i n i n g w i t h time. At 4 hours the r a t i o s kidney t o 
blood and l i v e r t o blood are about twice t h a t of tumour t o 
blood. 
Figures 4.45 ( a ) , (b) and (c) compare the b i o d i s t r i b u t i o n 
data f o r [Ga.9N3] i n both normal and HX118 tumour mice at l, 4 
and 24 hours. Differences between the two groups i n the amount 
of dose present i n the kidney, l i v e r and gut can be a t t r i b u t e d 
t o the v a r i a t i o n i n e x c r e t i o n r a t e between i n d i v i d u a l animals. 
The most important comparison i s at 24 hours ( f i g u r e 4.45 
(c)) , t h i s shows t h a t the % dose i n the skeleton i s as low i n 
the tumour mice as i n normal mice confirming the high i n v i v o 
s t a b i l i t y of [Ga.9N3]. 
[In.9N3] 
Figures 4.40 and 4.41 show the b i o d i s t r i b u t i o n of [In.9N3] 
over 1, 2 and 4 hours. As was seen f o r [Ga.9N3], the tumour t o 
blood r a t i o i s g r e a t e s t at 4 hours post i n j e c t i o n ( f i g u r e 
4.44). However, t h i s tumour t o blood r a t i o of 12 i s only about 
h a l f the concentration achieved w i t h [Ga.9N3]. The [ln.9N3] 
does have a lower tumour t o l i v e r r a t i o than [Ga.9N3], w i t h a 
co n c e n t r a t i o n of about 3 times more complex i n the tumour than 
i n the l i v e r at 4 hours. 
A comparison of the % dose/g at 4 hours w i t h t h a t of the 
other complexes examined ( f i g u r e 4.42) demonstrates t h a t 
[In.9N3] has a l a r g e r % dose/g i n the tumour than any of the 
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other complexes except [ G a . C i t r a t e ] . However w i t h [Ga.Citrate] 
t h i s i s also t r u e f o r the % dose i n the skeleton demonstrating 
the much more unstable nature of t h i s complex. 
[6a.9N3P3Ne3], [Ga.9N3C3Ph3] and [Ga.Citrate]. 
The b i o d i s t r i b u t i o n at 4 hours of [Ga.9N3P3Me3] , 
[Ga.9N3C3Ph3] and [Ga.Citrate] are p l o t t e d i n f i g u r e s 4.42 and 
4.43 along w i t h t h a t of [ln.9N3] and [Ga.9N3]. 
By 4 hours [Ga.9N3P3Me3] has v i r t u a l l y cleared from a l l 
the t i s s u e s except f o r small amounts i n the kidney and gut. 
The % dose/g tumour i s the lowest of a l l the complexes. The 
tumour t o blood r a t i o i s also low ( f i g u r e 4.44). 
The m a j o r i t y of the complex [Ga.9N3C3Ph3] i s being cleared 
by the h e p a t o b i l i a r y route, however the blood l e v e l at 4 hours 
i s s t i l l h igh r e f l e c t i n g the low i n v i v o s t a b i l i t y of t h i s 
complex as already demonstrated i n section 4.2. The % dose i n 
the tumour and the tumour t o blood r a t i o f o r [Ga.9N3C3Ph3] are 
both very low. 
The h i g h l y unstable complex [Ga.Citrate] has high blood, 
tumour and gut l e v e l s . When the tumour t o blood r a t i o i s 
c a l c u l a t e d ( f i g u r e 4.44), t h i s value i s the lowest seen. 
4.6.3. Conclusion. 
Of the complexes measured [Ga.9N3] gives the best tumour 
t o blood c o n t r a s t . This i s obtained at 4 hours post i n j e c t i o n 
when a tumour t o blood r a t i o of 22 i s seen. At t h i s time the 
concentration of [Ga.9N3] i n the tumour exceeds t h a t i n a l l 
the other t i s s u e s examined w i t h the exception of the kidney 
and l i v e r . 
The f a s t blood clearance and low % dose i n the skeleton at 
24 hours are i n d i c a t o r s of the high i n v i v o s t a b i l i t y of the 
[Ga.9N3] complex. Thus the concentration of g a l l i u m seen i n 
the tumour must be due t o d i f f e r e n t i a l r e t e n t i o n of the 
complex r a t h e r than from uptake of uncomplexed g a l l i u m as i s 
u t i l i s e d i n g a l l i u m c i t r a t e imaging (see s e c t i o n 4.1.2). 
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F i g u r e 4.38. % Doae/g of [Ga.9ir3] In EX118 Tumour Bearing Mice 
1 to 24 Hours POBt injection. 
[ G a . 9 N 3 ] 





F i g u r e 4.39. % Dose of [6a.9N3] in HX118 rumour Bearing Mice 1 
to 24 Hours Post Injection. 
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F i g u r e 4.40. % Doae/g of [In.9N3] in SX118 Tumour Bear lag Mice 
1 to 4 Soura Poat Injection. 
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F i g u r e 4.41. % Doae of [In,9N3] in BX118 Tumour Bearing Mice 1 
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F i g u r e 4.42. % Doae/g of Gallium and Indium JSacrocyclea in 
BX118 Timour Bearing Mice at 4 Houra Poat Injection. 
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F i g u r e 4.43. % Doae of Gallium and Indium Macrocyclea in HZ118 
Tumour Bearing Mice at 4 Houra Poat Injection. 
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F i g u r e 4.44. rumour to Blood Ratios of % Dose/g of Gallium and 
Indium Macrocycles. 
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F i g u r e 4.45 ( a ) . Comparison of % Dose/g and % Dose of 
[Ga.91f3] in Normal and HX118 Tumour Bearing Mice at 1 Hour 
Post Injection. 
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F i g u r e 4 . 4 5 (b) . Comparison of % Dose/g and % Dose of 













[Ga.9N3] % Dose/g at 4 Hours 

































F i g u r e 4.45 (c) . Comparison of % Dose/g and % Dose of 
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4.7. THE BIODISTRIBUTION OF [Ga. 9N3 .MISO] IN NORMAL 
AND TPMOUR BEARING MICE. 
4.7.1. I n t r o d u c t i o n . 
Drugs based on 2-nitroimidazoles such as Misonidazole 
(Miso) ( f i g u r e 4.46), are w e l l knovm f o r l o c a l i s i n g i n areas 
of hypoxia (low oxygen) i n malignant and normal tissues^S 
This l o c a l i s a t i o n a r i s e s from the enzymatic reduction of Miso 
which, a t low oxygen l e v e l s , forms a metabolite which reacts 
w i t h and c o v a l e n t l y binds t o adjacent macromolecules^^. The 
r a d i o l a b e l l i n g of Miso w i t h a -y e m i t t i n g isotope such as "^^ Ga 
Qy~ 99mrpc67,68 could p o t e n t i a l l y lead t o the imaging of 
hypoxic areas w i t h i n the body, i n p a r t i c u l a r the hypoxic 
regions of tumours. Also by l a b e l l i n g the Miso w i t h a 
therap e u t i c isotope, such as the jS" e m i t t e r ^^Y, there i s the 
p o s s i b i l i t y of tumour therapy. 
I n t h i s s e c t i o n the l a b e l l i n g of Miso w i t h [^ "^ Ga.gNS] i s 
in v e s t i g a t e d . The tumour used f o r these experiments i s the 
human melanotic melanoma HX118. This tumour has been shown t o 
accumulate 2 - n i t r o i m i d a z o l e s ^ ^ . Experiments by L.M. Cobb et 
a l using ^^ C^ and l a b e l l e d Miso'^0 showed accumulation of 
Miso i n normal t i s s u e s such as the oesophagus, eye l i d s , 
l i v e r and lungs i n a d d i t i o n t o tumour t i s s u e . Normal tissues 
would not be expected t o have areas of hypoxia, except f o r 
the l i v e r , and the accumulation of Miso i s ascribed t o the 
high l e v e l s of reductase a c t i v i t y i n these tissues''^. 
I n these experiments a range of tissues are examined t o 
determine whether the l a b e l l e d [Ga.9N3.Miso] ( f i g u r e 4.46) 
shows any behaviour c h a r a c t e r i s t i c of the 2-nitroimidazole 
moiety. The a b i l i t y t o detect tumours i s the u l t i m a t e aim of 
these i n v e s t i g a t i o n s , t h e r e f o r e the complex [Ga.9N3] i s 
compared t o the [Ga.9N3.Miso] as the former complex has 
already demonstrated high tumour t o blood contrast (section 
4.6) . 
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Figure 4.46. Chemical Structures of 9N3.Miso and Misonidazole 







P r e s e n t a t i o n of R e s u l t s . 
Figures 4.47 t o 4.52 give the % dose and % dose/g from 
both [Ga.9N3] and [Ga.9N3.Miso] at 4, 8 and 24 hours i n mice 
bearing xenografts of the human melanotic melanoma HX118. 
Figures 4.53 t o 4.56 give the % dose and % dose/g from both 
[Ga.9N3] and [Ga.9N3.Miso] i n normal mice. Tissue t o blood 
r a t i o s are given i n f i g u r e s 4.57 t o 4.61. 
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F i g u r e 4.47. % Dose/g of [Ga. 9N3 .Miso] and [Ga.9N3] in HX118 
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F i g u r e 4.48. % Dose of [Ga.9N3.Miso] and [Ga.9N3] in HX118 































F i g u r e 4.49. % Dose/g of [Ga. 9N3.Miso] and [Ga.9N3] in HX118 
Tumour Bearing Mice 8 Hours Post Injection. 
8 Hours 










F i g u r e 4.50. % Dose of [Ga. 9N3 .Miso] and [Ga.9N3] in HX118 
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F i g u r e 4.51. % Dose/g of [Ga. 9N3.Miso] and [Ga.9N3] in HX118 

















Figure 4.52. % Pose of [Ga. 9N3 .Miso] and [Ga.9N3] in HX118 
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F i g u r e 4.53, % Dose/g of [Ga. 9N3.Miso] and [Ga.9N3] in Normal 
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F i g u r e 4.54. % Dose of [Ga. 9N3 .Miso] and [Ga.9N3] in Normal 
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F i g u r e 4.55. % Dose/g of [Ga. 9N3 .Miso] and [Ga.9N3] in Normal 
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F i g u r e 4.56. % Dose of [Ga.9N3.Miso] and [Ga.9N3] in Normal 
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F i g u r e 4.59. Tissue to Blood Ratio at 24 Hours in HX118 
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F i g u r e 4.60. Tissue to Blood Ratio at 1 Hour in Normal Mice. 
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From the i n f o r m a t i o n reported i n f i g u r e s 4.47 t o 4.56 i t 
can be concluded t h a t the major d i f f e r e n c e between the 
b i o d i s t r i b u t i o n of [Ga.9N3] and [Ga.9N3.Miso] i s t h a t 
[Ga.9N3.Miso] i s e l i m i n a t e d from the mouse by h e p a t o b i l i a r y 
as w e l l as r e n a l e x c r e t i o n . This i s i n l i n e w i t h the f i n d i n g s 
of L.M. Cobb et a l , t h a t both and l a b e l l e d Miso are 
cleared from the mouse by the h e p a t o b i l i a r y as w e l l as renal 
routes. A f t e r 24 hours i n both tumour bearing and normal mice 
( f i g u r e s 4.51 and 4.55) there i s less dose l e f t i n the femur, 
lung, spleen and tiimour t i s s u e s from [Ga.9N3.Miso] than from 
[Ga.9N3]. This may be due t o the quicker drop i n blood dose 
( f i g u r e 4.54) f o r [Ga.9N3.Miso]. The low s k e l e t a l dose from 
[Ga.9N3.Miso] also r e f l e c t s the high i n v i v o s t a b i l i t y of 
t h i s g a l l i u m macrocycle complex. 
I n order t o assess whether any concentration of 
[Ga.9N3.Miso] was t a k i n g place i n hypoxic tissues such as the 
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tumour, oesophagus or eyes, the t i s s u e t o blood r a t i o s were 
c a l c u l a t e d from the % dose/g values. These are p l o t t e d i n 
f i g u r e s 4.57 t o 4.59 f o r mice bearing HX118 tumour and 
f i g u r e s 4.60 and 4.61 f o r normal mice. The best tumour t o 
blood c o n t r a s t obtained i s t h a t a t 4 hours from [Ga.9N3], 
t h i s give a tiomour t o blood r a t i o of 22. The highest tumour 
t o blood r a t i o obtained from [Ga.9N3.Miso] i s a value of 16 
at 8 hours. 
The a c t u a l amounts of [Ga.9N3.Miso] r e t a i n e d a f t e r 24 
hours i n t i s s u e s such as the oesophagus, eye l i d s and lungs 
are very low, but f i g u r e s 4.59 and 4.61 i n d i c a t e t h a t there 
i s some r e t e n t i o n of [Ga.9N3.Miso] over t h a t i n the blood. 
This together w i t h the observed h e p a t o b i l i a r y excretion, i s 
i n agreement w i t h the expected b i o l o g i c a l p r o p e r t i e s as seen 
f o r ^^C and Miso"^^. However, the only occasion where 
[Ga.9N3.Miso] shows any increased t i s s u e t o blood r a t i o s over 
those of [Ga.9N3] i s at 8 hours post i n j e c t i o n where there 
are s l i g h t l y higher t i s s u e t o blood r a t i o s f o r the tiimour and 
oesophagus ( f i g u r e 4.58). 
I n conclusion, b e t t e r tumour imaging can be obtained from 
the use of [Ga.9N3] without a t t a c h i n g i t t o Misonidazole. 
4.8. [7lGa.9N3] FOR NMR. 
The p r i n c i p l e s of nuclear magnetic resonance imaging have 
been discussed i n chapter i (secti o n 1.3). Although i t i s the 
protons of water which are the most o f t e n studied i n MRI, any 
n u c l e i which possess spin and a magnetic moment are s u i t a b l e 
f o r d e t e c t i o n by NMR. The "^ G^a isotope of g a l l i i i m i s s u i t a b l e 
f o r d e t e c t i o n by NMR at high s t r e n g t h f i e l d s . The chemical 
s h i f t of the g a l l i u m nucleus i s a s e n s i t i v e probe of the 
symmetry and c o - o r d i n a t i o n environment of complexes of 
g a l l i u m . The complexation of "^ G^a t o the macrocycle 9N3 
generates a n e u t r a l complex of high s o l u b i l i t y , low 
o s m o l a l i t y and high i n v i v o s t a b i l i t y . The chemical s h i f t of 
t h i s complex i n water i s +172 ppm, w i t h a r e l a t i v e l y narrow 
l i n e w i d t h of 200 Hz. 
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Figure 4.62. NMR Spectra. 
(a) 100 111 of 20 mM ["^loa.SNS] i n PBS, 
(b) HX 118 Tumour Mass. 
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(c) 500 /tl of Urine from the Mouse Post Injection of 
[7lGa.9N3]. 
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(d) [•'iGa.gNB] and ^iQaCla reference standard 
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The [Ga.9N3] complex has already been shown t o clear 
r a p i d l y from the mouse v i a the kidneys (section 4.2), and t o 
concentrate i n xenografts of the human melanotic melanoma 
HX118 ( s e c t i o n 4.6) . I n t h i s experiment, a mouse bearing a 
xenograft of HX118 was i n j e c t e d w i t h 250 jul of 20 iriM 
['^lGa.9N3] i n PBS. A f t e r about 1 hour NMR spectra were 
obtained v i a a sample c o i l s i t t i n g e i t h e r around the sample 
( l i q u i d i n a small v i a l ) or d i r e c t l y above the tumour ( s t i l l 
i n s i t u i n an anaesthetised mouse). Spectra were obtained f o r 
the f o l l o w i n g : -
(a) 100 ^1 of 20 mM [7lGa.9N3] i n PBS. 
(b) HX 118 tumour mass. 
(c) 500 /xl of u r i n e excreted from the mouse post 
i n j e c t i o n of ['^^Ga.9m] . 
(d) Both ['^iGa.9N3] and '^lGaCl3 as reference standards. 
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Conclusions 
For the HX 118 tumour there was i n s u f f i c i e n t 
c o n centration of ['^^Ga.9N3] t o allow f o r proper detection, 
although there i s a possible peak at the resonant frequency 
expected f o r [7iGa.9N3], at 172 ppm, (Sga = 0 PPni/ f o r 
Ga(H20)63 + ) . 
The u r i n e sample has a cle a r s i g n a l f o r ['^lGa.9N3] as 
opposed t o '^^GaCl3 i n d i c a t i n g t h a t the g a l l i u m complex has 
been excreted i n t a c t . 
4.9. GALLIUM AND INDIDM EXPERIMENTAL. 
Throughout the f o l l o w i n g experimental procedures, gold 
l a b e l q u a l i t y chemicals and metal f r e e p l a s t i c ware were used 
t o reduce any metal contamination. The suppliers of apparatus 
and reagents used, together w i t h the p u r i t y of reagents are 
l i s t e d i n Appendix I . Gallium-67 was supplied as g a l l i i i m 
c h l o r i d e i n 0.04M HCl c a r r i e r f r e e , >10 mCi/mg Ga.(>370 
MBq/mg Ga), t l / 2 = 78 hours, 7's= 93, 185 and 300 KeV. Indium-
I l l was supplies as indiiim c h l o r i d e i n 0.04M HCl c a r r i e r 
f r e e . t^/2= 67 hours, 7's= 171 and 245 KeV. 
4.9.1. Preparation of Gallium and Indiiun Macrocycle Con^lexes 
for Biological Use 
The methods of pr e p a r a t i o n of the g a l l i u m and indium 
macrocycle complexes were very s i m i l a r . The r a d i o a c t i v e 
s o l u t i o n s of both gallium-67 and i n d i u m - i l l were both 
e s s e n t i a l l y c a r r i e r f r e e . The "^^ Ga was >10 mCi/mg Ga, i . e . a 
100 fiCi sample of ^ '^ Ga contained <10 ng of stable Ga (<0.014 
nmoles) . The mm was also >10 mCi/mg I n , i . e . a 100 /xCi 
sample of m i n contained <10 ng of stable I n (<0.009 
nmoles). 
Maximum l a b e l l i n g e f f i c i e n c y was achieved w i t h the 
a d d i t i o n of 10% c a r r i e r t o the r e a c t i o n mixture. The amount 
of contaminating cations present i n the r e a c t i o n mixtures was 
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kept t o the minimum by the use of high p u r i t y (e.g. A l d r i c h 
'gold l a b e l ' ) chemicals and metal f r e e p l a s t i c s throughout. 
The metal macrocycle complexes were p u r i f i e d by HPLC 
a f t e r the a d d i t i o n of DTPA t o bind any unreacted g a l l i u m or 
indium. Formation of the [Ga.DTPA]^- or [In.DTPA]2- complex 
not only prevented contamination of the HPLC column w i t h 
r a d i o a c t i v i t y , but also provided the means by which the 
percentage l a b e l l i n g of g a l l i u m or indium macrocycle complex 
could be measured accurately. A 10 f o l d molar excess of DTPA 
over macrocycle was s u f f i c i e n t t o complex a l l unreacted Ga3+, 
In3+ or any other cations which may have been present. When 
t e s t i n g very small amounts e.g. 1 /xl of 2 mM macrocycle 
s o l u t i o n , a 50 times molar excess of DTPA over macrocycle was 
used t o complex any small absolute amounts of contaminating 
c a t i o n s . 
A l l the g a l l i u m and indium complexes were prepared by 
methods s i m i l a r t o those employed f o r the preparation of 
[Ga.9N3]. For the indium complexes, ^ ^ ^ I n and lnCl3 c a r r i e r 
were used. This method i s set out below w i t h any v a r i a t i o n s 
used i n the other preparations l i s t e d i n Table 4.5 and 4.6. 
Preparation of [Ga.9N3] 
250 fil O f a s o l u t i o n c ontaining 200 mM ammonium acetate 
pH 5.0, 2 mM 9N3, 0.2 mM GaCls (10% c a r r i e r ) + 100-200 ixCi 
'^^ Ga, was incubated at 310K (37^0) f o r 30 minutes. 
The formation of [Ga.9N3] and other complexes was 
measured at 30 minutes by adding 1 /xl of the r e a c t i o n mixture 
t o 50 times molar excess of DTPA over macrocycle (2 /xl of 100 
mM DTPA) . This was then made up t o 100 /xl w i t h HPLC running 
b u f f e r (0.2 M ammonium acetate pH 6.8, 10% a c e t o n i t r i l e w i t h 
AX300 coliimn, or 0.15 M ammonium acetate pH 6.8 w i t h Poros 
Q/M column) and incubated f o r 5 minutes. The percentage 
l a b e l l i n g was then analysed by anion exchange HPLC. I f the % 
of [Ga.9N3] or of the other complexes was >90% the r e a c t i o n 
mixture was quenched w i t h DTPA. I f the l a b e l l i n g was less 
than 90% the r e a c t i o n mixture was incubated f o r a f u r t h e r 
p e r i o d a t 370c and the percentage complex formation re-
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examined. When there was no f u r t h e r increase i n complex 
formation the r e a c t i o n mixture was quenched by adding 10 fil 
of 500 mM DTPA (10 times molar excess over macrocycle) . This 
mixture was then separated by HPLC, the [Ga.9N3] (or other 
complex) peak being c o l l e c t e d manually (dropwise i n t o a 
polyethylene tu b e ) . 
For [Ga.9N3] and [ln.9N3] the l a b e l l i n g e f f i c i e n c y was 
u s u a l l y g reater than 98%. On an AX300 anion exchange column 
run a t l ml/min w i t h 0.2 M ammoniiim acetate pH 6.8, 10% 
a c e t o n i t r i l e running b u f f e r , [Ga.9N3] elutes at 3.9 min 
foll o w e d by [Ga.DTPA]^- at about 17 minutes. 
On a Poros Q/M anion exchange column run at 2 ml/min w i t h 
0.15 M ammonium acetate pH 6.8 running b u f f e r , [In.9N3] 
e l u t e s a t l.O min followed by [In.DTPA]2- at 2.1 minutes. 









E l u t i o n 
time (min) 
AX300 Poros Q/M 
3.9 



















DTPA 17 2.1 
9N3.MiS0 4itM 9N3.Miso 
50% c a r r i e r 
95 4.4 
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% l a b e l l i n g 
9N3Me3C3 
9N3C3Ph3 3 hour i n c u b a t i o n 
9N3P3Me3 
9N3P3iPr3 l hour i n c u b a t i o n 
9N3P3Ph3 









E l u t i o n 
time (min) 









4.9.2. P a r t i t i o n Coefficients of Indium Coisplexes 
The indium macrocycle complexes were prepared as 
described i n se c t i o n 4.9.1. 
The method followed f o r the measurement of p a r t i t i o n 
c o e f f i c i e n t s was the same as t h a t f o r the gadolinium 
complexes i n se c t i o n 2.6.3. 
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A t y p i c a l data set i s given below f o r [In.9N3P3Ph3] 
P Log P F Log p 
Octanol/water 2 . 44 0 . 39 Octanol/PBS 1. 71 0 . 23 
0.5 ml/0.5 ml 2. 67 0.43 0.5 ml/0.5 ml 1. 74 0 . 24 
Octanol/Water 0 . 98 -0.01 Octanol/PBS 0. 82 -0 . 08 
0.75 ml/0.25 ml 1. 09 0 . 04 0.75 ml/0.25 ml 0 . 87 -0. 06 
Octanol/Water 3 . 46 0.54 Octanol/PBS 3. 44 0 . 54 
0.25 ml/0.75 ml 4. 04 0.61 0.25 ml/0.75 ml 3 . 56 -0. 55 
Average 2 . 45 0.33 Average 2. 02 0 . 24 
SD 1. 23 0.26 SD 1. 21 0. 28 
P Log P P Log p 
Butanol/Water 4. 63 0 . 67 Butanol/PBS 2. 96 0 . 47 
0.5 ml/0.5 ml 4. 79 0 . 68 0.5 ml/0.5 ml 3 . 00 0. 48 
Butanol/Water 2. 21 0.34 Butanol/PBS 1. 74 0 . 24 
0.75 ml/0.25 ml 2 . 38 0.38 0.75 ml/0.25 ml 1. 75 0. 24 
Butanol/Water 7. 13 0 . 85 Butanol/PBS 5. 58 0 . 75 
0.25 ml/0.75 ml 7. 57 0.88 0.25 ml/0.75 ml 5. 91 0. 77 
Average 4. 78 0 . 63 Average 3 . 49 0 . 49 
SD 2. 27 0.23 SD 1. 84 0. 23 
Table 4.7. A Summary of Partition Coefficients for Indium 
Macrocycles. 
Indiiua Octanol \Water Octanol \PBS Butanol \Water Butanol \PBS 
Complex LOG P SD LOG P SD LOG P SD LOG P SD 
9N3 -4.92 0.29 -4.51 0.46 -2.54 0.04 -2.98 0. 04 
9N3Me3C3 -3.38 0.07 -3 . 62 0.21 - 1 . 79 0.03 -2 .22 0.01 
9N3P3Me3 -3 . 80 0.11 -3 . 68 0.31 -1.88 0. 02 -2.06 0.01 
9N3P3iPr3 -1.92 0.02 - 1 . 89 0. 04 -0 .98 0.12 -0.99 0.13 
9N3P3Ph3 0.33 0.26 0 .24 0.28 0 . 63 0.23 0.49 0.23 
9N3P3BZ3 0.13 0.22 0 .10 0.21 0.54 0.20 0.34 0.21 
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4.9.3. Biodistribution Studies 
B i o d i s t r i b u t i o n studies were c a r r i e d out on 7 g a l l i u m and 
7 indium complexes whose preparations are described i n 
s e c t i o n 4.9.1. A l l complexes had t h e i r p u r i t y checked by HPLC 
before i n j e c t i o n i n t o animals. 
The b i o d i s t r i b u t i o n s were conducted on c o n g e n i t a l l y 
athymic nude male mice ( MFI-nu/nu/Ola/Hsd) aged 13 t o 16 
weeks w i t h an average weight of 36 g. Between three and f i v e 
mice were k i l l e d f o r each complex at each time p o i n t . 
Gallium or indium complexes were administered i n t r a 
venously v i a the t a i l v e i n at a dose of approx. 0.1 /xmol/kg, 
7.5 /xCi/mouse. 
Mice were k i l l e d by an i n t r a - p e r i t o n e a l i n j e c t i o n of 
pentobarbitone. A sample of cardiac blood was taken and the 
f o l l o w i n g t i s s u e s dissected:- b r a i n , both femurs, both 
kidneys, l i v e r , g a l l bladder, lungs, heart muscle, s a l i v a r y 
glands, spleen, stomach, small i n t e s t i n e (from the p y l o r i c 
s phincter t o the s t a r t of the caecum), caecum, large 
i n t e s t i n e , samples of f a t , s k e l e t a l muscle and skin. 
A l l samples were weighed w i t h the exception of the gut. 
For c a l c u l a t i o n s of t o t a l t i s s u e dose, the mass of both the 
blood and the skeleton were taken as 10% of the body weight. 
Tissue samples were assayed by the same methodology as used 
f o r 153Q(J samples i n s e c t i o n 2.6.3. 
Summary tables are presented i n Chapter 4.2 and 4.3. 
4.9.4. Tumour Localisation studies. 
The mice used f o r these studies were c o n g e n i t a l l y athymic 
nude mice (MFl-nu/nu/Ola/Hsol) as used i n the above studies. 
Mice aged 8 t o 10 weeks were i n j e c t e d subcutaneously i n each 
f l a n k w i t h a suspension of c e l l s from the r e g u l a r l y passaged 
hioman melanotic melanoma HX 118. A f t e r 6 t o 8 weeks when the 
tumours had grown t o a size of at l e a s t 0.05 ml, they were 
used f o r tumour l o c a l i s a t i o n studies. Gallium or indium 
complexes were i n j e c t e d v i a the t a i l v e i n . a t a dose of 10 t o 
25 /xCi per mouse. Mice were k i l l e d a t set times a f t e r 
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a d m i n i s t r a t i o n of the l a b e l l e d complex by i n t r a p e r i t o n e a l 
i n j e c t i o n of pentobarbitone. Blood and t i s s u e samples were 
taken and analysed as pr e v i o u s l y . 
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R a d i o i s o t o p e s were purchased f r o m Amersham I n t e r n a t i o n a l p i c . 
Gadolinium-153 as Ga d o l i n i u m c h l o r i d e i n 0.IM HCl, 0.5-5 
mCi/mg Gd.(18.5-185 MBq/mg Gd), t l / 2 = 242 days, 7= 97-103 
KeV, X-rays= 41-47 KeV. 
Y t t r i u m - 9 0 as Y t t r i u m c h l o r i d e i n 0.02M HCl c a r r i e r f r e e . 
t l / 2 = 64 hours, 0' average energy 0.935 MeV. 
Gallium-67 as G a l l i u m c h l o r i d e i n 0.04M HCl c a r r i e r f r e e , >10 
mCi/mg Ga.{>370 MBq/mg Ga), t l / 2 = 78 hours, 7's= 93, 185 
and 300 KeV. 
I n d i i i m - l l l as I n d i i i m c h l o r i d e i n 0.04M HCl c a r r i e r f r e e . 
t l / 2 = 67 hours, 7's= 171 and 245 KeV. 
Reagents used i n the preparation of ligand-metal complexes 
A l l c h e m i c a l s used were o f h i g h p u r i t y ;-
A c e t i c a c i d 99+%, g o l d l a b e l , ( A l d r i c h ) . 
Ammonium a c e t a t e 99+%, g o l d l a b e l , ( A l d r i c h ) . 
BOPTA, donated by Bracco I n d u s t r i a Chimica, SpA, M i l a n , 
I t a l y . 
C i t r i c a c i d anhydrous 99+%, g o l d l a b e l , ( A l d r i c h ) . 
DTPA a n h y d r i d e , (Sigma). 
G a d o l i n i u m ( I I I ) c h l o r i d e hexahydrate 99.999%, g o l d l a b e l , 
( A l d r i c h ) . 
G a l l i i a m ( I l I ) c h l o r i d e 99.99+%, g o l d l a b e l , ( A l d r i c h ) . 
H y d r o c h l o r i c a c i d 35.0%, <lppm Fe, A r i s t a r , (BDH). 
i n d i u m ( I I I ) c h l o r i d e 99.999%, g o l d l a b e l , ( A l d r i c h ) . 
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Macrocycles and DTPA(NHBz)2 were s y n t h e s i s e d i n t h e Chemistry 
Department o f Durham U n i v e r s i t y by P r o f e s s o r D Parker, Dr 
K Pulukkody, Mr T Norman, Miss F Smith and Mr R Matthews. 
9N3.Miso, Miss F Smith Durham U n i v e r s i t y . 
Potassium h y d r o x i d e p e l l e t s 99.99%, g o l d l a b e l ( A l d r i c h ) . 
Water was p u r i f i e d by a M i l l i Q system, ( M i l l i p o r e ) . 
Y t t r i u m c h l o r i d e anhydrous 99.9%, g o l d l a b e l , ( A l d r i c h ) . 
A d d i t i o n a l reagents 
A c e t o n i t r i l e , HPLC grade, ( A l d r i c h ) . 
A l d r i t h i o l ( D i t h i o d i p y r i d i n e ) , ( A l d r i c h ) . 
Ammonium A c e t a t e 98.0%, AnalaR grade,(BDH). 
B72.3 monoclonal a n t i b o d y , ( C e l l t e c h L t d . ) . 
B u t a n - l - o l 99.5%, AnalaR grade, (BDH). 
N e t h y l maleimide, (Sigma). 
[ G d . l 2 N 4 P 4 M e 4 ] D r . B . Boyce C e l l t e c h L t d . 
[Gd.12N4P4BZ4]", Dr K Pulukkody Durham U n i v e r s i t y . 
2 - l m i n o t h i o l a n e . H C l [ T r a u t s Reagent], ( P i e r c e and W a r r i n e r 
(UK) L t d ) . 
O c t a n - l - o l 99%, GPR, (BDH). 
P e n t o b a r b i t o n e , ( V e t e r i n a r y Drugs Co. PLC). 
PBS, Phosphate B u f f e r e d S a l i n e , Dulbeccos'A' t a b l e t s , ( O x o i d ) . 
Sodium d i h y d r o g e n orthophosphate, anhydrous, >99.0%, (Sigma) 
Di-sodium hydrogen orthophosphate anhydrous, >99.0%, (Sigma). 
APPARATUS 
A l l m e t a l complexes were p u r i f i e d by HPLC performed on a 
H e w l e t t Packard HPLC system c o n s i s t i n g o f a H.P.85B HPLC 
c o n t r o l l e r , H.P. HPLC pump u n i t (HP 1090) connected t o a 
Beckman r a d i o i s o t o p e d e t e c t o r (model 170) and an LKB c h a r t 
r e c o r d e r . Columns used were SynChropak AX300 4.6 x 250 mm 
a n a l y t i c a l column (Hichrom L t d . ) o r Poros Q/M 4.6 x 100 mm 
a n a l y t i c a l column ( P e r S e p t i v e B i o s y s t e m s ) . 
HPLC a n a l y s i s o f r a d i o l a b e l l e d p r o t e i n - m a c r o c y c l e 
c o n j u g a t e s was performed on an LKB HPLC system c o n s i s t i n g o f 
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an LKB 2150 HPLC pump, an LKB 2152 LC c o n t r o l l e r , an LKB 2158 
UVICORD SD w i t h a 280 nm f i l t e r t o m o n i t o r p r o t e i n 
c o n c e n t r a t i o n and a Beckman r a d i o i s o t o p e d e t e c t o r (model 170) 
connected t o an LKB c h a r t r e c o r d e r . Du Pont B i o S e r i e s GF-250 
columns 9.4 x 250 mm were used (Hichrom L t d . ) . 
U l t r a free-Mc Durapore 0.22 /xm f i l t e r s ( M i l l i p o r e ( U K ) 
L t d . ) were used f o r f i l t e r i n g h i g h c o n c e n t r a t i o n macrocycle 
complexes b e f o r e i n j e c t i o n i n t o mice. 
A l l p i p e t t e t i p s (Anachem) and m i c r o t e s t tubes (BioRad 
Labs.)[500 ^ 1 and 1.5 ml] were m e t a l f r e e . 
2 ml screw capped eppendorf tubes ( S a r s t e n d t ) were used 
f o r p a r t i t i o n c o e f f i c i e n t e xperiments. 
5 ml p o l y e t h y l e n e v i a l s (Hughes and Hughes) were used t o 
h o l d r a d i o a c t i v e samples f o r measurement on t h e LKB 
compugamma . 
An eppendorf c e n t r i f u g e 5415 (Anderman) was used t o 
c e n t r i f u g e a l l r e a c t i o n m i x t u r e s . 
S p e c t r o p h o t o m e t r i c measurements were made on a Beckman 
DU-50 s e r i e s s p e c t r o p h o t o m e t e r . 
M i n i - m o n i t o r s ( M i n i - i n s t r u m e n t s ) were used t o d e t e c t 13 and 
7 r a d i o a c t i v i t y . 
A Compugamma (LKB Wallac) equipped w i t h a 3" N a l ( T l ) w e l l 
t y p e c r y s t a l was used t o measure r a d i o a c t i v i t y i n i n d i v i d u a l 
samples. 
The pH o f s o l u t i o n s was measured u s i n g a Whatman pH n 
sensor, a H o r i b a compact pH meter C-l (Whatman S c i e n t i f i c 
L t d ) , o r BDH pH s t r i p s . The pH s t r i p s had t h e advantage t h a t 
samples as s m a l l as 0.5 /xl c o u l d be removed and a p p l i e d t o 
t h e s t r i p f o r measurement. 
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